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Abstract 
Cisplatin is a first line chemotherapeutic agent for lung cancer however, although patients 
may respond to therapy, resistance often develops with tumour recurrence and disease 
progression. Somatic alterations in the tumour may alter therapeutic responses. Consequently 
a model of cisplatin resistance in lung cancer derived A549 cells has been created to examine 
the genomic changes that occur as chemo-resistance develops. 
Drug resistance was induced in A549 cells through multiple rounds of cisplatin dosage and 
recovery over two different time courses. The concentration of cisplatin required to inhibit 
growth (inhibitory concentration [IC] value) was calculated at each round and cycles were 
continued until the IC value increased at least four-fold. Cells were harvested and total RNA 
extracted for whole transcriptome microarray analysis. Data was analysed using R statistics 
and associated packages, Affy, Limma, Mfuzz and WGCNA. 
A five-fold increase in IC value was generated over successive doses in both regimes, 
accompanied by highly significant changes in gene expression. To explore these changes, 
temporal expression clustering and extensive network analyses were performed across the 
rounds of cisplatin dosing, as well as an untreated cell culture time course that acted as a 
comparison to the two treated regimes. 
The results gathered from this robust model suggest that differences in dose and frequency of 
chemotherapy may affect genomic changes at specific loci that confer cisplatin resistance. 
Interesting and relevant pathways and genes have been discovered. In combination with 
analyses on a small patient cohort, these results have provided insights into the mechanism of 
cisplatin resistance and have highlighted new clinical biomarkers of potential use in 
prognosis of patients undergoing cancer treatment. 
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1 Introduction 
One in eight deaths worldwide is caused by cancer. There are more than 100 distinct tumour 
types, with diverse risk factors and epidemiology, which can originate from most of the cell 
types and organs of the human body. Lung cancer is the most common cause of cancer-
related death globally and in the UK alone has an incidence rate of approximately 41,500 per 
annum (2009) and a mortality rate of approximately 35,000 per annum (2010), (data 
combined from the Office for National Statistics [ONS] 2011, Information Services Division 
[ISD] Scotland 2011, Welsh Cancer Intelligence and Surveillance Unit 2011, Northern 
Ireland Cancer Registry 2011). Worldwide 1.61 million people were diagnosed with lung 
cancer in 2008 (World Cancer Research Fund, http://www.wcrf.org) whilst in the UK it is the 
second most common cancer.  By sex, lung cancer is the second most common in men, 
following prostate and the third most common in women after breast and bowel cancers 
(from data combined from ONS, ISD Scotland 2011, Welsh Cancer Intelligence and 
Surveillance Unit 2011, Northern Ireland Cancer Registry 2011). The majority (75%) of lung 
cancer cases occur in the over 65 years of age group (data combined from ONS 2007-2009, 
ISD Scotland 2007-2009, Welsh Cancer Intelligence and Surveillance Unit 2007-2009, 
Northern Ireland Cancer Registry 2007-2009) and most patients (68%) present with advanced 
disease, Stage III or IV (see Section 1.2), (National Cancer Registration 
Service/http://www.cancerresearchuk.org,). There is a strong correlation between one-year 
relative survival rate and the stage of disease at diagnosis, i.e. those with later stage disease at 
diagnosis have a lower relative survival chance. This late stage presentation combined with 
relative chemo-refractoriness results in poor survival rates – less than 9% (not age-
standardised) survive five years after diagnosis (ONS and ISD Scotland). 
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1.1 Diagnosis and Symptoms 
Initial symptoms of lung cancer include:- 
 Persistent coughing 
 A change in a long term cough 
 Shortness of breath 
 Coughing up sputum with signs of blood in it (haemoptysis) 
 An ache or pain when breathing or coughing (pleuritic pain) 
 Loss of appetite 
 Fatigue 
 Weight loss 
 
Less common symptoms, although they are generally indicative of more advanced or later 
stage lung cancer, include:- 
 A hoarse voice  
 Difficulty swallowing  
 Finger clubbing  
 Swelling of the face caused by an obstruction of the superior vena cava 
 Swelling in the neck caused by enlarged lymph nodes  
 Pain or discomfort under the ribs, from the liver  
 Shortness of breath caused by pleural effusion (Figure 1.1) 
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Figure 1.1  Diagram showing a build-up of fluid between the visceral and parietal pleura of the lungs 
(pleural effusion) which results in shortness of breath (http://www.cancerresearchuk.org). 
Endocrine symptoms can occasionally present. Some types of lung cancer cells produce 
peptides or hormones that either enter the bloodstream or act on local organs and may cause 
symptoms that seem to be unrelated to the lung cancer. These 'paraneoplastic symptoms' are 
uncommon.  
Symptoms vary from person to person but may include: 
 Confusion or forgetfulness  
 Pins and needles or numbness in the fingers or toes 
 Muscle weakness 
 General drowsiness, weakness, dizziness or confusion 
 Thrombosis 
Lung cancers growing at the very top of the lung (apices) are called 'pancoast tumours'. These 
tumours can cause very specific symptoms, most commonly severe shoulder pain. They can 
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also cause 'Horner's syndrome' which is a collection of signs and symptoms caused by the 
tumour compressing the cervical sympathetic nerve chain. Features include drooping or 
weakness of one eyelid (ptosis), small pupil in the same eye (mieiosis), and loss of ability to 
sweat (anhydrosis) on the same side of the face in which the eye is affected.  
 
1.2 Types, Subtypes and Stages of Lung Cancer 
There are two major types of lung cancer classified as small cell lung cancer (SCLC), and 
non-small cell lung cancer (NSCLC), which were historically grouped together due to their 
similar prognosis and management. NSCLC accounts for up to 85% of cases and is generally 
split into two major subtypes; squamous cell carcinoma and adenocarcinoma, which are 
complemented by a large number of other rarer sub-types e.g. large cell carcinoma, and 
pleomorphic carcinomas. 
Currently, squamous cell carcinoma is the most common NSCLC type seen in the UK and it 
is usually observed in smokers. It originates from the squamous epithelial cells that line the 
airways, often at the lung hila (above and behind the cardiac impression) and in the bronchial 
bifurcation (the point where the two bronchi split from the trachea) (Figure 1.2). 
Adenocarcinoma also develops in the cells that line the airways; invariably the mucus 
secreting cells e.g. goblet cells. Consequently it is often found in the peripheral areas of the 
lung (Figure 1.3). Adenocarcinoma however is becoming as common as squamous cell 
carcinoma in the UK due to the increasing prevalence of smoking of “low tar” cigarettes.  In 
other Western countries such as the USA, adenocarcinoma is the most frequent histological 
subtype, whereas in Eastern countries (e.g. China) squamous carcinoma still predominates. 
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Figure 1.2 40x magnification of Squamous Cell Carcinoma of the lung. Image reproduced courtesy of 
Professor Andrew Nicholson, Consultant Histopathologist, Royal Brompton and Harefield Hospitals 
NHS Foundation Trust. 
 
Figure 1.3 40x magnification of Adenocarcinoma of the lung, showing neoplastic cells arranged in 
papillary groups or glands. Image reproduced courtesy of Professor Andrew Nicholson, Consultant 
Histopathologist, Royal Brompton and Harefield Hospitals NHS Foundation Trust. 
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SCLC accounts for 12% of lung cancers and is predominantly related to smoking. The cells 
are small and contain dense neurosecretory granules that are visible under the microscope 
(Figure 1.4). Consequently it has historically been known as “oat cell” cancer due to its 
appearance. It generally grows rapidly, metastasizes to lymph nodes and distant organs early 
in disease progression, sooner than is usually observed for NSCLC, and so tends to be 
advanced at the point of diagnosis. This, together with its initial exquisite chemosensitivity, 
means that chemotherapy is the most common treatment of SCLC (see Section 1.6). It is 
frequently associated with distinct endocrine/paraneoplastic syndromes as a result of the 
neuroendocrine hormones produced by the tumour.  
 
Figure 1.4 200x magnification of Small Cell Carcinoma of the lung. Image reproduced courtesy of 
Professor Andrew Nicholson, Consultant Histopathologist, Royal Brompton and Harefield Hospitals 
NHS Foundation Trust. 
NSCLC is classified into four stage groupings to classify differing prognostic groups, 
referred to as stages. The currently used version is the Union for International Cancer Control 
(UICC) version 7 stage grouping (Goldstraw et al., 2007). Stage I is only located in the lungs 
with no involvement of the lymph nodes. Stage II is in the lung but involves nearby lymph 
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nodes or large node negative tumours. Stage III is also described as locally advanced disease, 
and is classified by a heterogeneous group of tumour findings: stage IIIA include tumours 
which have spread only to lymph nodes on same side of mediastinum as the primary cancer, 
as well as tumours without mediastinal lymph node involvement when these are either large, 
involve other lung lobes on the same side, or invade mediastinal structures; and stage IIIB 
where the cancer may have spread to mediastinal lymph nodes on the opposite side of the 
primary tumour, or in the supraclavicular fossa (nodes just above the collar bone), or involves 
the mediastinal nodes on the same side of the tumour as the primary but with a tumour 
invading the mediastinal structures. Stage IV is the most advanced stage of cancer and is 
described as advanced disease. The cancer has spread to both lungs or to another part of the 
body such as the liver or other organs, or causes a pleural or pericardial effusion. The UICC 
staging also uses the tumour/lymph node/metastases (TNM) system to define the stage of 
disease. The tumour (T) descriptor can range from T0, where there is no evidence of a 
primary tumour, to T3, where the tumour may be large (over 7cm in diameter), or T4 
indicating invasion into its surrounding structures, or that it has caused different nodules in a 
different lobe of the same lung. The lymph node descriptor (N) indicative of involvement 
may range from N0, no regional node metastasis, to N3, where there is involvement of 
opposite sided mediastinal lymph nodes or nodes in the supraclavicula fossa or scalene nodes. 
Metastasis can either be M0, no distant metastasis, or M1a, presence of a malignant pleural or 
pericaridal effusion, or lung metastases in the opposite lung, or M1b, presence of distant 
metastases e.g. in the bones or liver. The TNM descriptors are grouped into stage groupings 
(Stage I-IV) (Table 1.1). 




Table 1.1 Tumour/Node/Metastasis Staging in lung cancer. As tumour size and local invasion 
increases (T0 to T4), the stage of disease increases too. If nodal involvement increases (N0 to N3), 
smaller tumours may lead to a more advanced stage of disease. Once distant metastasis has been 
observed (M1a or M1b), the cancer is classed as Stage IV. Reproduced with permission from 
Lippincott Williams and Wilkins/Wolters Kluwer Health: Journal of Thoracic Oncology (Goldstraw 
et al., 2007), copyright (2007). 
SCLC was previously clinically classified as either limited stage or extensive stage by the 
Veterans Administration Lung Study Group (VASLG) staging system. Here, in limited stage 
SCLC, the tumour does is not associated with distant metastases, or pleural or pericardial 
effusion, and is encompassable by a single radical radiotherapy field, usually involving one 
side of the lung and associated lymph nodes. Extensive stage refers to tumour spread to other 
regions of chest not encompassable within a radical radiation field or parts of body (Zelen, 
1973). This system however has now been updated by the UICC version 7 staging system for 
SCLC, with the latter being based on a TNM classification akin to that for NSCLC (Vallières 
et al., 2009). 
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1.3 Causes of Lung Cancer 
In lung cancer, smoking is the primary risk factor and tobacco is estimated to cause almost 
90% of all deaths (Parkin, 2011). More than 60 years ago, case-control studies between 
smokers and non-smokers with the incidence of lung cancer left no doubt that there is a direct 
association between smoking and carcinoma of the lung (Doll and Hill, 1950, Levin et al., 
1950, Wynder and Graham, 1950). The carcinogenic chemicals in tobacco smoke, such as tar, 
arsenic, hydrogen cyanide, carbon monoxide, benzene and formaldehyde, are known to 
damage the tissues of the airways and lungs, as well as inducing mutations in the DNA of 
their cells. Several years after cessation of smoking, lung cancer risk decreases (Cogliano et 
al., 2011). Other chemical exposures such as asbestos, passive smoking, metal dust, and 
diesel exhaust fumes have also been linked to lung cancer risk (Cogliano et al., 2011).  
After smoking, radon, a naturally occurring gas found in granite (Health Protection Agency, 
http://www.hpa.org.uk), is the second most important risk factor for lung cancer. Other 
possible risk factors include previous lung disease, such as tuberculosis or pulmonary 
fibrosis, lowered immunity, and nutritional and dietary patterns 
(http://www.cancerresearchuk.org, Goldstraw et al., 2011, van Meerbeeck et al., 2011). 
Studies have also shown increased risk if there is prior family history of lung cancer in 
particular a first-degree relative (Scagliotti et al., 2009b) and this is independent of smoking 
and other recognized risk factors (Coté et al., 2012). Genetic variation in certain germline 
genes such as those involved in carcinogen metabolism, DNA damage repair, cell cycle 
control, and apoptosis, is also thought to have an influence on lung cancer risk (see Sections 
1.4 and 1.5 below).  
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1.4 Lung Cancer Biology 
Cancer arises due to the mutation of genes (see Section 1.5) leading to various hallmarks of 
cancer including: self-sufficiency of growth signals, insensitivity to anti-growth signalling, 
apoptosis evasion, limitless replicative ability, angiogenesis control, invasion and metastasis 
(Hanahan and Weinberg, 2000). These carcinogenesis-driving mutations generally occur in 
either oncogenes or tumour suppressor genes (TSGs).  
Oncogenes are the altered versions of proto-oncogenes: when a proto-oncogene is mutated or 
when there is a change in their expression patterns, neoplastic transformation can occur. 
These mutations and expression changes tend to act in a dominant fashion, where a single 
alteration in one copy can promote uncontrolled growth. Oncogenes are often growth factors 
or their receptors (such as epidermal growth factor [EGF]) or their downstream signalling 
molecules (such as Kirsten Rat Sarcoma Viral Oncogene Homolog [KRAS]).  
TSGs are normal cellular genes that generally operate in a recessive manner where loss of 
both functioning copies is required for tumorigenesis (Knudson’s two hit hypothesis). They 
are often genes that have some control over the cell cycle or those involved in DNA repair 
mechanisms, such as nucleotide excision repair, mismatch repair and base excision repair. 
p53 is a key example of a TSG that is mutated in a multitude of cancers, from colon and 
breast cancers through to leukemia and lymphomas, and inherited mutations in the gene can 
lead to Li-Fraumeni Syndrome. This leads to increased susceptibility to a variety of cancers, 
including lung cancer, and is passed from parent to child in an autosomal dominant fashion. 
Lung cancer evolves due to the interaction of both environmental and genetic susceptibility 
factors that influence carcinogenesis. Unrelated factors such as hormonal and viral factors 
may also play an important role (see Section 1.3). 
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Smoking-related cancers often develop in the central airway, the primary point of tissue 
injury, whereas in most tumours unrelated to smoking tissue injury occurs and develops in 
the peripheral airway. This injury leads to genetic and epigenetic changes, such as base 
changes, insertions, deletions and promoter methylation. These changes can result in 
alterations in the transcriptome, such as the activation of inflammation and apoptosis 
pathways, or more local changes in particular gene expression of growth factor pathways e.g. 
the epidermal growth factor receptor (EGFR) pathway. In addition, mutation rates also 
increase in the presence of substantial exogenous mutagenic exposures such as tobacco 
smoke, naturally occurring chemicals such as aflatoxins (related to liver cancer) or radiation 
(UV) (Stratton et al., 2009). These changes may persist for some time and eventually lead to 
aberrant pathway activation and cellular function to produce premalignant changes, including 
dysplasia and clonal patches (Figure 1.5). As this continues, further alterations can lead to 
invasion and angiogenesis and thus early-stage cancer eventually leading to advanced cancer 
and metastasis (Herbst et al., 2008).  
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Figure 1.5 Diagram illustrating the evolution of lung cancer that is smoking-related (top) and non-
smoking-related (bottom). The diagram indicates the potential localization of the cancer mass by stage 
of the disease as well as providing details of the molecular and cellular features, treatment approaches 
and the potential role of molecular markers. Reproduced with permission from (Herbst et al., 2008), 
Copyright Massachusetts Medical Society. 
Lung cancers that are related and unrelated to smoking (such as SCLC and NSCLC 
adenocarcinoma respectively) have very different somatic molecular profiles as exemplified 
by the difference in the mutational status of a number of key genes i.e. p53, KRAS, EGFR and 
erythroblastic leukemia viral oncogene homolog 2 (ERBB2, also known as HER2). 
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A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathological processes or pharmacological responses to a 
therapeutic intervention. Within the tumour, these characteristics, such as a DNA sequence, 
gene expression signature or copy number variant, can be objectively measured or evaluated 
as an indicator of a given phenotype, for example, a pharmacological response in a disease 
versus normal state. Biomarkers may be predictive of risk, prognosis, and sensitivity to 
treatment and can work in addition to the traditional staging system (see Section 1.2). They 
may be stage specific, spanning the whole disease course from early stages through to the 
later stages and may define mechanisms of therapy resistance (Herbst et al., 2008). As they 
are measurable characteristics they are clinically useful. A simple test, such as genotyping a 
tumour sample, may quickly indicate sensitivity or resistance to a particular treatment (a 
predictive biomarker). With biomarker directed therapy, it is be possible to personalize 
treatment, giving the correct treatment to the correct patient at the correct time. The 
biomarker may not predict any therapeutic utility but indicate prognosis (prognostic 
biomarker e.g. KRAS mutations are associated with poorer prognosis). Some biomarkers can 
be both predictive and prognostic (e.g. EGFR mutations predict superior outcomes with 
EGFR-directed therapies and also independently confer an improved prognosis compared 
with EGFR wild-type tumours). 
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1.5 Genetics, Genomics, Transcriptomics and Pharmacogenomics 
Mutations occur sporadically in carcinogenesis and these often give the host cell key 
characteristics that allow disease progression, sometimes referred to as the hallmarks of 
cancer.  These characteristics include self-sufficiency in growth signals, irresponsiveness to 
anti-growth signals, evasion of apoptosis, limitless replicative potential, angiogenesis, and 
invasion and metastasis (Hanahan and Weinberg, 2000). Mutations may also affect response 
to chemotherapy. Possible mutations include simple point mutations, amplification and/or 
overexpression of genes, changes in gene copy number and structural rearrangements – 
Mutant Allele Specific Imbalances (MASI). Oncogenes, such as KRAS, EGFR and other 
genes in similar pathways (Figure 1.6), are recognized to be of particular importance, 
especially in response to chemotherapeutics. Many genes have been shown to play a role in 
NSCLC carcinogenesis, both as substantial players or drivers, as part of coordinated control, 
or as potential susceptibility loci. 
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Figure 1.6 Pathway diagram showing multiple pathways and their signalling molecules, such as 
EGFR, RAS, PI3K, AKT and ERBB2. Illustration reproduced courtesy of Cell Signaling Technology 
Inc. (http://www.cellsignal.com). 
 
1.5.1 EGFR (also known as HER1 or ERBB1)  
The EGFR gene is located on the short arm of chromosome 7 on the plus strand, is almost 
10,000 base pairs long, contains 28 exons, and contains over 1,200 amino acids. The EGFR 
protein, along with its ligands, regulates important processes such as proliferation, apoptosis, 
and angiogenesis, all of which are vital for tumour progression (Herbst et al., 2008). 
Signalling is triggered by binding of growth factors causing dimerisation of EGFR molecules 
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or heterodimer formation with closely related molecules such as ERBB2 (Human Epidermal 
Growth Factor Receptor 2, also known as HER2). Auto-phosphorylation and trans-
phosphorylation of the receptors through their tyrosine kinase domains (exons 18-24 in 
EGFR) results in downstream effecter recruitment and activation of proliferative and cell-
survival signals (Lynch et al., 2004) (Figure 1.7).  
 
Figure 1.7 Schematic showing dimerisation of EGFR and its signalling pathways, PI3K/AKT and 
RAS/RAF, and their influence on downstream cellular functions. Reproduced with permission from 
(Herbst et al., 2008), Copyright Massachusetts Medical Society.  
EGFR over-expression has been observed in the development of NSCLC in 40-80% of cases 
(Lynch et al., 2004, Herbst et al., 2008) and somatic EGFR mutations are thought to be early 
events in tumorigenesis. These are more frequently found in female adenocarcinoma patients 
and patients of East Asian origin (30-50% of East Asians compared to 10% of Americans). 
EGFR rearrangements in the extracellular domain of the molecular are rare (Lynch et al., 
2004). Somatic mutations are usually found within the EGFR tyrosine kinase domain, often 
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near the ATP cleft, where ATP binds to enable phosphorylation (Lynch et al., 2004), and 
most mutations in adenocarcinomas involve in-frame deletions in exon 19 or substitutions in 
exon 21 (L858R) (Lynch et al., 2004, Herbst et al., 2008). The heterozygous nature of EGFR 
mutations is evidence for its dominant oncogenic effects as the mutations are not found in 
normal lung tissue DNA (Paez et al., 2004) providing evidence for their somatic acquisition. 
These mutations are also seen more commonly in never-smoking related cancers (Sholl et al., 
2009) and in comparatively younger age groups (less than 55 years old) (Gandhi et al., 2009).  
EGFR mutations are known to be markers for therapy choices as they may lead to truncated 
proteins that are sensitive to tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib. 
These biological small molecules act by inhibiting the ATP cleft within the tyrosine kinase 
domain (Lynch et al., 2004) by competing out ATP and thus block the proliferative action of 
the downstream activation of PI3K (phosphoinosifide 3-kinase)/AKT signalling. The 
predictive value of EGFR mutations for use of gefitinib has been strengthened by the results 
of seven randomised Phase III trials that specifically compared TKIs used as a first-line 
therapy with traditional platinum-based therapy (see Section 1.6) in patients with advanced 
NSCLC. Both progression free survival and response rates for gefitinib were improved 
compared to platinum-based chemotherapy in the first-line setting of metastatic EGFR-
mutated NSCLC (Antonicelli et al., 2013). 
Resistance to TKIs however always occurs. This resistance can be intrinsic or more usually 
develops after TKI treatment (acquired resistance) (Engelman et al., 2007). Acquired 
resistance has been demonstrated to occur through two major mechanisms. A second 
mutation (T790M) encoded by exon 20 of the EGFR gene and within the tyrosine kinase 
domain of the molecule has been shown to confer resistance to EGFR TKIs, in the presence 
of either wild-type (wt) or mutant EGFR. Tumours harbouring this double mutant appears to 
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have the same resistance to tyrosine kinase inhibitors as those with wt EGFR (Pao et al., 
2005a). Germline transmission of this mutation has also been reported (Bell et al., 2005). The 
other commonest mechanism is the recruitment of other kinases. For example amplification 
of another receptor tyrosine kinase proto-oncogene MET (mesenchymal epithelial 
transcription factor) has also been shown to render susceptible EGFR mutants resistant to 
TKIs (Engelman et al., 2007). This happens by initiating PI3K/AKT signalling and its 
downstream proliferative effects via ERBB3. Intrinsic resistance in EGFR mutants may 
happen through insertions in exon 20 of EGFR, loss of the PTEN gene, activation of MET, 
absence of EGFR expression or mutations in HER2 tyrosine kinase (Toschi and Cappuzzo, 
2010). PTEN homozygous deletion and the absence of its protein confers resistance to TKIs, 
again by PI3K/AKT pathway interference (Gandhi et al., 2009). TKI sensitivity has also been 
significantly associated with EGFR copy number gains in vitro although in vivo evidence is 
conflicting (Gandhi et al., 2009, Toschi and Cappuzzo, 2010) (see Section 1.5.8). 
MET also forms heterodimers with EGFR, HER2, HER3 and RET. These other ERBB family 
proteins may additionally have a key role in cancer themselves their depletion may induce 
apoptosis in association with AKT/ERK signalling inhibition as well as reduction of cell 
migration and STAT3 signalling (Tanizaki et al., 2011). Other methods of acquiring TKI 
resistance include increased signalling through parallel pathways such as VEGF and IGF1R, 
mutation and activations of PIK3CA, and transformation into a small-cell lung cancer 
phenotype (Antonicelli et al., 2013).  
The prevalence of EGFR mutations in NSCLC tumours ranges from approximately 15% in 
Caucasians to almost 50% in East Asians, with the majority (95%) of these being found in 
adenocarcinomas (Antonicelli et al., 2013).  
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1.5.2 KRAS 
The KRAS gene is located on the reverse strand of the short arm of chromosome 12, is nearly 
6,000 base pairs long, has four coding exons and the resultant protein consists of 188 amino 
acids. Somatic KRAS mutations are prevalent in many cancers, ranging from colorectal and 
pancreatic cancer to leukemia (Loriot et al., 2009). In NSCLC, activating mutations are 
generally limited to adenocarcinoma and are almost always mutually exclusive of EGFR 
mutations (Pao et al., 2005b, Herbst et al., 2008, Adams and Harvey, 2010) and BRAF 
mutations (Soh et al., 2009). KRAS activating mutations however are one of the most 
common molecular changes in NSCLC (Roberts and Stinchcombe, 2013). The mutations are 
more commonly seen in smokers in contrast to EGFR where mutations are seen in non-
smokers (Sholl et al., 2009). Mutations are often smoking related G>T transversions (Herbst 
et al., 2008) and hotspots have been found in the GTPase domain of the gene in codons 12, 
13 and 61 (Loriot et al., 2009). This area is key for the function of the protein; the GTP 
hydrolysis performed by this domain leads to the negative regulation of signal transduction. 
Mutations in this area can lead to interference with the GTPase activity and reduced negative 
regulation. Downstream effectors of KRAS, such as BRAF, MEK1 & 2 and ERK1 & 2, may 
also be mutated. MEK and ERK gene amplifications however have not been observed in lung 
cancer. 
KRAS mutations tend to be classically associated with the adenocarcinoma histology 
(mutated in 20-30% [Roberts and Stinchcombe, 2013]). In contrast to EGFR mutations, 
KRAS mutations are more frequent in male, smoking patients and are also less commonly 
identified in other NSCLC subtypes such as squamous carcinomas and large cell carcinoma 
(Gandhi et al., 2009). 
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KRAS mutated tumours have intrinsic resistance to tumour response to EGFR TKIs such as 
gefitinib or erlotinib (Pao et al., 2005b, Gandhi et al., 2009), although there is some evidence 
for prolonged disease stabilization under this therapy. This is not surprising since KRAS sits 
downstream of EGFR and therefore inhibiting upstream EGFR would not be predicted to 
benefit. It is possible however, that these particular KRAS mutants may have increased EGFR 
copy number (Toschi and Cappuzzo, 2010). KRAS mutational status in general appears to be 
associated with poor survival, prognosis (Mascaux et al., 2005) and diminished response to 
most systemic therapies (Adams and Harvey, 2010). Despite this it may still be a useable tool 
in guiding therapy, for example whether a targeted agent or conventional chemotherapy 
should be used (Loriot et al., 2009). 
BRAF (v-raf murine sarcoma viral oncogene homolog B1), a downstream effector of KRAS, 
is a serine threonine kinase enzyme that links RAS GTPases with the MAPK family, the 
controllers of cell proliferation. Mutations in BRAF have been well documented in 
melanomas, with the majority (80%) of mutations affecting exon 15 with a missense mutation 
Val600Glu (V600E). Lung cancers harbouring BRAF mutations (approximately 1-3% of 
adenocarcinomas) have a more diverse range of mutations, although V600E is by far the most 
common variant observed.  There are very few instances of the missense mutation Val600Glu 
but often Leu596Val and Gly468Ala in the kinase domain and activation domain respectively 
are found. BRAF mutations also appear to be generally mutually exclusive of KRAS and 
EGFR mutations (Vijayalakshmi and Krishnamurthy, 2011). 
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1.5.3 ALK and Other Gene Rearrangements 
The somatically acquired translocation of involving the genes echinoderm microtubule-
associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) is highly specific to 
NSCLC and was first described in 2007 (Soda et al., 2007, Shaw et al., 2009). It is caused by 
an inversion on chromosome 2p leading to a fusion gene of the N-terminal of EML4 and the 
C-terminal of ALK leading to expression of a chimeric tyrosine kinase. EML4 is found on the 
forward strand of the short arm of chromosome 2, consists of 5,549 base pairs with 23 exons 
and with a protein of 981 amino acids. ALK is also found on the short arm of chromosome 2 
but on the reverse strand and consists of 6,220 base pairs, 29 coding exons with a protein of 
1,620 amino acids. 
It is suggested that the basic domain within EML4 may mediate dimerisation of EML4-ALK. 
There is also some indication for diversity in the EML4 breakpoint region, which may or may 
not have an effect on this dimerisation capability and hence tyrosine kinase activity (Soda et 
al., 2007). 
The translocation has been detected in both smokers and non-smokers and is distinct from 
EGFR mutations. It tends to be observed in young never smokers, more frequently male, and 
ALK positive tumours usually have signet ring morphology by light microscopy. This 
morphology however can be difficult to see with the small biopsy material that is usually 
used for diagnostic purposes. The cells of the tumour contain large quantities of mucin, which 
pushes the nucleus to the edge of the cell, giving them the appearance of a signet ring. A 
number of other ALK fusion partners have also been identified (Shaw and Engelman, 2013). 
The translocation tends to be mutually exclusive of both EGFR and KRAS mutations. Patients 
are generally younger and do not benefit from TKI treatment, possibly due to constitutive 
ALK signalling (Toschi and Cappuzzo, 2010). Response to chemotherapy is generally similar 
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to tumours harbouring wt ALK and EGFR, although pemetrexed does demonstrate increased 
activity. The constitutional activation of the ALK kinase conferred by the oncogenic fusion 
can however be effectively blocked using small molecule inhibitors of ALK e.g. crizotinib 
with dramatic clinical benefits (Shaw et al., 2009).  
In addition to the rare somatic fusion protein, EML4-ALK, others have been seen as well, 
granted less frequently. The translocation of kinesin family member 5B (KIF5B) to the ret 
proto-oncogene (RET) has been seen exclusively in adenocarcinomas that harbour neither an 
EGFR nor a KRAS mutation (Takeuchi et al., 2012). A number of RET inhibitors are licensed 
or in development, and trials of RET kinase inhibitors e.g. vandetanib in NSCLC are 
ongoing. Another rare somatic fusion is the translocation of the c-ros oncogene receptor 
tyrosine kinase (ROS1). Although little is known about the roles of wild-type ROS1, 
oncogenic gene fusions involving its 3-prime region have been identified in various human 
cancers including NSCLC (Davies et al., 2012). These ROS1 fusions have principally 
observed in adenocarcinomas (Takeuchi et al., 2012).  Due to sequence homology between 
ROS and ALK kinase, ALK kinase inhibitors show efficacy against ROS1 fusion 
adenocarcinomas and an ongoing trial of crizotinib in ROS1 fusion NSCLCs has 
demonstrated remarkable efficacy. 
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1.5.4 Developmental Genes: PAX9, TTF1, NKX2-8 and Shh  
Genes involved in lung development by nature of their function have undergone prior 
investigation and been implicated in tumorigenesis.  Genes have included those encoding the 
transcription factors thyroid transcription factor (TTF-1), NK2 homeobox 8 (NKX2-8) and 
Paired Box 9 (PAX9) (Hsu et al., 2009), all three being located on chromosome 14q13 
(Herbst et al., 2008, Hsu et al., 2009). The co-activation of TTF-1 and NKX2-8 has been 
associated with clusters of patients with poor survival. Cell lines harbouring this co-activation 
have been shown to exhibit resistance to cisplatin doublet chemotherapy as well as to 
taxanes, gemcitabine and vinorelbine, reflecting the importance of understanding genetic 
signatures and cooperation between multiple genes and their expression patterns in cancer. 
These signatures representing transcription factor statuses have both prognostic and 
predictive value and may give indications for individual treatment and therapeutic options 
(Hsu et al., 2009). 
Sonic Hedgehog (Shh) is another gene involved in lung development and consequently may 
have a role in regeneration and carcinogenesis. After acute injury of the airways, the 
hedgehog pathway is extensively activated in the epithelium. It has been suggested that 
epithelium progenitors that retain Hh signalling may progress into a SCLC malignancy 
(Watkins et al., 2003). This may indicate a possible treatment by blockade of the Hh pathway 
particularly in cases of SLCLC with poor prognosis (Watkins et al., 2003). 
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1.5.5 DNA Repair and Nucleotide Excision Repair (NER): ERCC1, RRM1 and BRCA1  
When an exogenous agent causes damage to DNA, the structure and chemistry of the DNA 
duplex undergoes changes. The nucleotide excision repair (NER) pathway removes this 
damage by recognizing the alteration through the xeroderma pigmentosum C (XPC) protein, 
which in turn recruits further proteins (XPA and replication protein A [RPA]) that facilitate 
specific base damage recognition. The area around the DNA damage is unzipped by helicase 
activities of XPB and XPD. The heterodimeric sub-complex of Excision Repair Cross-
Complementation 1 (ERCC1) – XPF then binds the NER complex and, with XPG, enables 
the removal of a 27-30 nucleotide fragment of DNA (containing the damaged base) to be 
removed. The DNA is then repaired by DNA polymerase δ/ε with other accessory replication 
proteins and DNA ligase restores the strand’s integrity (Figure 1.8). Through this mechanism 
of detection, protein recruitment, removal of the damage and re-synthesis, genetic integrity at 
the base pair level is maintained.   
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Figure 1.8 a | Nucleotide excision repair (NER) operates on base damage caused by exogenous agents 
(such as mutagenic and carcinogenic chemicals and photoproducts generated by sunlight exposure) 
that cause alterations in the chemistry and structure of the DNA duplex. b | Such damage is 
recognized by a protein called XPC, which is stably bound to another protein called HHRAD23B 
(R23). c | The binding of the XPC–HHRAD23 heterodimeric sub-complex is followed by the binding 
of several other proteins (XPA, RPA, TFIIH and XPG). Of these, XPA and RPA are believed to 
facilitate specific recognition of base damage. TFIIH is a sub-complex of the RNA polymerase II 
transcription initiation machinery which also operates during NER. It consists of six subunits and 
contains two DNA helicase activities (XPB and XPD) that unwind the DNA duplex in the immediate 
vicinity of the base damage. This local denaturation generates a bubble in the DNA, the ends of which 
comprise junctions between duplex and single-stranded DNA. d | The subsequent binding of the 
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ERCC1–XPF heterodimeric sub-complex generates a completely assembled NER multi-protein 
complex. e | XPG is a duplex/single-stranded DNA endonuclease that cuts the damaged strand at such 
junctions 3' to the site of base damage. Conversely, the ERCC1–XPF heterodimeric protein is a 
duplex/single-stranded DNA endonuclease that cuts the damaged strand at such junctions 5' to the site 
of base damage. This bimodal incision generates an oligonucleotide fragment 27–30 nucleotides in 
length which includes the damaged base. f | This fragment is excised from the genome, concomitant 
with restoring the potential 27–30 nucleotide gap by repair synthesis. Repair synthesis requires DNA 
polymerases  or , as well as the accessory replication proteins PCNA, RPA and RFC. The covalent 
integrity of the damaged strand is then restored by DNA ligase. g | Collectively, these biochemical 
events return the damaged DNA to its native chemistry and configuration. ERCC1, excision repair 
cross-complementing 1; PCNA, proliferating cell nuclear antigen; POL, polymerase; RFC, replication 
factor C; RPA, replication protein A; TFIIH, transcription factor IIH; XP, xeroderma pigmentosum. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer (Friedberg, 2001), 
Copyright 2001.  
 
Aberrations in DNA repair pathways are well documented in several cancers, from colon 
cancers with microsatellite instability to breast cancer with inherited defective BRCA genes, 
the latter being members of the Homologous Recombination pathway. Alterations in NER 
have also been documented in lung cancer.  
Excision Repair Cross-Complementation (ERCC1) is located on chromosome 19q and is 
involved in the process of  NER (Gazdar, 2007). Increased ERCC1 protein expression has 
been associated with lack of response to platinum-based chemotherapy (Adams and Harvey, 
2010) and poor survival in cisplatin-treated patients (Rosell et al., 2003).  In contrast patients 
with low expression levels or an absence of ERCC1 tend to have a prolonged median survival 
time and improved response to platinum chemotherapy.  There is some evidence suggesting 
that the effect may be sex specific where men with ERCC-negative tumours treated with 
carboplatin and gemcitabine had a significantly increased survival compared with those 
harbouring ERCC-positive tumours (Chen et al., 2010). Down-regulation of the complex of 
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ERCC1 and XPF (another NER protein) has also been shown to result in sensitization to 
cisplatin (Arora et al., 2010). Recent data however has indicated that platinum resistance due 
to ERCC1 expression is conferred by a specific ERCC1 isoform that is difficult to measure 
using standard methodology (Friboulet et al., 2013). As such most studies measuring ERCC1 
are likely to be strongly biased. 
Ribonucleotide reductase M1 (RRM1) is an enzyme that is essential for deoxyribonucleotide 
production prior to DNA synthesis in the cell cycle and NER. It has been shown to predict 
response to therapeutic agents, with high levels of protein expression leading to 
chemotherapy (cisplatin and gemcitabine) resistance (Rosell et al., 2003, Adams and Harvey, 
2010,).  In contrast to ERCC1 expression, high co-expression of ERCC1 and RRM1 has been 
shown to be associated with statistically significant increased disease-free and overall 
survival in early stage (Stage I) NSCLC patients. ERCC1 and RRM1 are not molecular 
predictors of efficacy to the same extent as EGFR mutations or ALK rearrangements (Besse et 
al., 2013). 
BRCA1 is involved in transcription coupled repair (Friedberg, 2001) and is well known to 
play a role in both hereditary and sporadic breast and ovarian cancers. Low BRCA1 
expression in cisplatin-treated NSCLC patients has been associated with prolonged, 
progression-free survival whilst poorer median survival associates with high BRCA1 levels 
(Toschi and Cappuzzo, 2010). This implied involvement of BRCA1 in NSCLC chemo-
resistance is however based on observations from studies of ovarian and breast cancers and 
not NSCLC per se (Toschi and Cappuzzo, 2010). Activation of poly(ADP-ribose) 
polymerase-1 (PARP-1) in response to DNA damage is an important mechanism to keep 
homeostasis or to trigger apoptosis (Ahmad et al., 2010). PARP inhibitors have already 
shown potent anti-tumour activity (Ashworth, 2008) in both hereditary and sporadic breast 
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and ovarian cancers that are deficient in BRCA1, which has led to the suggestion that those 
NSCLC tumours with sporadic BRCA1 loss could also benefit from PARP inhibition (Paul et 
al., 2010) and trials of these inhibitors in NSCLC and SCLC are ongoing.  
Another DNA repair pathway is non-homologous end joining (NHEJ). This mends double-
stranded breaks (DSB) in DNA and helps prevent large chromosomal changes within the 
cancer genome. It has been shown that cisplatin-induced DNA lesions that are physically 
close to the termini of DSB (within 6 base pairs) can inhibit rejoining (Sears and Turchi, 
2012) which it could be implied may lead to further gross chromosomal changes.  
 
1.5.6 Cell Cycle Regulators 
Genes as well as proteins involved in the regulation of the cell cycle have also been 
associated with NSCLC. In one study (Weir et al., 2007) two significant focal deletions in 
well documented TSGs: CDKN2A and CDKN2B were observed in patients. CDKN2A and 
CDKN2B are both involved in the inhibition of two cyclin-dependent kinases, CDK4 and 
CDK6, whose amplification has also been observed (Weir et al., 2007). Another homozygous 
deletion in CDKN2A was observed in a separate study (Ikediobi et al., 2006) that also 
interestingly found a loss in methylation profile of CDKN2A.  
The wide reach of cell cycle regulators may mean that they are also involved in or feed into 
other important molecular pathways, some of which have been discussed already (Sections 
1.5.1 and 1.5.2), and may affect lung cancer indirectly, such as EGFR, KRAS and BRAF 
(Eymin and Gazzeri, 2010). It is possible that they may be of use in combined therapies or 
prognoses. 
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1.5.7 Other Miscellaneous Somatic Mutations 
Certain genes may harbour rare somatic mutations in NSCLC tumours. These include various 
mutations and Copy Number Gains (CNGs) in the fundamental, cell development and growth 
PI3K signalling pathway. These have tended to be observed for squamous cell carcinomas 
(Yamamoto et al., 2008, Gandhi et al., 2009, Adams and Harvey, 2010). One of the PI3K 
subunits (PIK3CA) is on a chromosomal location (3q26) that is frequently amplified in lung 
cancers (Vijayalakshmi and Krishnamurthy, 2011). Adenocarcinomas with PIK3CA gains 
(approximately 20% [Wojtalla and Arcaro, 2011]) tend to also have other gene mutations 
suggesting further mutations may be required for progression.  
Increased activation of another molecule (by amplification, over-expression, or over-
activation) involved in the PI3K pathway, v-akt murine thymoma viral oncogene homolog 1 
(AKT) has also been seen. This, based on immunohistochemical investigations of tumour 
samples, appears to be more balanced between the squamous cell and adenocarcinoma 
subtypes (68% versus 62% respectively (Wojtalla and Arcaro, 2011)) than PIK3CA 
mutations. Over-expression of AKT has also been associated with low expression of the TSG: 
phosphatase and tensin homolog (PTEN). This is an important negative regulator of the 
PI3K/AKT signalling pathway and its loss through homozygous deletion or mutation is well 
documented in many different cancers although genetic alterations are rare in NSCLC. Loss 
or reduced expression of the PTEN protein, potentially through transcriptional or translational 
control, has been reported (Kokubo et al., 2005). The molecular mechanism underpinning 
this observation however remains unclear but, if elucidated, it could offer further therapeutic 
targets. Alterations in this pathway are an obvious target for therapy especially at the start of 
tumour progression as they appear to happen early on. There are several potential gene 
targets within the pathway (PI3KCA, AKT, and the mammalian target of rapamycin [mTOR]) 
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that could be used to alleviate the pro-survival signals in the cancer and induce apoptosis 
(Figure 1.6 and Figure 1.7).  
Serine/threonine kinase 11 (STK11, also known as LKB1) may have a role in premalignant 
lesion development as it also interacts with the PI3K/AKT pathway and is a negative 
regulator of mTOR signalling (Gill et al., 2011). Loss of heterozygosity (LOH) or 
homozygous inactivation of STK11 has been seen in tumours that subsequently demonstrate 
more frequent metastasis (Ji et al., 2007).  It may work in cooperation with KRAS activation 
to initiate pulmonary neoplasia and its methylation status may be of importance (Ikediobi et 
al., 2006, Ji et al., 2007, Herbst et al., 2008).  
Mutations in ERBB2, another member of the EGFR kinase family, have been reported mostly 
in a small fraction of adenocarcinomas. Opinion is divided as to who is affected; current and 
ex-smokers (Stephens et al., 2004, Ikediobi et al., 2006) or similar populations to those with 
EGFR mutations i.e. female non-smokers (Tomizawa et al., 2011). Little difference however 
has been seen in overall patient survival of ERBB2 mutants compared to EGFR mutants and 
those patients harbouring wt EGFR and wt ERBB2. Nonetheless patients with the mutations 
may benefit from anti-ERBB2 therapy such as trastuzumab, afatinib or dacomitinib 
(Tomizawa et al., 2011). 
Thymidylate synthetase (TYMS) is an enzyme that is critical in maintaining the dTMP 
(thymidine-5-prime monophosphate) pool for DNA synthesis and repair. It is considered 
among the targets of newer anti-folate drugs, such as pemetrexed, while allelic variants of 
TYMS have been shown to interfere with platinum activity in vitro. In many studies, 
expression is reported as an unfavourable prognostic factor, although occasionally it has been 
associated with a favourable outcome (Kotoula et al., 2012). Further investigation revealed 
that aberrant intra-tumoral TYMS predicted shorter progression free survival than normal 
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(Kotoula et al., 2012). Data from a number of studies are however conflicting and so the 
clinical utility of this target remains unknown. 
The discoidin domain receptor tyrosine kinase 2 (DDR2) is another potential target for lung 
cancer. Some novel somatic mutations have been reported in a proportion (3.8%) of 
squamous cell lung cancers and these oncogenic gain-of-function mutations could be 
potentially important therapeutically. Sensitivity of the mutated tyrosine kinase to dasatinib, a 
TKI, has been reported although the mechanism of transformation promoted by DDR2 is still 
unclear (Hammerman et al., 2011). A trial of dasatinib in DDR2 mutant NSCLC is ongoing 
[reference number NCT01514864]. 
As already mentioned earlier (Section 1.5.1), receptor tyrosine kinases have been shown to 
play a vital role in lung cancer development. The fibroblast growth factor receptor 1 (FGFR1) 
is another receptor that has been shown to have increased expression and elevated copy 
number in some squamous cell carcinomas (approximately 10%) (Kohler et al., 2012). No 
significant associations, however, between expression and clinico-pathological parameters 
have been elucidated. Its amplification has already been associated with cancer cell survival 
and chemotherapy resistance (Kohler et al., 2012). Trials of FGFR kinase inhibitors, e.g. 
AZD4547, in FGFR-amplified tumours are ongoing [reference number NCT01795768]. 
Whole-genome linkage analysis also identified CD44, a cell-surface glycoprotein involved in 
cell-cell interactions, cell adhesion and migration, as important in conferring resistance 
against carboplatin, another platinum compound that is used in NSCLC chemotherapy 
(Shukla et al., 2009). 
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1.5.8 Other Alterations – Structural Rearrangements, Copy Number Alterations, Mutant 
Allele Specific Imbalances, Uniparental Disomy and Loss of Heterozygosity 
As well as somatic mutations (point, insertion or deletion) accumulating during cancer 
growth, other types of mutation that occur in cancer can affect subsequent gene expression. 
These include somatic Copy Number Alterations (CNAs) (gain and loss), structural 
rearrangements, loss of heterozygosity (LOH), uniparental disomy (UPD) and mutant allele 
specific imbalances (MASI). 
MASI may occur after somatic mutation by UPD, amplification of the mutated gene or by 
polysomy with the mutated gene (Figure 1.9). MASI has been observed in cell lines and 
tumours harbouring oncogenic mutations. KRAS mutations have frequently demonstrated 
complete or relative MASI (Mitsudomi et al., 1991) and activating EGFR exon 19 deletion 
mutations have been seen in great excess in lung adenocarcinoma (Lynch et al., 2004, Paez et 
al., 2004). More recently the frequent presence of copy number gains (CNGs) of mutant 
forms of the same gene has been found in tumour cells. 
 
Figure 1.9 Three different ways of acquiring MASI – 1) after somatic mutation by UPD where one 
copy of the chromosome carrying the mutated gene is replicated; 2) where the mutated gene is 
amplified; or 3) by polysomy of the chromosome carrying the mutated gene. Figure taken from Soh et 
al., 2009 (PLoS One, 4, e7464: open access journal). 
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Genome wide approaches such as single nucleotide polymorphism (SNP) arrays have been 
invaluable in enabling evaluation of dynamic chromosomal and focal changes of CNAs and 
LOH. Novel lesions have been identified with amplification and/or LOH across several 
organs. UPD is frequently observed in several cancers. It typically arises when two copies of 
the same chromosome are inherited from one parent. The acquisition of UPD leads to 
homozygosity for any pre-existing gene mutations, with selective retention of the mutated 
allele. Acquired UPD, caused by the loss of one chromosome during cell division followed 
by the duplication of the remaining homologous pair, is associated with oncogenic sporadic 
mutations. It has been reported in hematopoietic malignancies (FLT3 and WT1 mutations in 
acute myeloid leukemia; JAK2 mutations in myeloproliferative disorders [Fitzgibbon et al., 
2005]).  
To date, acquired UPD in solid tumours has only been observed in TSGs that require two hits 
to be inactivated (Soh et al., 2009). Most inactivating mutations of TSGs are frequently 
accompanied by wt allele loss.  In one study of cell lines derived from multiple tumour types 
20% of activating oncogene mutations were found to be homozygous. MASI detection 
requires oncogenic mutation identification, analysis of copy number of the mutant gene in 
tumour cells and determination of the relative ratio of mutant to wt allele (Soh et al., 2009). 
CNAs and MASI could play an important role in understanding lung cancer pathogenesis and 
once more is known about their biological and clinical significance they may provide 
prognostic markers that indicate tumour and patient response to therapy. 
In tumours, CNGs in EGFR, KRAS and ERBB2 (Gandhi et al., 2009) have been frequently 
found (>10%) with gains in EGFR nearly twice as common as any other gene. Unlike other 
mutations, CNGs on the whole appear to have no bias towards any histological subtype with 
the exception of PI3K and BRAF gains which appear to be limited to squamous cell 
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carcinoma and adenocarcinoma respectively. Mutual exclusivity of CNGs has not been found 
but there is a significant association between mutation and CNG of individual genes.  They 
are not completely random.  For example mutant EGFR leads to increased likelihood of 
EGFR gain and mutant KRAS leads to increased likelihood of KRAS gain but the mutation 
must precede the CNG (Gandhi et al., 2009). In addition, MASI is exhibited with the mutant 
allele almost always in excess compared to the wt but UPD MASI is less frequent than CNG 
(Gandhi et al., 2009). 
 
1.5.9 Germline genetics: Susceptibility Loci 
Multiple genome wide association studies (GWAS) have uncovered many regions associated 
with increased risk of lung cancer. One of the most significant associations seen for both 
smokers and non-smokers is to a region on chromosome 15q25.1 (Amos et al., 2008, Hung et 
al., 2008, Wang et al., 2008). This region is known to contain several genes (CHRNA5, 
CHRNA3 and CHRNB4) each encoding subunits of the nicotinic acetylcholine receptor, the 
latter having a known role in nicotine dependence. It is suggested that carcinogens N’-
nitrosonornicotine and nitrosamines found in tobacco may facilitate neoplastic transformation 
by stimulating angiogenesis and tumour growth by interaction with nicotinic acetylcholine 
receptors (Hung et al., 2008). Through the acetylcholine receptor pathway, cancer cell 
proliferation, survival, migration, invasion and angiogenesis are promoted (Amos et al., 
2008). The gene for proteasome alpha 4 subunit isoform 1 (PSMA4), a component of the 
ATP- and ubiquitin-dependent non-lysosomal pathway, also resides in this chromosomal 
region.  Unlike the nicotine dependence genes, PSMA4 does not have an obvious part to play 
in disease etiology and progression (Amos et al., 2008). 
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Other susceptibility loci that have been reported include a region on chromosome 5p15.33 
(McKay et al., 2008, Wang et al., 2008) containing the reverse transcriptase component of 
telomerase (TERT) (Weir et al., 2007). This is essential for telomerase synthesis and may 
allow cells to avoid senescence. CLPTM1L (cleft lip and palate transmembrane protein 1-like 
protein), a well conserved gene that induces apoptosis of lung cancer in genotoxic exposures, 
such as tobacco smoke, as well as enhancing cisplatin-mediated cell death when 
overexpressed (http://www.genecards.org). Both TERT and CLPTM1L are therefore 
excellent potential targets for therapy.  
Chromosome 6p21.33 has also been reported to be associated with risk of disease and within 
this region of association resides the candidate gene VEGFA that may be involved in 
angiogenesis (Weir et al., 2007, Wang et al., 2008). Other candidate susceptibility genes 
contained within 6p21.33 include BAT3 (HLA-B associated transcript 3), which is involved 
in apoptosis and acetylation of p53, and MSH5 (MutS Homolog 5), a mismatch repair 
(MMR) protein.  
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1.6 Treatment and Therapy 
Treatment of lung cancer is usually dependent on cancer type, stage, performance status and 
co-morbidities, such as Chronic Obstructive Pulmonary Disease (COPD), which may limit 
the patient’s tolerance to chemotherapy. 
Due to its early and rapid metastatic capacity, SCLC is regarded as a systemic disease, the 
cornerstone treatment of which is platinum-based chemotherapy. If diagnosed at an early 
enough stage, long term survival is achievable by consolidating chemotherapy with 
radiotherapy. If diagnosed when not “radically” treatable (late stage or extensive stage 
disease) treatment is palliative, aimed at improving quality of life and survival and is usually 
through chemotherapy. Although initially exquisitely chemo-sensitive, on relapse SCLC is 
relatively chemo-refractory and associated with poor survival. 
NSCLC treatment is dependent on Stage (see Section 1.2). For Stages I and II, surgery is 
preferable if the patient is medically fit. If not, radical radiotherapy is an alternative. 
Unfortunately this is unusual as early diagnosis of the cancer is rare. For Stage II and III 
tumours, adjuvant chemotherapy may be used after surgery to decrease the chance of relapse. 
Stage III tumours are usually treated with combined-modality therapy including 
chemotherapy and radical radiotherapy with-or-without surgery. For patients with Stage IV 
NSCLC, the main aim of treatment is palliation, to improve survival, control the cancer 
growth, and alleviation of symptoms through tumour shrinkage. Chemotherapy and small 
molecule kinase-inhibitor therapy are the main modes of treatment. 
Currently, the gold standard of chemotherapy for NSCLC is platinum doublet therapy where 
a platinum compound; a DNA cross-linking agent such as cisplatin (cis-
diamminedichloroplatinum (II)), is combined with another anti-mitotic (such as a nucleoside 
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analogue [gemcitabine], microtubule inhibitor [paclitaxel], topoisomerase inhibitor 
[etoposide/ camptothecin]) or a thymidylate synthase inhibitor, such as pemetrexed. 
 
Figure 1.10 Cisplatin cross-links DNA and in doing so interferes with cell division. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Wang and Lippard, 
2005), Copyright 2005. 
Cisplatin is one of the most potent anti-cancer therapies and displays significant clinical 
activity in many solid tumours. Cytotoxicity is generally mediated through apoptosis 
induction and cell cycle arrest resulting from its interactions with DNA (Figure 1.10). The 
DNA lesions cisplatin creates are intra-strand DNA adducts and mono-adducts, both repaired 
by the NER pathway, and inter-strand cross-links. All inhibit and block DNA replication 
resulting in cell death (Arora et al., 2010, Barr and O'Byrne, 2010). 
Cisplatin is one of the most commonly used chemotherapy agents for NSCLC in fit patients, 
and is generally given to the patient by intravenous injection at 75-80mg/m
2
 every 21 days 
usually in combination with another drug such as gemcitabine, for up to six cycles. Side 
effects include damage to the kidney and nerves, hearing loss, nausea and vomiting but the 
latter can be controlled with other drugs.  
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Targeted therapies have been designed and synthesized based on oncogenes identified to be 
important in NSCLC carcinogenesis, such as EGFR. EGFR inhibitors developed include 
gefitinib and erlotinib (see Section 1.5.1). 
Some NSCLC patients have intrinsically chemo-resistant disease while others become 
chemo-resistant during the treatment process, with disease that either progresses through or 
remains stable whilst receiving chemotherapy. In particular the molecular mechanisms 
underlying platinum-resistance are still largely unknown. Two to 30% of all NSCLC patients 
are inherently platinum resistant and disease still progresses during early cycles of platinum 
chemotherapy. It is possible the resistance is mediated by reduced intracellular accumulation 
of cisplatin, enhanced drug inactivation by metallothionine and glutathione, increased repair 
activity of DNA damage, decreased formation of DNA-platinum adducts, and altered 
expression of oncogenes and regulatory proteins (Adams and Harvey, 2010, Barr and 
O'Byrne, 2010). 
 
1.6.1 Molecular Mechanisms of Cisplatin Resistance 
The mechanisms of cisplatin resistance can be grouped into four categories of alterations; 1) 
those that involve steps preceding cisplatin binding to DNA, 2) those that directly relate to 
the binding of cisplatin to the DNA, 3) those concerning the lethal signalling pathway(s) 
elicited by cisplatin-mediated DNA damage, and 4) those affecting molecular circuitries that 
do not present obvious links with cisplatin-mediated DNA damage (Galluzzi et al., 2012). 
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1.7 Aims 
In order to understand the underlying features of the mechanisms resulting in chemo-resistant 
lung cancer and disease relapse, genomic approaches will be used, initially in immortalised 
cell lines and then in patient tissue, with the ultimate hope of identifying potential 
biomarkers. With this directed approach of controlled exposure to chemotherapy in 
immortalised cells, it is hoped that, by modelling in vivo conditions, important clinically 
usable biomarkers will be identified.  Any potential biomarkers will be investigated further 
and, ideally, confirmed in patient tissue.  
 Establish a cisplatin resistant in vitro cell model using the A549 NSCLC cell line. 
 Investigate different cisplatin dosing time courses to mirror standard treatment 
regimes. 
 Examine global gene expression changes over the dosing time course using 
microarrays. 
 Perform temporal expression clustering analysis to explore mRNA expression over 
the cisplatin dosing time course.  
 Explore potential co-regulation of genes through network analysis. 
 Develop any key findings from the in vitro model further by interrogating a set of 
platinum-treated patient tissue samples. 
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2 General Materials and Methods 
2.1 Materials 
2.1.1 Solutions and Reagents 
All solutions used in cell culture, MTT assays, and cisplatin dilutions were supplied by 
Sigma-Aldrich, UK, and prepared under aseptic conditions in a Class 2 microbiological 
safety cabinet [Biomat Class II] unless otherwise stated. All solutions and reagents used in 
DNA and RNA extraction and RNA processing for gene expression microarray analysis were 
provided by the manufacturers stated.  
 
Solutions used in Cell Culture 
Complete Media 
Dulbecco’s Modified Eagles Medium (DMEM) was supplemented with 4mM L-Glutamate, 
heat-inactivated 10% Foetal Calf Serum (FCS), 50000 units of Penicillin and 50mg 
Streptomycin and kept at 4
o
C until required. All supplements to DMEM were filter-sterilised 
first using a 0.2 plus filter cap (Sarstedt, Germany) and a suitably sized syringe. 
 
Trypsin-EDTA (10X) 
5.0g porcine trypsin and 2.0g EDTA were added to 1 litre 0.9% sterile sodium chloride 
(NaCl). For culture use, this solution was diluted 1:10 with Phosphate Buffered Saline (PBS). 
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Cell Freezing Medium – Dimethyl sulfoxide (DMSO) 




DMSO alone was also a reagent used for the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays (see Section 2.2.2). 
 
Cis-diamminedichloroplatinum(II) solution (Cisplatin) 
A ten ml volume of 1mM cisplatin solution was prepared by dissolving three milligrams of 
cisplatin powder in 0.9% NaCl. The solution was filter sterilized using a 10ml syringe with a 
0.2 plus filter cap before immediate use in cell culture experiments. 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
MTT powder was dissolved in Hanks Balanced Salt Solution (HBSS) to give a 100mg/ml 
solution.  This solution was used to access cell viability during generation of the cisplatin 
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A549 Cell Line 
A549 cells were obtained from American Type Culture Collection (ATCC, 
http://www.lgcstandards-atcc.org/). They are an adherent cell line that is alveolar basal 
epithelium in morphology with a population doubling time of approximately 22 hours. They 
were first developed in 1972 through the removal and culturing of cancerous lung tissue in 
the explant tumour of a 58 year old Caucasian male (Giard et al., 1973). The ATCC 
standardly conduct characterisation of genotype and karyotype of the parent cells prior to 
distribution. A549 is a hypotriploid human cell line with a modal chromosome number of 66, 
occurring in 24% of cells. Cells containing 64 (22%), 65, and 67 chromosomes occur at 
relatively high frequencies but ATCC have reported the rate of cells with higher ploidies is 
low (0.4%). There were six markers present in single copies in all cells, including der(6)t(1;6) 
(q11;q27); ?del(6) (p23); del(11) (q21), del(2) (q11), M4 and M5. Most cells were found to 
have two X and two Y chromosomes, although one or both Y chromosomes were lost in 40% 
of 50 cells analysed. Chromosomes N2 and N6 had single copies per cell; and N12 and N17 
usually had 4 copies (http://www.lgcstandards-atcc.org/products/CCL-185). Further 
information on the use of A549 cells can be found in Chapter 3 Section 3.1. A range of 
seeding densities have been used over the course of the experiments detailed in this thesis 
(Chapter 3 Section 3.2).  
 
2.2 Methods 
This section provides detailed information on the laboratory procedures carried out for this 
thesis. Unless otherwise stated, all practical work was carried out by the author and all 
centrifugations were carried out using a benchtop microfuge (Eppendorf 5424). 
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2.2.1 Cell Culture of A549 Cell Lines 
All cell culture work was conducted in a Class 2 microbiological safety cabinet [Biomat 
Class II] within a designated cell lines tissue culture laboratory using standard aseptic 
technique. Unless otherwise stated, all incubations took place in a RS Biotech Galaxy S 
incubator at 37
o
C with 5% carbon dioxide (CO2) 
The frozen aliquot of A549 cells were revived by rapid thawing in a 37
o
C water bath after 
which they were then added to 17ml of pre-warmed (37
o
C) complete media in a 75cm
2
 flat 
bottomed flask [Falcon]. Cells were allowed to revive further by incubating them for three 
hours during which time they started to adhere to the flask surface. After this, the cells were 
detached and reseeded in order to remove the dimethyl sulfoxide (DMSO) present in the 
cryoprotectant medium as it has an element of toxicity. The cells were detached using 10ml 
of 1X Trypsin-EDTA followed by an incubation of 5 minutes at 37
o
C after which the trypsin 
was neutralised by addition of an equal volume of pre-warmed complete media. Cells were 
then harvested by centrifuging the culture medium (containing the cells) for 4 minutes at 500 
x g [Heraeus®, Labofuge® 400R Centrifuge, Thermo Scientific].  The resulting supernatant 
was removed by suction and the pellet re-suspended in ten ml of complete media, and the 
required quantity of cells seeded in a 150cm
2
 flat bottomed tissue culture flask containing 
20ml of complete media. 
During the period of cell culture, media was changed every three days or, if the cell density 
was close to 85% confluence, the cells were passaged. To passage the cells, cells were once 
more detached from the tissue culture flask surface and then re-seeded at a lower density in a 
fresh 150cm
2
 tissue culture flask. Media was removed using a sterile pipette and cells then 
washed with 15ml of Phosphate Buffered Saline (PBS) which was then discarded. 10ml of 
1X Trypsin-EDTA was added to the flask and then incubated for a minimum of 5 minutes, or 
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until the cells were detached, at 37
o
C under CO2. Ten ml of complete media was added to the 
flask to neutralise the trypsin, and cells were then recovered by centrifugation (as detailed 
above). The resultant cell pellet was re-suspended in 10ml of media and 10µl of this re-
suspended cell solution was combined with 90µl of Trypan Blue to allow cell viability 
counting. 10µl of this mix was applied to a haemocytometer and the viable cells counted 
under the light microscope. Uncoloured, viable cells in all four large squares (highlighted by 
red boxes, Figure 2.1) of the haemocytometer were counted, summed, and averaged. The 





Figure 2.1  Diagram showing the haemocytometer layout under a light microscope. To calculate the 
number of cells present in a solution, the average cell count per square ([number of cells in square A + 




A suitable number of cells were taken from this volume and used to seed the required plate or 
flask. Depending on the use of the cells for the next procedure, this varied from 100,000 to 
two million cells. 
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For long-term cryopreservation of the cell lines, a number of cell aliquots were prepared and 
stored frozen under liquid nitrogen. Cells were allowed to reach 85% confluence before being 
pelleted as described above for passaging. They were then re-suspended in a sterile solution 
of 10% DMSO and 90% FCS. One ml aliquots were dispensed into one ml cryotubes that 
were then placed within a polystyrene box at -80
o
C for 24 to 48 hours to allow a process of 
slow freezing to minimise the formation of ice crystals that can disrupt cell integrity. After 
incubation at -80
o
C, the cell aliquots were transferred to liquid nitrogen for long term storage.  
 
2.2.2 Generation of Cisplatin-Resistant Cell Lines and Round Zero: IC25/IC50 Calculation 
An overview of the experimental design for cisplatin dosing of cells is shown in Figure 2.2. 
Chemotherapy naive A549 cells were split and seeded into 96-well plates at a density of 2.5 x 
10
3
 cells per well and incubated overnight. Taking the sterilised 1mM cisplatin (cis-
diamminedichloroplatinum (II)) solution (see Section 2.1.1) a range of cisplatin 
concentrations (0.01µM to 100µM) in complete media were prepared by serial dilution. The 
cells in the 96-well plate were treated in triplicate for each of the concentrations and 
incubated for 72 hours. Complete media only and cells with complete media (labelled M and 
M+C controls respectively) were also incubated for the same period of time.  
Immediately after incubation, cell viability was measured using the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Media with or without 
cisplatin was aspirated off the cells at the end of the 72 hours incubation. One hundred mg/ml 
MTT dissolved in HBSS was added to each well and incubated for approximately 45 
minutes. During this time, any viable cells present reduce the yellow coloured tetrazolium 
salt to formazole (purple coloured). Consequently the amount of formazole produced equates 
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directly to the number of viable cells present. MTT was then removed from the plate and 
DMSO was used to dissolve the formazole to enable absorbance readings to be taken at 
550nm and 595nm. The absorbance readings were then used to calculate the percentage 
survival compared to M+C controls. This was achieved by using the mean absorbance 
readings from all the M+C controls on the plate (n=3) as 100% survival for that plate and 
calculating survival of the other concentrations accordingly. IC50 values for dose response 
were calculated using GraphPad Prism version 5.03 for Windows (GraphPad Software, San 
Diego California USA, http://www.graphpad.com). For IC25 values, the IC50 value was 
simply halved. Once calculated, this value was used for the cisplatin dosage of the cells for 
the subsequent round (Round 1). 
Chemo-naive cells were seeded at a density of 2 x 10
6
 cells (approximately 70% confluency) 
for IC50 2 week recovery/3 week recovery/4 week recovery or 0.75 x 10
6
 well plates cells 
(approximately 50% confluency) for IC25 1 week recovery/IC50 2wk recovery.  Cells were 
allowed to adhere overnight. The following day, cells were treated with the correct IC value  
for 72 hours to generate Round 1 cells, after which, cells were washed with PBS and 
replenished  with complete media. For seeding densities of 2 x 10
6
 cells, splitting of cells was 
performed immediately post drug removal. 
Cells were allowed to recover in complete media, with replenishment with fresh media every 
three or four days. Cells were split when ≥ 85% confluency was attained. Recovery periods 
were maintained for all subsequent rounds of cisplatin dosing and after each recovery period 
cells were: 1) split into 96-well plates for Round 1 IC25/50 calculations by cisplatin dosing 2) 
seeded into 6-well culture plates (at 7.5 x 10
4
 cells per well), and cultured until >80% 
confluency for DNA and RNA extraction 3) transferred to a fresh flask of media for 
continuation of the round and future splits for drug treatment and 4) transferred into a fresh 
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flask for subsequent freezing of an aliquot of cell for long term storage in liquid nitrogen in a 
cryovial. 
The cells for continuation of the round were allowed to recover, reseeded at the correct 
density and were subject to the next IC25/50 cisplatin concentration, calculated from the 96-
well plate, for 72 hours (Figure 2.2).This generated the next round (Round 2) of cells. These 
successive rounds of cisplatin dosing, IC25/50 values calculation and DNA and RNA 
extraction continued until the IC25/50 values had increased five-fold. DNA was extracted 
alongside RNA to provide the option for further and future experiments, such as sequencing 
analyses across the time course (see Chapter 7 Section 7.1.4). 
The cells from the 6-well culture plate were subject to lysis and homogenisation. Six hundred 
µl of RLT Buffer [Qiagen, UK] containing 1% β-mercaptoethanol was added to each well 
and incubated for 5 minutes. To maximise lysis, a 200µl pipette tip was used to scratch the 
bottom of each well, before the solution of buffer and cell lysate was transferred to an 
autoclaved eppendorf tube and stored at -80
o
C prior to subsequent RNA extraction (Section 
2.1.4.1).   
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Figure 2.2 Flow diagram outlining repeated dosing of A549 cells with cisplatin. Figure shows the 
various time points for dose response and nucleic acid extraction. 1) 96-well plates used for 
concentration titrations and subsequent calculation of IC25/50 value using the MTT assay 2) DNA 
and RNA are harvested for future high throughput genomic investigations. 3) The same offspring cells 
subjected to the next round of cisplatin dosing. 4) Freezing of cells at each round for long term storage 
in liquid nitrogen. 
Parental cell lines split and seeded at 0.75x106/2x106
1) 96-well plate
Dose response to find IC25/50 
for surviving cells 
(Round 1 IC25/50 )
2) 6-well plate
Cells harvested











Surviving Round 1 cells treated with Round 1 
IC25/IC50 cisplatin dose for 72 hours. Cells 
allowed to recover for 1 week/3 weeks before 
split
1) 96-well plate
Dose response to find IC25/50 














Following day, cells treated with Round 0 IC25/IC50 
value of cisplatin  for 72 hours. Cells allowed to 
recover for 1 week/3 weeks before split
3) Flask
Surviving Round 2 cells treated with Round 2 
IC25/IC50 cisplatin dose for 72 hours. Cells 
allowed to recover for 1 week/3 weeks before 
split
Repeat rounds until 
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2.2.3 Global Gene Expression 
2.2.3.1 RNA Extraction from Cultured Cells 
Before starting any work involving RNA, all surfaces were wiped with 70% ethanol followed 
by RNase Zap [Sigma]. RNA Dedicated pipettes and pipette filter tips were used at all times 
to avoid contamination or RNA degradation. 
The lysed cells (Section 2.1.3) were carefully thawed on ice and then total RNA extracted 
according to manufacturer’s protocols using the RNeasy Mini Kit [Qiagen]. QiaShredder 
columns [Qiagen] were used to homogenise and shear the cells by applying the RLT 
buffer/cell mix to the column and centrifuging at 16,000 x g for 2 minutes.  An equal volume, 
600µl, of 70% ethanol was added to the QIAshredded lysates followed by mixing by 
inversion. The samples were successively passed through the column twice to bind the RNA 
by centrifugation (8,000 x g for 30 seconds). The flow-through was reapplied and spun under 
the same conditions to increase yield. The spin columns were washed with 600µl of buffer 
RW1 twice (8,000 x g for 30 seconds) and, again, to optimise yield, each flow-through was 
re-applied.  
Any DNA contamination in the sample was degraded by incubation with DNase-1. A stock 
solution of DNase-1 was prepared by dissolving solid DNase (1500 Kunitz units) in 550µl of 
RNase-free water. For each set of extractions, a solution was prepared using 10µl of this 
DNase-1 stock solution added to 70µl of RDD buffer, per sample extracted. 80µl of this 
DNase-1/RDD solution was placed in the centre of each spin column membrane before being 
incubated for 15 minutes at room temperature (approximately 20
o
C) on the bench. A further 
wash of 500µl buffer RW1 was performed with five minutes incubation at the same 
temperature. The spin column was centrifuged for 30 seconds at 8,000 x g before two washes 
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with 500µl of RPE, the first for 30 seconds at 8,000 x g and the second for four minutes at 
13,000 x g to allow the silica gel membrane to dry fully. RNA was eluted in 30µl RNase-free, 
Diethylpyrocarbonate (DEPC)-free water [Ambion, Invitrogen], with an incubation of five 
minutes at room temperature before three minutes at 13,000 x g. The flow-through was 
reapplied, incubated at room temperature for a further five minutes before another spin of 
eight minutes at 13,000 x g. This resulted in an increase in overall yield of approximately 
30%.  
The quantity and quality of the extracted RNAs were measured using a Thermo Scientific 
NanoDrop® ND-1000 UV-Vis spectrophotometer and the Agilent 2100 Bioanalyzer 
respectively. Microarray experiments require high quality RNA to obtain accurate, reliable 
results and an idea of quantity is needed for downstream procedures. A one in three dilution 
(using RNase- and DEPC-free water) was prepared using a 1µl aliquot of the RNA sample 
and 1µl of this dilution was used on the NanoDrop® to calculate the concentration in ng/µl, 
taking into account the dilution factor. The overall yield obtained was calculated using this 
concentration multiplied by the volume eluted from the spin column. 
 The Agilent Bioanalyzer chip combines micro-fluidics, capillary electrophoresis and a 
fluorescent dye (that binds to the nucleic acid) enabling one to access the quality and integrity 
of an RNA sample. An RNA ladder and 1µl of the one in three RNA dilutions, used for the 
NanoDrop® concentration calculations, were loaded onto the chip. The sizes and masses of 
the samples are determined as the fluorescence dye-RNA molecules complex pass through 
the micro-channels. Analysis of the resultant electropherogram calculates the area under the 
18S and 28S ribosomal RNA peaks to give a ratio that indicates the integrity and quality of 
the RNA, as well as providing an RNA Integrity Number (RIN). Only RNAs that had a 
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stringent RIN ≥ 8 underwent global gene expression. The electropherogram (Figure 2.3) can 
also be visually assessed for sample integrity/degradation. 
 
Figure 2.3 Example of an RNA electropherogram from the Agilent Bioanalyzer showing the two 
distinct peaks on the fluorescence versus time in seconds trace. The 18S peak is located at 
approximately 42 seconds while the 28S peak sits at approximate 49 seconds. No degradation is 
visible as shown by the lack of degradation products that would blur the distinction between these two 
peaks. 
 
2.2.3.2 RNA Preparation and Microarray Hybridisation for Global Gene Expression 
Analysis 
All incubations were carried out on a MJ Tetrad Thermocycler [Genetic Research 
Instrumentation (GRI)] to ensure uniform incubation temperatures. Samples were processed 
to fragmentation in batches of four or eight and from labelling to chip hybridisation in 
batches of 16 or 24, depending on the format of the array plate used. 
Each extracted sample RNA processed goes through cDNA synthesis of two strands, the 
second of which is subject to in vitro transcription (IVT) to generate anti-sense RNA 
overnight. Random primers are annealed to this anti-sense RNA, once it has been purified, to 
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generate a second cycle cDNA. The anti-sense RNA is then removed by hydrolysis and the 
remaining cDNA strand is purified ahead of fragmentation into small lengths. This is then 
subject to labelling, hybridisation to the microarray and subsequent washing and staining. 
Figure 2.4 shows the schematic of the basic protocol. 
 
Figure 2.4 Outline of the RNA Processing Protocol, adapted and redrawn from the Affymetrix 
GeneChip WT Terminal Labeling and Hybridization User Manual. 
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Two hundred nanograms of total RNA was used to synthesise double-stranded cDNA using 
the Ambion® Whole Transcript (WT) Expression Kit [Applied Biosystems, USA] according 
to the manufacturer’s protocols. This kit is optimized for use with human Affymetrix 
GeneChip® Arrays (http://www.ambion.com/techlib/prot/fm_4411973.pdf and 
http://media.affymetrix.com:80/support/downloads/manuals/wt_term_label_ambion_user_ma
nual.pdf). A Poly-A RNA control was added to the target total RNA sample to provide an 
exogenous positive control to monitor the entire target labelling process. Five µl of this RNA 
was subject to first strand cDNA synthesis through a reverse transcription procedure, where 
the RNA is primed with primers containing a T7 promoter sequence, with incubation for one 
hour at 25
o
C followed by a further hour at 42
o
C. DNA polymerase and RNase H were then 
used to simultaneously degrade the RNA and synthesise the second cDNA strand by 
incubating for one hour at 16
o
C followed by 10 minutes at 62
o
C.  IVT was performed using 
T7 RNA polymerase, overnight to produce and amplify the anti-sense cRNA. This required 
16 hours incubation at 40
o
C.  
The anti-sense cRNA was then purified of enzymes, salts, inorganic phosphates and 
unincorporated nucleotides to improve its stability, and the yield calculated using the 
Nanodrop® with size distribution confirmed to yield fragments of the correct size with the 
majority between approximately 800-1400 nucleotides, using the Agilent 2100 Bioanalyzer 
(Figure 2.5). 
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Figure 2.5 Example of a cRNA electropherogram. It can be seen that the two defined peaks seen in 
the total RNA sample (Figure 2.3) at 42 and 49 seconds no longer appear. Instead, two main less 
distinct peaks can be seen around 24 seconds and between 28-40 seconds, which is as expected for 
unfragmented cRNA. Most of these fragments in this second peak will be between 800-1400 
nucleotides in length. The presence of spikes within this second peak between 28-40 seconds is due to 
the enrichment of certain T7 RNA transcript lengths generated in the IVT reaction. 
Sense-strand cDNA was synthesised by reverse transcription of cRNA (10µg) using random 
primers. Two µl of the primers were annealed to the cRNA with incubation for five minutes 
at 70
o
C followed by five minutes at 25
o
C. The reverse transcription involves incubation with 
the reverse transcription enzymes for ten minutes at 25
o
C, followed by 42
o
C for 90 minutes 
then 70
o
C for ten minutes. RNaseH, a non-specific endonuclease, degrades the cRNA 
template in an incubation for 45 minutes at 37
o
C followed by five minutes at 95
o
C, to leave 
single-stranded cDNA, which was then purified as detailed for the anti-sense cRNA, yield 
calculated using the Nanodrop® and size distribution confirmed to be under 1000 nucleotides 
for the majority of fragments, using the Bioanalyzer (Figure 2.6). 
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Figure 2.6 Example of cDNA electropherogram from the Agilent Bioanalyzer. After the initial 
marker peak, approximately 22 seconds on the horizontal time axis, there is a clear single curve 
ranging from approximately 25-35 seconds, indicating the reduction in size of the cDNA from the 
cRNA (Figure 2.5). The majority now are smaller than 1000 nucleotides. This one clear round peak 
also shows the absence of the spikes observed due to the T7 RNA transcripts. 
The Affymetrix GeneChip® WT Terminal Labelling Kit was used to fragment 5.5µg of the 
prepared single-stranded cDNA. This was performed by incubating this cDNA with 10X 
cDNA fragmentation buffer, 10U/µl uracil-DNA glycosylase (UDG) and 1,000U/µl 
apurinic/apyrimidinic endonuclease 1 (APE1) for one hour at 37
o
C followed by two minutes 
at 93
o
C. The fragmented samples were once more analysed for size using the Bioanalyzer to 
ensure all transcripts after this reaction were short nucleotide fragments of between 40-70 
nucleotides (Figure 2.7).   
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Figure 2.7 Example of a fragmented cDNA electropherogram from the Agilent Bioanalyzer showing 
all RNAs present in the fragmented sample are of small size between 40-70 nucleotides, as shown by 
their short run time, between 21s and 27s on the horizontal time axis. 
The fragmented single-stranded cDNA samples were stored at -20
o
C until 16 or 24 had been 
prepared after which labelling by terminal deoxynucleotidyl transferase (TdT) using the 
Affymetrix proprietary DNA Labelling Reagent was performed by incubating at 37
o
C for one 
hour, followed by ten minutes at 70
o
C. The hybridisation cocktails and hybridisation 
efficiency controls were then added: 3nM of Control Oligonucleotide B2 and 20X Eukaryotic 
Hybridisation Controls (BioB, BioC, BioD, Cre). The hybridisation cocktails were denatured 
at 95
o
C for five minutes followed by 45
o
C for 5 minutes before being placed in the 
hybridisation plate.  
The GeneTitan® Instrument [Affymetrix] was prepared for the Gene 1.1 Sense Target (ST) 
Array Plates by preparing the wash buffers A and B and the stains 1, 2 and 3 (Table 2.1). The 
stain trays and covers used to hold the stains were static neutralised by using an anti-static 
gun that emits a stream of positive ionised air over the objects surface as the trigger is pulled 
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and a stream of negative air ions as the trigger is released. The required stain solutions and 
array holding buffer were placed in the necessary wells of the static-neutral trays and loaded 
into the GeneTitan® according to the manufacturer’s protocols, along with the array plate, 
the Scan Tray and the hybridisation plate containing the denatured hybridisation cocktail 
samples. Sample names and locations on the arrays were entered into the control portal to 
allow tracking and subsequent labelling of the data generated. The use of the GeneTitan® 
enables multiple samples to be run in parallel, hence samples being run in batches of 16 or 
24. Five runs in total were conducted to ensure complete coverage of the two chosen cisplatin 
dosing regimes; three runs used 16 array plates and two runs used 24 array plates. Each 
triplicate sample, prepared at the rounds of dosing during the treatment time course, was run 
for validation purposes. 
Reagent Amount Required for 
One Array Plate 
Number of Plates that can be Processed using the 
GeneTitan Hybridization, Wash and Stain Kit for 
WT Array Plates (P/N 901622) 
16-Format 24-Format 
Wash A 920 mL 1 1 
Wash B 300 mL 1 1 
Stain 1 and 3 105 μL/well 6 4 
Stain 2 105 μL/well 6 4 
Array Holding 
Buffer 
150 μL/well 6 4 
Table 2.1 Volumes required to process Gene 1.1 ST Array plates per run 
At all stages in the RNA processing pipeline, from extraction to microarray running, 
experiments were performed in batches. These were carefully recorded as any substantial 
batch effects can be corrected for during subsequent analyses. An example of a common 
batch effect occurs when samples that need to be compared are run across several array 
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plates; the fluorescence intensities between the array plates may not be the same, purely due 
to the difference in experimental variables, such as the array plate itself, and so batch 
correction is used to allow these comparisons to take place.  
 
2.2.3.3 Global Gene Expression Microarray Quality Control and Normalisation 
Raw intensity measurements of all probe sets were corrected for background fluorescence, 
normalised and converted into expression measurements using Affymetrix Power Tools 
(APT). The CEL files of microarrays were subject to probeset summarisation through robust 
multi-array averaging (RMA). Post processing was conducted in R Statistics v2.15 with 
associated packages, “Affy” and “Limma” [both Bioconductor, USA 
(http://www.bioconductor.org)] (Chapter 4 Section 4.2.2). 
 
2.2.3.4 Differential Expression Analysis 
Differential expression analysis was conducted in R with associated packages “Affy” and 
“Limma” (Linear Models for Microarray Data) [Bioconductor 
(http://www.bioconductor.org)]. Across the time courses, each transcript cluster’s RMA-
normalised expression at each and every time point was contrasted with every other in the 
dosing regime, i.e. in the IC50 Dose 3 Week Recovery regime time point 0 was contrasted 
with time points 1 to 10, time point 1 was contrasted with time points 2 to 10, time point 2 
was contrasted with time points 3 to 10 etc. until all points and genes were compared. This 
generated a T statistic for each gene and from all the T statistics, a moderated F statistic was 
generated taking into account all possible comparisons and allowing examination for any 
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significant change across the whole time course, giving a single test for each transcript cluster 
on the Gene 1.1 ST array. By using the F-distribution, the F-statistics generate p-values.  
The p-value for a particular gene is equal to the probability that the expression levels over the 
time course come from the same distribution therefore if it is small it infers significant 
differential expression. The overlap of the statistical distributions is important and will 
depend on the variances. Multiple testing and false positives may cause problems with these 
data sets as thousands of tests are performed. To avoid these potential pitfalls, the Benjamini 
& Hochberg (B-H) correction method was applied to control of the expected false discovery 
rate (FDR), which sets the probably of a false positive. A threshold FDR-adjusted p-value of 
less than or equal to 1E-08 were used for cell culture experiments in order to reduce the 
number of genes taken through to further analysis to a more manageable number, 
approximately 1,500 genes (Chapter 4 Section 4.3). 
 
2.2.3.5 Temporal Expression Profiling by Fuzzy C-means Clustering 
For fuzzy c-means clustering, data that were summarised at the transcript cluster level were 
imported into R. C-means clustering was used to group the significantly differentially 
expressed transcripts into discrete and stable clusters of time series data using the “Mfuzz” 
package [Bioconductor (http://www.bioconductor.org)]. C-means clustering allows each 
transcript to belong to a particular cluster to a certain degree or weighting; it is either strongly 
or weakly associated with a cluster, it does not sit within a cluster. This allows smaller 
changes to be detected than the more stringent and ubiquitous hard k-means clustering. 
The genes in each cluster were analysed using Database for Annotation, Visualisation, and 
Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov) (Dennis et al., 2003) to provide 
Page | 75 
 
Gene Ontology (GO) term enrichment analysis, functional annotation clustering as well as 
details of the gene families found within the annotation clusters (Chapter 4 Section 4.4). 
 
2.2.3.6 Weighted Gene Co-expression Network Analysis 
The differential gene expression data generated in Chapter 4 Section 4.3 has also been subject 
to weighted gene co-expression network analysis (WGCNA [Langfelder and Horvath, 2008]) 
in order to provide insights into potential signalling pathways of interest and suggest genes 
that may act as hubs. It allows correlation patterns among genes across microarray samples to 
be described and find modules strongly correlated to traits of interest as well as highly 
interconnected genes that may be potential hubs. In this work the trait of interest used was the 
IC25 or IC50 value, depending on the dosage used for that particular time course. Genes 
within each module were analysed using DAVID to provide GO term enrichment analysis, 
functional annotation clustering as well as details of the gene families found within the 
annotation clusters, if appropriate (Chapter 5 Section 5.2). 
 
2.2.4 DNA Extraction from Cultured Cells 
DNA extractions were performed according to manufacturer’s protocols [Qiagen]. DNA was 
extracted from harvested cells using the QIamp Mini Kit. The harvested cell pellet was 
subjected to Qiagen protease action and cell lysis using buffer AL before incubation at 56
o
C 
for 10 mins. The lysed cells then underwent ethanol precipitation and multiple washes in spin 
columns using buffers AW1 and AW2 to bind the DNA to the column. Elution was 
conducted with buffer AE and the eluted DNA was stored at -20
o
C until use in further 
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analyses. The quantity of the extracted DNA was measured using the Thermo Scientific 
NanoDrop®.  
 
2.2.5 Lung Cancer Patient Tissue Work 
Samples were obtained from two sources for use in this thesis; RESTORE-AIR – 
Randomised Evaluation of STents to Open REstricted AIRways in patients with centrally 
placed non-small cell lung cancer, and EQUALITY – Expression QUAntitative trait Loci 
mapping In Tumours collected at biopsy. Information pertaining to these two studies can be 
found in Chapter 6 Section 6.2 and Section 6.3 respectively. Results from tissue extraction 
are described in Chapter 6 Section 6.4. The combination of these two datasets to allow 
comparisons between platinum treated versus non-platinum treated patients as well as the 
necessary outlier detection and removal and microarray quality control is detailed in Chapter 
6 Section 6.5. Differential expression analyses conducted were similar to those outlined in 
Section 2.2.3.4 and is defined in Chapter 6 Section 6.6.  
 
2.2.5.1 Collection of Patient Tissue and RNA Extraction 
After obtaining the clinical diagnostic sample from rigid bronchoscopy or biopsy, three sets 
of research biopsies were taken. Tumour tissue and paired normal carina tissue were biopsied 
and immediately placed in RNAse inactivation buffer (RNAlater [Qiagen]). A second set of 
tumour and paired normal tissue were snap frozen in liquid nitrogen and subsequently stored 
at -80
o
C. A final set of tumour and paired normal tissue were subsequently fixed and 
processed by routine methods (Formalin-Fixed Paraffin-Embedded [FFPE]) in the hospital 
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Histology Department. Rigid bronchoscopy can only access proximal tumours and thus, most 
tumours were either squamous NSCLC (majority) or SCLC. 
The extraction of total RNA from patient lung tissue involves the same overall steps as 
outlined in Section 2.2.3.1, i.e. lysis and homogenisation, Proteinase K digest, total RNA 
binding, wash and DNase digest, and elution of the RNA. 
Each sample was thawed from -80
o
C storage and weighed to determine its size. Three 
hundred µl of RLT lysis buffer [QIAgen], containing 1% β-Mercaptoethanol [Sigma], was 
added to the tissue before homogenisation with the TissueRuptor. The sample was subjected 
to several 30s homogenisations up to a maximum of five with the sample being held on ice in 
between bursts until the lysate was uniformly homogeneous. 90µl of RNase-free water was 
added to the lysate along with 10µl of Proteinase K solution [QIAgen], mixed thoroughly 
before incubation at 55
o
C for two hours. 
After the incubation, the samples were centrifuged at 13,000 x g for three minutes at room 
temperature. The supernatant (900µl) was transferred into a new microfuge tube and 450µl of 
100% ethanol was added and mixed by pipetting. Seven hundred µl of the sample, including 
any precipitate formed, were placed in an RNeasy mini spin column inside a 2ml collection 
tube and centrifuged at room temperature for 15s at 8,000 x g. The flow through was 
discarded, the remainder of the sampled added to the RNeasy mini spin column and the 
centrifugation repeated. 350µl of Buffer RW1 was used to wash the spin column by 
centrifugation for 15s at 8,000 x g at room temperature. A DNase digest followed as detailed 
in Section 2.2.3.1. A further wash of the spin column with 350µl of Buffer RW1 followed 
using the same centrifuge settings and the flow through was discarded. The spin column 
membrane was further washed with 500µl of Buffer RPE by centrifugation for two minute at 
8,000 x g at room temperature. The spin column was then transferred to a new collection tube 
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and centrifuged at full speed for one minute to dry the membrane and reduced the possibility 
of carrying any Buffer RPE over. The bound RNA was eluted from the spin column by the 
addition of 50µl of RNase-free water to the membrane, followed by centrifugation for one 
minute at 8,000 x g. 
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3 Generation and Optimisation of a Model of Cisplatin Resistance 
using A549 Cells 
3.1 Introduction to Cell Culture Models 
Model systems using different types of tissue culture to investigate the biology behind 
various conditions in vitro are well known. There are various types of culture, each with their 
own advantages and disadvantages (Masters, 2000). A primary culture is created by directly 
taking tissue from an individual, and then extracting and growing cells from it in vitro. It is 
possible to create a cell line so that, once transferred to a subsequent culture flask, a relatively 
uniform population of proliferative cells will emerge as a result of selection. They will 
continue to grow until the end of their natural proliferative lifespan but senescence will occur. 
Little tissue-specific differentiation occurs during proliferation, although functional tissue 
may be regenerated, given the correct signals. These normal cells have a limited lifespan in 
culture so they can only be used over a short period before they senesce. 
If dealing with cancerous tissue, the cells can provide a snapshot of the tumour at the time of 
biopsy and be representative of the cells that divide when the tissue of origin is wounded. In 
spite of the fact that cancer cells express telomerase and so can elongate their telomeres, 
potentially delaying the inevitable senescence observed with normal cells. They cannot be 
cultured easily and potentially still senesce anyway, so transfection with viral gene products 
is common to extend their lifespan. These products can sequester genes of the cell, such as 
p53 and Rb, thereby increasing potential passage numbers. The similarities seen between this 
immortalisation of cell lines and carcinogenesis are evident as the cell lines begin to acquire 
the hallmarks of cancer (Chapter 1 Section 1.4).  Only highly aggressive cancer cells have 
accumulated enough genetic changes required for unlimited growth in vitro (Masters, 2000). 
These continuous cancer cell lines, such as the A549 cells used in the investigations outlined 
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in this thesis, need to be grown with commercial tissue culture medium containing FCS, 
which supplies the source of nutrients such as hormones and growth factors that are needed 
for the cells to grow and proliferate. Cancer cells from tissue can be extremely difficult to 
grow in culture. In spite of their apparently limitless growth potential, it is sometimes easier 
to generate a normal tissue cell line than one from the cancer cells themselves. Invariably, 
only metastatic cancers can be established as a continuous cell line as they have gathered 
sufficient number of driver mutations to undergo continued uncontrolled growth.  
Although few studies have examined the representativeness of cancer cell lines with their 
tumours of origin, direct comparisons have been made with respect to genotype and 
phenotype. These have revealed that cultures retain many properties from the corresponding 
tumour for long periods, with reports of NSCLC cell lines retaining properties for a median 
period of over three years (Wistuba et al., 1999). Gene expression studies have revealed 
consistent similarities between cell lines from the same origin and consistent differences 
between cell lines of different origins. Even drug sensitivity has been shown to be retained in 
cisplatin-hypersensitive testicular cancer cells (Walker et al., 1987). Cell line models 
however tend not to represent the variety and heterogeneity of cancers seen in the clinic. As 
cell lines require multiple changes to enable growth in vitro, late stage, fast growing, poorly 
differentiated tumours tend provide continuous cell lines (Masters, 2000).  
Cell lines do provide a virtually unlimited supply of cells with similar genotype and 
phenotype. Their use therefore avoids variation between individuals and bypasses ethical and 
potential cost issues associated with their equivalent in vivo experiments. The use of a cell 
line also allows the investigator more control over variables, such as drug exposure, than 
would be possible in animal or human systems. As culture systems become more advanced, a 
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greater proximity and similarity to the organism of interest is possible, as seen with three-
dimensional tissue culture. 
The established A549 cell line is widely used as an in vitro model for type II pulmonary 
epithelial cell models for drug metabolism and so provides a suitable model system to 
examine the genetic responses of lung tumours to chemotherapy. Details on A549 cell line 
genotype and karyotype can be found in Chapter 2 Section 2.1.1. Further important genetic 
information about generic A549 cells, including potentially cancer-causing mutations 





CDS Mutation Somatic Status Zygosity Vaildated 
905949 CDKN2A p.0? c.1_471del471  
Reported in 
another cancer 









905949 KRAS  p.G12S c.34G>A 
Reported in 
another cancer 
sample as somatic 
Homozygous Verified 




905949 STK11 p.Q37* c.109C>T 
Reported in 
another cancer 
sample as somatic 
Homozygous Verified 
Table 3.1 Table indicating the known and verified cancer point mutations in A549 cells (Catalogue of 
Somatic Mutations in Cancer – Wellcome Trust Sanger Institute). AA mutation = Amino acid 
mutation, CDS mutation = coding sequence mutation. 
A549 cells have been used in the investigations in this thesis due to them being a manipulable 
system that can be exposed to the conditions under exploration. They are resilient and will 
grow for several passages and potentially in sub-optimal conditions. They have been used in 
many studies into various lung conditions including other lung cancer models. Antibiotics 
were added to the media to enable the long term passage of the cells, as required for 
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performing repeated measures on the successive generations, without the risk of acquiring 
infections. While the use of primary cancer cell culture, grown from a biopsy of tumour 
tissue, would provide a different system in which to characterise the potential response to 
chemotherapy, A549 cells provide an easy-to-set up, replicable, low-cost model that can 
survive for several months to provide the platform for the long time courses outlined in this 
chapter. 
 
3.2 Optimisation of Repetitive Cisplatin Dosing and Associated 
Techniques 
In order to establish the cell model, a number of variables had to be optimised. At the time of 
cell model initiation, there was little in the published literature on increasing cisplatin 
resistance in lung cancer cell lines through incremental steps over time. Comparisons were 
therefore drawn from other cell models; Li et al., (2009) induced cisplatin resistance by 
subjecting a single cisplatin-sensitive clone of the ovarian cancer cell line A2780 to multiple 
cycles of increasing doses of cisplatin. Cells were treated to three hour incubations of a range 
of cisplatin doses from 0.5 to 100 µM, allowed to recover for three days before the next 
round of cisplatin dosing. MTT assays were used to determine cell viability and subsequent 
dose response curves. This basic outline of a method was used as the starting point for the 
experiments carried out. 
As per standard protocols within the Molecular Genetics and Genomics Section (NHLI), cells 
were seeded at a density of 2.0 x 10
5
 cells per well, followed by a 24 hour starvation step 
before drug dosing commenced. For the treatment of cells with 1mM cisplatin dissolved in 
0.9% NaCl solution (Chapter 2 Section 2.1.1), different solutions were used, including 0.9% 
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NaCl solution alone as it would be administered in a clinical setting, or as an addition to 
serum-free media (SFM). Concentrations of the drug ranging from 0.1µM to 300µM and 
were performed in triplicate. MTT assays were performed both immediately after drug 
removal and 24 hours later. Each dose response plate was normalised to the controls (cells 
with drug vector only) for that particular plate (Figures 3.1 and 3.2). It can be seen that the 
MTT performed 24 hours after the end of the incubation with cisplatin using either drug 
vector led to a decrease in cell viability at the higher drug concentrations. This may be 
indicative of the cisplatin impacting the viability of the cells some time after their incubation. 
Comparison between  Immediate  MTT
and 24hrs after Incubation MTT - 0.9% NaCl

































Figure 3.1 Dose response with cisplatin in 0.9% NaCl solution after a 3 hour incubation for the 
concentration range 0.1µM to 300µM.  
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Comparison between  Immediate  MTT
and 24hrs after Incubation MTT - SFM

































Figure 3.2 Dose response for cisplatin in serum free media (SFM) after 3 hour incubation over a 
range of concentrations from 0.1µM to 300µM. Minimal difference was observed between the MTT 
performed immediately after incubation and 24 hours later for the lower concentrations of cisplatin 
below 30µM but a divergence in viability seems to occur at the higher concentrations. 
When 0.9% NaCl solution was used for drug delivery, problems arose during aspiration with 
apparently viable cells, both treated and untreated with cisplatin, (purple following MTT 
application) failing to remain adherent to the bottom of the plate. Using SFM instead of 0.9% 
NaCl solution for cisplatin delivery appeared to solve both these problems. From Figure 3.3, 
it can be seen that cells treated with cisplatin using SFM have a range of viability across all 
drug doses trialled. The desired gradual decrease in viability at the higher cisplatin 
concentrations, seen to a slight but insufficient extent in the 24 hours MTT data in Figure 3.2, 
is not evident.  
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24 hour incubation
































Figure 3.3 Dose response of cells seeded at 0.1 x 10
6
 cells per well with triplicate cisplatin 
concentrations in SFM incubated for 24 hours. Data shown is mean survival (n=3) with standard error 
of the mean (SEM) error bars. There appears to be little change in cell viability (survival compared to 
controls) across the cisplatin concentrations as almost all the error bars overlap one another.    
 
3.2.1 Variability due to Seeding Density 
Another variable that required optimisation was cell seeding density. It is possible that 
difference in the initial number of cells present on cisplatin application could vary their 
subsequent survival; if they are stressed, such as over-confluence, before cisplatin exposure, 
they may not respond to the drug in the same way. Cell seeding was therefore decreased to 
2,500 cells per well to ensure the cells were less than 70% confluency at the time of drug 
dosing; this also approximately matched the work done by Li et al., (2009). In reducing the 
seeding density, complete media could also be tested as a drug delivery method, and thus 
allow the cells being treated with cisplatin to be more representative of the in vivo 
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environment, i.e. fed with the normal nutrients required for growth, without the potential 
problem of over-confluence. 
Cisplatin was dispensed in complete media and untreated cells were maintained in the same 
complete media over the period of incubation, which was also extended to 72 hours. Cells 
were seeded the day before drug treatment and unlike previous experiments, no serum-
starvation step was performed in an attempt to replicate an in vivo situation and to see if this 
had an impact on cell viability. MTT assays were carried out immediately after drug removal. 
Although there was a dramatic improvement in the results obtained through the 
implementation of these changes, it was still found that control cells failed to survive better 
than some of the lower cisplatin concentrations (Figure 3.4). This was rectified by adding a 
one well exclusion zone, filled with PBS, around the edge of the 96-well plates used in 
cisplatin dosing in order to prevent evaporation of media or cisplatin solutions. In addition to 
this, an extra media only and Media + Cells (M+C) control was added to the central region of 
the plate (Figure 3.5). 
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Trial of New Conditions































Figure 3.4 Dose response using new conditions of 2,500 cells per well, 72 hour incubation with 
cisplatin in complete media with MTT performed immediately after drug removal. Error bars show 
SEM, where n=6. The percentage survival of cells at the higher concentrations of cisplatin reflects the 
burden of the drug on replicating cells. The data here could also imply that cells exposed to low 
concentrations of cisplatin appear to survive better than controls in complete media. 
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Figure 3.5 Ninety six well plate maps indicating well contents for the cisplatin dosing. During optimisation experiments, evaporation from wells 
had been found to be problematic. Therefore to prevent evaporation from the experimental wells, the outer wells (shaded in grey) of both 96 well 
plates were filled with 200µl PBS [Sigma-Aldrich, UK]. Untreated cells were used for the Control wells labelled Media + Cells (M+C). These 
wells were used for percentage survival comparisons (calculated by the MTT assay) for the IC25/50 calculation.  
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As these conditions yielded such an enhancement on previous attempts, they were used as the 
basis for all future cisplatin incubations. These changes enabled IC50 values to be calculated 
with ease due to the alteration in survival across the cisplatin concentration titration. In spite 
of this, repeats of cisplatin dosing on chemo-naive A549 cells found there were 
inconsistencies in IC50 values obtained.  It was therefore decided to investigate the stability 
of the cisplatin (Section 3.2.2).  
 
3.2.2 Cisplatin Stability 
Cisplatin is a light sensitive compound and degradation can occur after storage. It was 
established that, after just three or four days of storage, large differences in IC50 value were 
observed. As can be seen from Figures 3.6 and 3.7, Round 0 IC50 value was found to differ 
by 7µM between a fresh cisplatin solution and one prepared a few days earlier. Consequently, 
for all subsequent experiments cisplatin concentrations were made up fresh on the day of 
treatment. 
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Round 0 - Three day old cisplatin solution
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Figure 3.6 IC50 calculation showing drug degradation leading to apparently increased Round 0 IC50 
value (12µM) compared to that calculated from multiple experiments with freshly prepared cisplatin 
(Figure 3.7). This is one example of the typical results obtained before realisation of the problems 
observed with cisplatin (n=2 with SEM error bars). Each cisplatin concentration was performed in 
triplicate for the dose response and normalisation was done for each plate individually before mean 
calculation and plotting. 
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Round 0 - Freshly prepared  cisplatin solution
































Figure 3.7 IC50 calculation showing Round 0 IC50 = 5µM (n=6, with SEM error bars). For all these 
experiments cisplatin was prepared fresh on the day of treatment. Each cisplatin concentration was 
performed in triplicate for the dose response and normalisation was done for each plate individually 
before mean calculation and plotting. 
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3.3 Trials of Dosing using Optimised Conditions 
After successful optimisation of the basic protocol for the cisplatin dosing, the rounds of drug 
dosing of the cells commenced (Chapter 2 Section 2.1.3). Cells were seeded at a density of 
2.0 x 10
6
 cells per flask (approximately 70% confluency at time of drug treatment) and dosed 
with the IC50 value (calculated by the MTT assay) commencing with a concentration of 5µM 
for the chemo-naive (Round 0) cells. After 72 hours incubation, the cisplatin was removed 
and the cells were split, and allowed to recover for various lengths of time: 4 days, 1 week, 2 
weeks, 3 weeks and 4 weeks. Recovery was assessed by studying the cells return to normal 
growth patterns (Figures 3.8 – 3.10). It was observed that normal cellular growth did not 
restart within one week and therefore, at this stage, four days and 1 week recovery periods 
were discontinued. Figure 3.8 shows an example of how normal, chemo-naive cells appear 24 
hours after cell splitting. Figure 3.9 shows an example of how stressed cells appear after ten 
days of recovery whilst Figure 3.10 shows stressed cells with some patches of normal growth 
occurring, again at ten days recovery.  
 
Figure 3.8 Normal cells 24 hours after split (seeding density of 2 x 10
6
 cells) showing healthy growth, 
with fairly uniform shape, size and structure. Taken at 10x magnification. 
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Figure 3.9 Cells at ten days recovery showing stressed characteristics, including elongation, loss of 
defined structure and granularisation, which may be indicative of transition from an epithelial to a 
mesenchymal morphology. Cells were originally seeded at a density of 2 x 10
6
, which was followed 
by drug dosing with Round 0, IC50 = 5µM. Taken at 10x magnification. 
 
 
Figure 3.10 Cells at ten days into recovery. Originally cells were seeded at a density of 2 x 10
6
, which 
was followed by Cisplatin dosing with the Round 0, IC50 = 5µM.  Stressed cells can be observed (A) 
with similar characteristics to those seen in Figure 3.9, alongside patches of normal growth (B) 
similar to that seen in Figure 3.8. Taken at 10x magnification. 
B 
A 
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Cell seeding densities were then tested with the shortest remaining IC50 recovery time (2 
weeks) by using  0.75 x 10
6
 cells per flask (<50% confluency at drug dosing, Figure 3.11) as 
well as the  2 x 10
6
 cells per flask (70% confluency at drug dosing).  
0.75 x 106 Cell Seeding  Density - IC50 Round 1
































Figure 3.11 0.75 x 10
6
 seeding density. IC50 Round 1 calculation (IC50 = 11.5µM, n=2) after 2 
weeks recovery post Round 0 IC50 = 5µM dosing. Each cisplatin concentration for dose response has 
been performed in triplicate and normalised to the mean survival of the control cells grown in 
complete media per plate. Error bars show SEM. 
As it had previously been reported in a study of A549 cells that IC50 dosing was too toxic for 
continued cell growth (Barr and O'Byrne, 2010), and dosing with IC25 concentration was 
also investigated   Unlike IC50 dosing where 4 days and one week recovery periods did not 
result in restoration of normal cellular growth, it was found that for IC25 dosing (seeding at 
0.75 x 10
6
 cells per flask) recovery did occur within 1 week (Figure 3.12). 
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IC25 Round 3
































Figure 3.12 0.75 x 10
6
 seeding density. IC25 Round 3 calculation (IC25 = 7µM, n=2) after 1 week 
recovery post Round 2 IC25 = 4µM dosing. Each cisplatin concentration for dose response performed 
in triplicate and normalised to the mean survival of the control cells grown in complete media per 
plate. Error bars show SEM. 
Comparisons between the two seeding densities tested revealed a gradual (if not significant) 
increase in IC50 value across the rounds (linear regression analysis in Prism – 0.75 x 106 cell 
seed p-value = 0.3117, r
2 
= 0.2507; 2 x 10
6
 cell seed p-value = 0.0713, r
2 
= 0.5978). More 
deviation between the rounds especially for the 0.75 x 10
6
 seeding was seen compared to the 
IC25 values (Figure 3.13). 
To investigate any potential differences in resulting IC50 values due to the cell seeding 
density, a Friedman’s test was performed on the data. This showed no significant difference 
over the period of five completed rounds of cisplatin treatment (Friedman chi-squared = 0.2, 
p-value = 0.6547). 
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Seeding  Density Comparison



















Figure 3.13 Comparison of 0.75 x 10
6 
cell seed and 2 x 10
6
 cell seed over five rounds of IC50 dosing. 
IC50 values plotted from two separate cisplatin dose responses at each round. 0.75 x 10
6
 cell seed p-
value = 0.3117, r
2
 = 0.2507; 2 x 10
6
 cell seed p-value = 0.0713, r
2
 = 0.5978. 
When comparing the different recovery periods initially, 2 weeks, 3 weeks and 4 weeks 
(Figure 3.14), a gradual increase in IC50 was observed for all three. The most notable 
increase and the only one showing statistical significance was the 3 week recovery, where 
IC50 increased from 5µM at Round 0 to 20µM at Round 5 (p-value = 0.0287, r
2
 = 0.7367). 2 
week recovery and 4 week recovery (p-value = 0.4107, r
2
 = 0.2325 and p-value = 0.7396, r
2
 = 
0.04243 respectively) had more gradual increases in IC50 values but similar to the results 
from the seeding density comparison (Figure 3.13), large fluctuations were seen between 
Rounds 2 and 4.  
Using the non-parametric Friedman’s test (R Statistics v.15.1), it was found that there was no 
significant difference between the three different recovery periods (Friedman chi-squared = 
0.1333, p-value = 0.9355) and paired Wilcoxon Signed Rank tests between each of the 
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regimes (2 week versus 3 week, 3 week versus 4 week, and 2 week versus 4 week) also 
revealed no statistical significance between the different regimes (2 week versus 3 week – p-
value = 0.8551; 3 week versus 4 week– p-value = 1; 2 week versus 4 week – p-value = 
0.4227). 
Based on these findings, the IC50 dosing with 3 weeks recovery time course was selected for 
the model. As it is likely that different dosing schedules may incur different genetic changes 
over the time of treatment and therefore be useful models of different clinical situations the 
IC25 dosing with 1 week recovery was also run in parallel. Both models were run until their 
IC values had increased four-fold. The mean IC values for all data obtained from the two cell 
culture models are given in Table 3.2. 
Recovery  Period  Comparision




















Figure 3.14 Comparison of 2 week, 3 week and 4 week recovery periods over four to five rounds of 
IC50 dosing. IC50 values plotted from two separate cisplatin dose response curves at each round. 
Linear regression analysis (Prism); 2 week recovery p-value = 0.4107, r
2
 = 0.2325; 3 week recovery 
p-value = 0.0287, r
2
 = 0.7367; 4 week recovery p-value = 0.7396, r
2
 = 0.04243. 
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Table 3.2 Details of mean IC50 and IC25 values calculated for each round of cisplatin dosing under all conditions tested. All values are given in µM. See 
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3.4 Increasing Cisplatin Resistance 
A consistent gradual trend has been observed in the IC25 dose 1 week recovery schedule 
(Table 3.2 and Figure 3.15) with the increase from IC25 = 2.5µM at Round 0 to IC25 = 
10µM after fifteen doses of cisplatin. A statistically significant positive correlation between 
the number of cisplatin doses and increase in IC25 value was detected (linear regression 
analysis [Prism, GraphPad], p-value = 2E-04, r
2
 = 0.6342). 
IC25 Dosing  1 Week  Recovery














Figure 3.15 Plot of the mean for IC25 values from the cisplatin dose response at each time point from 
chemo-naive cells round 0 to round 15. A significant increase in IC25 value can be seen from 2.5µM 
to 10µM (p-value = 2E-04, r
2
 = 0.63). 
 
Page | 100  
 
A four-fold increase of IC50 after a total of ten rounds was observed (Figure 3.16) in the 
IC50 dose with 3 weeks recovery between each round of cisplatin treatment. Chemo-naïve 
cells at Round 0 had an IC50 = 5µM that incremented to 21µM at round 10. As with the IC25 
dose 1 week recovery schedule, a statistically significant positive correlation between the 
number of cisplatin doses and increase in IC50 value was detected (linear regression analysis 
[Prism, GraphPad], p-value = 6E-04, r
2
 = 0.7508).  
IC50 Dosing 3 Week Recovery
















Figure 3.16 Plot of the mean for IC50 values from the cisplatin dose response at each time point from 
chemo-naïve cells round 0 to round 10. A significant increase in IC50 value can be seen from 5µM to 
21µM (p-value = 6E-04, r
2
 = 0.75). 
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3.5 Chemo-naïve Normal Cell Time Course 
Extensive in vitro cell culture over a long time period may cause global gene expression 
changes in its own right and it is important to take these in to consideration. One would 
anticipate that the largest and most significant fold changes in gene expression in the cell 
model will be due to the cisplatin exposure due to the selection pressure applied by the 
presence of the drug during growth over a period of time.  
To provide a control for the changing genomics of the A549 cell line over numerous rounds 
of normal cell culture, a time control was therefore set up. DNA and RNA from chemo-naïve 
cells were extracted at the same time intervals and approximately the same cell passage as for 
the cells subjected to successive rounds of cisplatin exposure in the IC50 dose 3 week 
recovery time course. 
 
3.6 Discussion 
The development of the two time courses of cisplatin dosing through optimisation of a 
multitude of variables outlined in this chapter has made it possible to steadily increase the 
dose of cisplatin required to inhibit cellular growth by 25% or 50%. Many obstacles to the 
initial set-up of this model and their subsequent solutions will make the products (DNA and 
RNA extracted at each treatment round) of this robust model of cisplatin treatment useful for 
future genomic analyses including those presented in the forthcoming chapters of this thesis. 
Both DNA and RNA from cell aliquots taken from each round of dosing were extracted (as 
described in Chapter 2 Sections 2.2.3.1 and 2.2.4) at the same time as the next cisplatin dose 
was applied to the cells. The cells of this next round were then allowed to recover prior to 
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determining the new IC value. This synchronisation should give an idea of the environment 
within the cells at the time of treatment. 
The final cisplatin time courses chosen involved a 72 hours incubation period with the drug at 
either IC25 or IC50 concentration. After this incubation the cisplatin was removed and the 
cells allowed to recover before the next IC25 or IC50 concentration was calculated, either 1 
week or 3 weeks later, respectively. Subsequent to the establishment of this cellular model, a 
paper has been published that suggests that 24 hours after 24 hours of cisplatin treatment 
would be a suitable point at which to investigate the effects of cisplatin within in the cell 
(Barr et al., 2013). In this paper they explored the biochemical and physiological properties 
of cisplatin within resistant cell lines compared to age-matched parent cell lines and 
discovered some interesting findings. In comparisons between resistant cell lines compared 
with the equivalent parent, chemo-naïve cells, those exposed to cisplatin constantly overcame 
the drug’s effects through reduced cisplatin-GpG adduct formation, enhanced DNA double 
strand breakage repair, decreased cisplatin induced apoptosis, and reduced cellular uptake of 
cisplatin. There also appeared to be an accumulation of cells in the G0/G1 phase of the cell 
cycle in the cisplatin-resistant cell lines compared to the parents, showing a move towards a 
stem cell phenotype with markers of EMT up-regulated. This will be discussed further in 
Chapter 7 Section 7.1. It would be interesting to compare the differences, if any, between 
varied incubation times with the drug. A possible expansion of this model, combining the 
methods from the Barr et al. paper (2013) would be to perform shorter incubations with 
cisplatin, between 6 and 24 hours, and to extract DNA and RNA immediately after the 
incubation was complete. The immediate surviving cells from these short incubations would 
hopefully contain more viable cells and so be amenable to DNA and RNA extraction at that 
time. 
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There will be many points to consider when exploring the data from these treated cells as 
evolutionary populations have been generated over the time courses. When cells are split, be 
it for dose response curves, cisplatin treatment, DNA or RNA extraction, or flask seeding for 
the continuation of the resistant line, the cell will not be genetically uniform. The underlying 
differences between the cells, though probably small, may cause some of the variation, seen 
in IC50 and IC25 values, observed at each time point (Figures 3.15 and 3.16). In some ways, 
this slight genetic diversity in the model may mimic the genetic heterogeneity of a tumour in 
the clinical setting as not every cell will have exactly the same genome. It is also possible that 
certain cells with driver phenotypes may proliferate and recover more quickly than others and 
thereby constitute a larger proportion of the cells in a given flask or well.  This again may be 
representative of a given tumour phenotype as clonal selection may occur in the cellular 
population. 
The heterogeneity introduced in this model could have been avoided by direct, deliberate 
clonal selection at each cell split. This may have been useful as it has been documented that, 
even with a small number of cells, average measurements of the population may not be 
representative of any individual cell (Wang and Bodovitz, 2010). Some success has recently 
been had in the field of single cell genomics (Zong et al., 2012) but these techniques are in 
their early stages and single cell selection, whole genome amplification, and elimination of 
contamination are experimentally challenging. As these methods become more main stream 
the importance of this field of research cannot be overlooked as the heterogeneity within a 
single tumour could be a key aspect to clinical management and treatment options, as well as 
potential for diagnostic usage, such as circulating tumour cells in the blood. Even as this 
technology becomes more widely available and more in depth, it would still generate a 
Page | 104  
 
demanding amount of work before the dose response, DNA and RNA extraction, and flask 
seeding procedures could be completed. 
Historically selection of cells or colonies has been done using immunological markers for 
stable cell line production, such as for transfected cells (Lu et al., 2011). This could have 
been done here to ensure a single surviving colony was used in the subsequent rounds of 
cisplatin dosing, DNA and RNA extraction, and dose response calculations. The selection of 
a single immunological phenotype would however not necessarily be selective enough to 
guarantee that the resulting cells were genetically identical. In order to produce perfect 
genetic clones, as the aims of this work would prefer, more complex and technically difficult 
methods would be required.  
This cellular model has its limitations and some of the general ones have already been 
discussed earlier (see Section 3.1). The mutation profile of untreated A549 cells (Table 3.1) 
could bias any further mutations acquired during the course of cisplatin treatment. It could be 
postulated that the mutations of potential drivers, STK11 and KRAS, may encourage other 
cooperative genes from within the same signalling pathway to be preferentially altered. 
Considering this, it would be beneficial to expand the dataset further by repeating the 
optimisation and dosing schedule with other lung cancer cell lines that have different, ideally 
known clinically common baseline mutations prior to treatment. 
Patients being treated with cisplatin in a clinical setting generally undergo six cycles each 
consisting of a single dose, between 50 to 100 mg/m
2
 intravenously over 6 to 8 hours, with 
three to four weeks recovery between cycles (Chapter 1 Section 1.5 and 
http://www.medicines.org.uk/emc/medicine/623/SPC/Cisplatin+1+mg+ml+Sterile+Concentr
ate).  
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In this model of cisplatin resistance, the concentrations of cisplatin the cells were exposed to 
initially at round 0 (IC50 value = 5µM, IC25 value = 2.5µM) equate to very similar 
concentrations in the area of the flasks used (0.75-1.5 mg in a 150cm
2
 flask), which is 
equivalent to the same 50 mg/m
2
 for the IC25 first cisplatin dosing and 100 mg/m
2
 for the 
first IC50 dosing. The use of 3 weeks recovery for the IC50 dosing time course also reflects 
well the recovery time between chemotherapy cycles in the clinical setting. The two key 
differences are the deliberate increase in cisplatin concentration over time, done to try and 
drive resistance relatively quickly, and the lengthened exposure to cisplatin, 72 hours versus 
6-8 hours in a clinical setting, the latter again being done to ensure selection for resistance.  
An additional consideration is that cisplatin is generally combined with another anti-mitotic 
(see Chapter 1 Section 1.5) when used to treat patients in the clinic. Different cisplatin 
combination therapies may lead to different outcomes for different subtypes of NSCLC, such 
as pemetrexed combined with cisplatin that appears to be less active in lung squamous cell 
carcinomas than in other types of disease, leading to longer progression-free survival and 
overall survival (Scagliotti et al., 2009a).  Modification of this established A549 cell model 
with differing drug combinations is another potential option for future investigations.  
Despite these recognised potential limitations to this model, cisplatin-resistance has been 
induced into this A549 cell line over a period of time and, with the procurement of DNA and 
RNA at each time point, has provided a wealth of data for genomic investigations over the 
two treated time courses. It allows for investigations over the entire period of cisplatin 
treatment, not just simple comparisons between parent/chemo-naïve versus resistant 
phenotypes. This model is a first step in dissecting the effects of cisplatin over the course of a 
treatment regime and may help in the understanding of the genetic and genomic mechanisms 
underpinning cisplatin resistance.  
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4 Global Gene Expression Analysis of Cisplatin Resistance  
4.1 Introduction to Global Gene Expression Analysis  
Global gene expression profiling allows examination of genome activity across the whole 
transcriptome. Understanding of the diversity of transcripts in and between individuals is 
evolving and becoming more complex, with transcript variants now known to include 
canonical, alternatively spliced, alternative start sites, alternative polyadenylation, retained 
introns, repeated exons, antisense transcription, chimeric transcripts and non-coding RNAs. 
All of these RNA variants may alter the phenotype of the sample of interest by causing 
changes at the protein level.  
It seems inevitable that an external stimulus, such as the dosing of cells with rounds of 
cisplatin, would have pronounced effects at the mRNA level leading to a variety of changes 
in the cells’ phenotype.  
There are various methods of exploring gene expression, such as quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR), expression microarrays and RNA 
sequencing (RNA-seq), each with their own benefits and pitfalls. In this work, global gene 
expression analysis was performed using microarray technology to gain a relatively 
comprehensive overview of the transcriptome (Fryer et al., 2002). 
Quantitative Real Time PCR (qRT-PCR) is useful to study specific genes and their behaviour 
under certain circumstances. It amplifies and quantifies the target cDNA molecule 
simultaneously, which is generated from the RNA isolated from tissues or cells of interest. It 
is a simple, accurate and potentially fully quantitative technique that can be used to focus on 
a selection of genes, for example, within a pathway or network of interest, although it is 
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essential to normalise the data to genes that do not alter their expression under different 
conditions. Consequently, the approach is not hypothesis-free – genes are selected as 
candidates based on their potential functions – and only a limited number of genes can be 
studied due to cost implications and the quantity of RNA required for the procedure, if the 
entire genome were to be investigated.  
RNA-seq is the new frontier in gene expression profiling. With the explosion in availability 
of Next Generation Sequencing, it has become feasible to sequence all transcripts within a 
sample. Theoretically it provides limitless sensitivity, accuracy and a broad dynamic range. 
Unlike qRT-PCR, RNA-seq is a hypothesis-neutral approach that has the capability to 
discover novel transcripts and isoforms as well as determining gene structure and sequence in 
one experimental protocol. The technology at present however is expensive, both in cost and 
RNA quantity required, and some studies have observed a GC bias in RNA-seq data. There 
may also be mapping ambiguity for paralogous sequences and an erroneous association 
between gene length and differential expression (Oshlack et al., 2010).  
Gene microarrays have been used here to study the global transcriptome. Historically, 
microarrays have been on the market longer than RNA-seq and so have improved drastically 
in content and robustness, as well as significant reduction in their cost. They allow 
comparisons between samples over tens of thousands of genes. Each sample is labelled with a 
different fluorescent dye and hybridised to the probes on the array. After multiple washes, the 
hybridised slide is scanned and the relative fluorescence of each probe is measured.  
In similarity with RNA-seq, microarrays are another hypothesis-neutral way of exploring the 
transcriptome. They also allow high-throughput processing of multiple samples, by 
automated hybridisation and washing steps for several arrays simultaneously. Further 
development and miniaturisation has also allowed for automated scanning through the use of 
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array plates. Microarrays are a relatively cheap, fast method of measuring expression levels 
of large numbers of genes simultaneously, however only known transcripts are detectable and 
low expression transcripts may not be identified. 
 
4.2 RNA Preparation: Extraction and Quality Control  
4.2.1 RNA Extraction from Cultured Cells 
RNA was extracted from homogenised, lysed A549 cells from each cisplatin dosing round 
and quantified and quality control checked as outlined in Chapter 2 Section 2.2.3.1. Every 
effort was made to ensure RNases did not interfere with extraction however on quantification 
of the triplicate samples for round 2 of the IC25 Dose 1 week recovery time course, 
negligible RNA was present. Consequently RNAs from this round were not included in the 
downstream analyses. All RNAs from cultured cells had RINs ≥ 9.5. 
 
4.2.2 RNA Preparation for Microarray Hybridisation 
Extracted and quantified RNA samples were prepared for and subject to microarray 
hybridisation, washing and scanning using the GeneTitan®, as outlined in Chapter 2 Section 
2.2.3.2. Any voids caused by bubbles or other artefacts would lead to areas on the array with 
no probe-sample hybridisation and so particular care was taken when setting up the 
hybridisation tray. 
During the scanning process, the scanner uses markers on the corners of each array to ensure 
all are aligned before their fluorescence is measured. This produces a CEL file, which stores 
Page | 109  
 
the results of intensity calculations that originate from the fluorescence reading. Ideally, the 
intensity of the fluorescence should be even across the whole of the array with no patches of 
overly bright or dim areas indicating even hybridisation, and no bubbles, voids or other 
artefacts. The fluorescence measurements are read by the scanner from a greyscale image; the 
false-colouring may make it easier to identify areas of sub-optimal hybridisation (Figure 4.1). 
Combining this CEL file with the manufacturer’s information about specific probes and their 
locations on each array, fluorescence can be assigned to each probe and hence its target 
transcript. All samples passed this first step of quality control and were therefore taken 
forward into the expression analysis. 
 
Figure 4.1 An example of a false-coloured hybridised array as scanned using the GeneTitan. There is 
no bias towards a single colour and intensity is relatively uniform across its entirity, with no 
extremely bright or dim areas on the array implying even hybridisation.  
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4.2.2 Microarray Quality Control, Normalisation and Transformation 
Quality control is vital in microarray experiments as it allows outliers to be detected, 
excluded and repeated if required. A single array on a plate may appear vastly different from 
all the others on that plate; they may appear as an obvious outlier on a log expression signal 
box and whisker plot (Sections 4.2.2.1 and 4.2.2.2). 
Normalisation between the arrays is required to correct for systematic differences between 
the samples and the arrays themselves that are not due to biological differences, such as 
overall spot intensity, array location on a plate, origin of a plate or scanning parameters. 
Statistical batch correction may be required hence the need for careful batch recording 
through the experimental processes (Chapter 2 Section 2.2.3.2). It also makes distributions 
comparable between all samples of interest. Robust Multiarray Averaging (RMA) 
normalisation was used for all datasets. Log transformation was also implemented to remove 
skew within the distributions and makes relative changes less sensible to errors. 
The CEL files (raw data) generated by the GeneTitan from the Affymetrix gene arrays were 
subject to probeset summarisation by using Affymetrix Power Tools (APT). These are a set 
of cross-platform command line programs that implement algorithms for analysing and 
working with Affymetrix microarray data. Multiple summarisation methods are available 
through APT, including Probe Logarithmic Intensity Error (PLIER) and RMA. Using APT 
allows one to:- 
 Conduct quantile normalisation using a subset (sketch) of the data which results in 
smaller usage. 
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 Analyse microarray data in probesets, which when combined with the sketch quantile 
normalisation allows the analysis of thousands of chips on a single computer or in 
parallel across a cluster of computers. 
 Save target normalisations and probe (feature) effects for later use. 
 Have the ability to group probesets into larger “meta” probesets as specified by the 
user via text file. 
APT also enables combination with databases, for example Affymetrix array probe 
annotation files, that retain information about the probes on each array.  
After processing all the microarrays through the APT algorithm, the resulting data set was 
subjected to further quality control measures. R and its associated packages “Affy” and 
“Limma” were used to generate box plots of expression intensities, hierarchical clustering 
plots and signal density distributions. Affymetrix software Expression Console was also used 
to calculate a variety of quality assessment metrics. After this additional round of quality 
control, differential expression analyses were conducted as detailed in Chapter 2 Section 
2.2.3.4. 
 
4.2.2.1 IC50 Dosing 3 Week Recovery 
Quality control measures, conducted in R Statistics v. 2.15.0 and its associated packages, 
revealed that no outliers existed for the IC50 Dosing 3 week recovery time course as 
illustrated by the box whisker plots and signal distribution histograms (Figures 4.2 and 4.3).   
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Figure 4.2 Log Expression Signal showing the box and whisker plots for each array file in the IC50 
dose 3 week recovery time course. It can be seen that no outliers exist as all 36 arrays have 
approximately the same median value with similar interquartile and total ranges. 
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Figure 4.3 Signal Distribution Histogram for all 36 arrays from the IC50 dose 3 week recovery time 
course. The pattern of the distributions for all the arrays is almost identical with no marked outliers. 
Individual probe set signal values, including the bacterial spike and polyA spoke probe sets 
were used as controls. Bacterial spike is the set of probe sets which hybridise to the pre-
labelled bacterial spike controls (BioB, BioC, BioD, and CreX) and it is used in identifying 
problems with the hybridisation and/or array. Each is spiked with a different concentration of 
fluorescence (BioB the lowest to CreX the highest). If they do not appear in the correct order 
when comparing intensities i.e. CreX the highest values and BioB the lowest values, it is an 
indication of hybridisation problems (example shown in Figure 4.4). 
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Figure 4.4 Bacterial spike signal values generated in Expression Console, showing each array from 
the IC50 dose 3 week recovery time course and its intensity for each bacterial spike hybridisation 
control. It can be seen that, as expected, the CreX control (red) has the highest intensity, followed by 
BioD (blue), BioC (pink) and BioB (green) respectively. 
 
The PolyA spike is the set of polyadenylated RNA spikes (Lys, Phe, Thr and Dap) and it can 
be helpful in identifying problems with target RNA preparation. Again, each of these four 
controls are spiked with difference concentrations of fluorescence and on scanning should 
appear in order of intensity; from Dap with the highest expected intensity, followed by Thr, 
Phe, and Lys respectively. 
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4.2.2.2 IC25 Dosing 1 Week Recovery 
Quality control analyses were performed as outlined in Section 4.2.2.1. These highlighted a 
potential problem with replicate 1 from Round 1; the box and whisker of log expression 
signal of the arrays suggest that it may be an outlier. To overcome this problem, a duplicate 
of the CEL file for replicate 3 was used and the quality control analyses rerun (Figure 4.5). 
In order for the two time courses to be comparable and simplify the analyses, a further four 
rounds were chosen for exclusion so the 15 rounds from the IC25 dose 1 week recovery were 
reduced to 11 (including round 0) in order to match the IC50 dose 3 week recovery time 
course. The increased number of comparisons that would result from contrasting all the 15 
rounds in the IC25 dose 1 week recovery time course could also lead to a greater chance of 
potentially falsely statistically significant results, simply due to conducting more 
comparisons. 
Rounds 1, 4, 8 and 12 were chosen for exclusion to take into consideration the prior 
hierarchical clustering (Figure 4.6) in which rounds 1 and 4 cluster together, slightly removed 
from the other rounds, and to give a well-balanced spread of observations across the entire 
time course (rounds 8 and 12). This pruning of the IC25 dose 1 week recovery time course 
made no significant changes to the conclusions of the experiments. 
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Figure 4.5 Left: Log Expression Signal of IC25 dose 1 week recovery. It can be seen that one box plot does not conform with the others as it has a smaller box and a lower 
median value, highlighted by red box. Right: Log Expression Signal of IC25 dose 1 week recovery. On replacement of the Round 1 Replicate 1 outlier array with a copy of 
another replicate from the same cisplatin round (highlighted with a red asterisk), the quality of the data taken forward is improved as all box and whisker plots have a similar 
median, interquartile range and total range. 
* 
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Figure 4.6 Hierarchical clustering plot of expression data for all time points for the IC25 dose 1 week 
recovery time course. It can be seen that rounds 1 and 4 appear as outliers. 
   
4.3 Differential Gene Expression Analysis 
Differential expression analysis is vital to identify significant changes in gene expression, 
both up- and down-regulated, across the whole time course. In the case of a time course drug 
dosing, it is worth investigating the dynamic process of genetic response within the cells as 
those genes that change expression in line with the cytotoxic drug may be causing changes in 
the cell to allow it to survive. These analyses will lead to further investigations such as 
network analysis that summarise the co-ordinated activity of the transcriptome (Chapter 5 
Section 5.2).  
For the differential expression over time analysis, each time point was contrasted with every 
other within each time course. In order to examine all potential changes in both the IC50 dose 
3 week recovery and the IC25 dose 1 week recovery time courses, a moderated F-statistic 
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was created for each gene across the entirety of both time courses (Chapter 2 Section 2.2.3.4), 
without simply focusing on start versus resistance end point alone.  
Using a significance threshold of 1E-08, the F-statistic and Benjamini-Hochberg (B-H) 
adjusted p-values reduced the 33,297 transcript clusters interrogated by the microarray to 
identify 1,515 transcripts that were significantly altered during the IC50 dose 3 week 
recovery time course and 1,474 transcripts significantly altered during the IC25 dose 1 week 
recovery time course.  
 
4.3.1 Top Differentially Expressed Genes from the Two Treated Time Courses 
Of the 1,515 significantly differentially expressed genes from the IC50 dose 3 week recovery 
time course, 183 genes were found to have a greater than three-fold increase or decrease in 
expression when comparing round 0 with the final round 10. Fifty nine of the genes had a 
greater than five-fold change in expression. It is interesting that the majority of these 183 
genes with large fold changes appear to decrease over the time course with approximately a 
third (67) showing an increase in expression. Overall, 673 genes were found to have 
increased fold change expression on comparison between rounds 0 and 10, while 842 had 
decreased fold change over the same period. 
Table 4.1 shows the top 25 differentially expressed genes (for a more comprehensive list [288 
gene with B-H adjusted p-value less than or equal to 1E-14], see E-Appendix 9.1.1). The top 
ten differentially expressed genes perform a variety of functions; a complement protein and a 
cytokine (C3 and GREM1 respectively), metabolism enzymes involved in the urea cycle 
(CPS1) and in the liver (BAAT), a heparin binding protein (C21orf63), an adhesion molecule 
(LUM), a metalloprotease (TLL1), a small nuclear RNA (snRNA, ENST00000517058 
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located on chromosome 5), a folate pathway gene (CRISPLD1), and an inhibitor of 
fibrinolysis (SERPINE1) (http://www.ncbi.nlm.nih.gov/gene). 
Although these top ten genes do not appear to be related to the lungs or cancer, other genes 
(for full listing see E-Appendix 9.1.1) do have more obvious links. Solute carrier family 6 
(amino acid transporter) member 14 (SLC6A14) is a specific amino acid transporter that has 
been identified as a novel drug target for oestrogen receptor-positive breast cancers 
(Karunakaran et al., 2011).  Mal, T-cell differentiation protein 2 (MAL2) is a transporter 
protein that has also been linked with breast cancer (Shehata et al., 2008) and shows an 
approximate 20-fold decrease between the start and end of the time course. Angiogenin 
(ANG) levels have been indirectly associated with tumour size through a correlation with 
increasing vascular endothelial growth factor (VEGF) concentration (Rozman et al., 2012). 
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Table 4.1 IC50 dose 3 week recovery; top 25 differentially expressed genes. Fold change (increase in green, decrease in red) shows change in expression 
when comparing the chemo-naive (round 0) cells with those from the end of the time course (round 10). 
ID Fold Change Rd0v10 F Statistic B-H adj.p.Value Gene Symbol > 3fold? > 5fold? 
8048026 1.25 518.14 4.54E-25 CPS1 
  8033257 0.10 429.02 3.08E-24 C3 Yes Yes 
8146967 0.03 417.97 3.08E-24 CRISPLD1 Yes Yes 
8162870 13.09 410.80 3.08E-24 BAAT Yes Yes 
8068202 0.13 398.05 3.85E-24 C21orf63 Yes Yes 
8104654 0.04 392.98 3.85E-24 
ENST00000517058, 
snRNA on Chr5 Yes Yes 
7965403 20.11 369.96 7.77E-24 LUM Yes Yes 
8098214 0.08 312.96 7.29E-23 TLL1 Yes Yes 
8135069 1.90 305.44 9.14E-23 SERPINE1 
  7982377 22.35 292.05 1.55E-22 GREM1 Yes Yes 
8029086 0.07 280.06 2.35E-22 CEACAM5 Yes Yes 
8148040 0.05 279.97 2.35E-22 MAL2 Yes Yes 
7973084 0.97 246.00 1.35E-21 ANG 
  8114920 0.61 242.75 1.42E-21 DPYSL3 
  8169504 0.02 242.63 1.42E-21 SLC6A14 Yes Yes 
8125530 2.59 233.96 2.23E-21 HLA-DMB 
  8142585 0.20 223.22 4.07E-21 CADPS2 Yes Yes 
8105302 9.95 221.66 4.24E-21 FST Yes Yes 
8103415 0.30 220.28 4.39E-21 C4orf18 Yes 
 8180078 2.71 217.91 4.86E-21 HLA-DMB 
  8151334 3.84 210.18 7.69E-21 MSC Yes 
 8001564 6.22 206.03 9.73E-21 DOK4 Yes Yes 
8054439 10.58 204.66 9.88E-21 ST6GAL2 Yes Yes 
8097910 1.79 204.54 9.88E-21 FGB 
  7969493 0.30 199.75 1.30E-20 SCEL Yes 
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Of the 1,474 significantly differentially expressed genes from the IC25 dose 1 week recovery 
time course, 88 genes were found to have a greater than three-fold increase or decrease in 
expression on comparison with round 0 with the final round 15; 22 of which had greater than 
five-fold change. In contrast with the IC50 dose 3 week recovery time course, the majority of 
the genes showed at least a three-fold increase in expression (75 of the 88) between round 0 
and round 15. Overall, 816 genes were found to have increased fold change expression on 
comparison between rounds 0 and 15, while 658 had decreased fold change over the same 
period. 
Table 4.2 shows the top 25 differentially expressed genes (for a more comprehensive list [379 
gene with B-H adjusted p-value less than or equal to 1E-14], see E-Appendix 9.1.2). The top 
ten genes from this time course appear to fall into more distinct categories than their 
counterparts from the IC50 dose 3 week recovery time course. One overlaps both top ten 
lists, BAAT, and only one other metabolism-related enzyme is in this top ten, fatty acid CoA 
reductase 2 (FAR2). Three members from the annexin family of calcium ion and 
phospholipid binding proteins (ANXA8, ANXA8L1, and ANXA8L2) show a slight increase 
in fold change from round 0 to round 15 (1.59, 2.55, and 1.60 respectively); their over 
expression has been linked to pancreatic ductal adenocarcinoma (Karanjawala et al., 2008). 
Molecules involved in adhesion and the extracellular matrix can also be seen in these top 
genes (neuronal cell adhesion molecule, NRCAM; filamin A interacting protein 1, FILIP1; 
and collagen and calcium binding EGF domains 1, CCBE1). CCBE1 is also down-regulated 
in ovarian cancer cell lines, suggesting a role for it in tumour suppression. It is conceivable 
that uroplakin 1B (UPK1B) and glypican 6 (GPC6) could also be having strong phenotypic 
effects in response to cisplatin treatment as a transmembrane protein and a proteoglycan 
implicated in cell growth and division (all http://www.ncbi.nlm.nih.gov/gene).  
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Table 4.2 IC25 dose 1 week recovery; top 25 differentially expressed genes. Fold change (increase in green, decrease in red) shows change in expression 
when comparing the chemo-naive (round 0) cells with those from the end of the time course (round 15). 
ID Fold Change Rd0v15 F Statistic B-H adj.p.Value Gene Symbol > 3fold? > 5fold? 
8142270 4.07 482.70 3.59E-31 NRCAM Yes 
 7927307 1.60 360.44 3.55E-29 ANXA8L2 
  8081826 0.90 349.15 4.20E-29 UPK1B 
  7954631 0.23 334.83 6.71E-29 FAR2 Yes 
 7933312 2.55 316.32 1.34E-28 ANXA8L1 
  7927367 1.59 315.04 1.34E-28 ANXA8 
  8162870 4.93 300.19 2.75E-28 BAAT Yes 
 7969613 4.90 279.01 8.99E-28 GPC6 Yes 
 8127646 4.06 256.54 3.62E-27 FILIP1 Yes 
 8023575 1.69 233.05 1.83E-26 CCBE1 
  7936494 1.13 224.94 3.14E-26 GFRA1 
  8139212 0.14 216.02 5.94E-26 GLI3 Yes Yes 
7927280 0.89 190.87 5.03E-25 PPYR1 
  8152617 3.65 189.61 5.26E-25 HAS2 Yes 
 7965156 0.97 182.08 1.01E-24 LIN7A 
  8114920 0.25 179.82 1.19E-24 DPYSL3 Yes 
 7957260 1.83 175.35 1.75E-24 GLIPR1 
  8175710 0.79 172.86 2.13E-24 CSAG2 
  8115327 6.10 169.99 2.72E-24 SPARC Yes Yes 
7977786 6.67 169.29 2.78E-24 SLC7A7 Yes Yes 
7965206 0.66 168.80 2.79E-24 SLC6A15 
  8066214 3.71 166.96 3.24E-24 TGM2 Yes 
 8151334 2.21 163.49 4.51E-24 MSC 
  8170580 0.81 155.05 1.11E-23 CSAG2 
  7902565 4.18 152.71 1.39E-23 LPHN2 Yes 
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Further down the list (for full listing see E-Appendix 9.1.2) are GLI family zinc finger 3 
(GLI3), a DNA-binding transcriptional activator and repressor of Sonic hedgehog signalling 
(Chapter 1 Section 1.6.4), and Chondrosarcoma-Associated Gene 2 (CSAG2), also known as 
the taxol-resistant-associated gene 3 protein, whose expression has been associated with 
chemotherapy resistance and neoplastic phenotypes (http://www.genecards.org). The 
presence of these genes and those from the IC25 dose 1 week recovery top ten differentially 
expressed genes and their more obvious links to hallmarks of cancer or potential drug 
resistance may indicate that the transcriptomes between the cells from the two time courses 
are quite different as a result of their divergent treatment courses.  
 
4.4 Temporal Cluster Analysis 
Transcripts were clustered according to their expression profiles, allowing transcripts with 
similar increases or decreases in expression to be visualised, potentially collecting the 
transcripts that may be working together. This was done using the fuzzy c-means algorithm to 
soft cluster the members (Kumar and E Futschik, 2007), which is a noise-robust cluster 
algorithm that can be used for time-series data. This is less stringent than the hard k-means 
clustering and allows smaller changes to be detected. Each point is associated with a cluster 
dependent on a membership value (m), which was chosen as 1.25 for all instances. The value 
of m is used to dictate how strongly each gene belongs to a cluster. Using m=1.25 ensures all 
genes are strongly associated with a particular cluster without removing flexibility. It is less 
stringent than k-means-like clustering (m ≤ 1.1) but not as dispersed as m ≥ 1.6 (Dembélé and 
Kastner, 2003). Expression for each gene was standardised so that its average expression is 
zero with a standard deviation of one. 
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It is standard procedure to perform clustering multiple times, varying the number of clusters 
and looking to find a satisfactory compromise between the number of genes per cluster, the 
number of clusters, and the observed temporal changes in expression. Overlap plots were 
used to help decide this with Principle Components Analysis (PCA) performed on each 
cluster to investigate the similarities and differences between them as well as allowing their 
graphically presentation (Section 4.4.1). 
Examination of the patterns of expression over the course of each time course identified 
clusters that either increased or decreased overall during cisplatin treatment. These clusters 
may be considered most likely to be biologically relevant and so were submitted to in-depth 
analysis by Gene Ontology (GO). Genes found within these increasing and decreasing 
expression clusters with highly significant differential expression (p-value less than 1E-14) 
were reviewed in the published literature. 
GO term enrichment analysis and functional annotations were generated using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) (Chapter 2 Section 2.2.3.5). 
The GO initiative aims to bring together the representation of gene and gene product 
attributes. It categorises genes into one of three main domains; cellular components, 
molecular functions, and biological processes. DAVID aims to provide functional 
interpretation and enhance the context of large gene lists. 
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4.4.1 Expression Clustering 
4.4.1.1 IC50 Dose 3 Week Recovery Time Course 
Temporal expression clustering was performed on the top 1,515 genes with a B-H adjusted p-
value of less than or equal to 1E-08 for significance in change in gene expression over the 
time course. After multiple iterations of cluster numbers, seven modules of genes were 
chosen that showed distinctive temporal patterns, characterised by their initial levels of 
abundance and variation in expression over cisplatin treatments (Table 4.3 and Figure 4.7). 
Cluster 1 2 3 4 5 6 7 
No. of 
Genes 
230 227 187 167 209 325 170 
Table 4.3 Number of genes within each Expression Cluster for the IC50 dose with 3 week recovery 
time course.  
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Figure 4.7 IC50 Dosing with 3 Week Recovery: fuzzy c-means cluster analysis. The change in log2 fold expression of genes within each cluster are shown 
over the course of the cisplatin rounds, highlighting some of the large fold changes seen over the course of treatment. The depth of red colour shows how 
strongly each gene is associated with a particular cluster. The bottom right overlap plot shows the PCA between the clusters; the blue line shows the similarity 
between clusters 3 and 6, however the two start at different levels so the two clusters were not combined.  
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Clusters 2 and 5 are of particular interest because they exhibit either a general increase 
(Cluster 2) or a general decrease (Cluster 5) over the course of cisplatin dosing. GO analysis 
for these two clusters was conducted using DAVID, to investigate potential signalling 
pathways (as detailed in Chapter 2 Section 2.2.3.5). 
For Cluster 2, the most enriched functional annotation (enrichment score of 4.73 [3 
significant figures (sf)]) contained mainly signalling peptides and glycoprotein terms (up to 
37% of the members of the expression cluster), and genes encoding proteins that are found in 
the extracellular region (B-H adjusted p-value 3.26E-05 [3 sf]). The second most enriched 
functional annotation cluster (enrichment score of 2.44 [3 sf]) were EGF and EGF-like 
domains (up to 6% of the number of molecules in the expression cluster) (B-H adjusted p-
value 1.17E-03 [3 sf]). These two functional annotation groups suggest these up-regulated 
genes are having effects on the signalling cascades within the cell. 
Similar functions to those of Cluster 2 were observed for Cluster 5.  The two most enriched 
functional annotation clusters (enrichment score of 5.93 and 4.97 [3 sf]) contained signalling 
peptides and glycoprotein terms (up to 36% of the number of molecules in the expression 
cluster; B-H adjusted p-value 1.44E-05 [3 sf]) or were proteins in the extracellular region (up 
to 31% of the number of molecules in the expression cluster). Functional annotation group 3 
(enrichment score 4.38) constituted responses to various stimuli or substances, such as 
organic substances (13% of number of molecules in the expression cluster; B-H adjusted p-
value 1.29E-04) or endogenous stimulus (9% of number of molecules in the expression 
cluster; B-H adjusted p-value 8.18E-05). Another significant functional annotation suggested 
the enrichment of adhesion molecules within this cluster, with terms such as basolateral 
plasma membrane (6% of number of molecules in the expression cluster; B-H adjusted p-
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value 1.40E-04) and anchoring junction (5% of number of molecules in the expression 
cluster; B-H adjusted p-value 5.48E-04) appear as the most significant. A full listing of the 
genes in Clusters 2 and 5 is available in E-Appendix 9.1.3. 
The genes showing the most significant differential expression from these two clusters of 
interest are discussed later in Section 4.6. 
 
4.4.1.2 IC25 Dose 1 Week Recovery Time Course 
Temporal expression clustering was performed on the top 1,474 genes with a B-H adjusted p-
value of less than or equal to 1E-08 for significance in change in gene expression over the 
time course. After multiple iterations of cluster numbers, six modules of genes were chosen 
that showed distinctive temporal patterns, characterised by their initial levels of abundance 
and variation in expression over cisplatin treatments (Table 4.4 and Figure 4.8). 
Cluster 1 2 3 4 5 6 
No of Genes 118 103 323 286 359 285 
Table 4.4 Number of genes within each Expression Cluster for the IC25 dose with 1 week recovery 
time course. 
Clusters 3 and 6 are of particular interest due to the patterns they exhibit over the course of 
cisplatin dosing – general increase (Cluster 6) and general decrease (Cluster 3). For these two 
clusters, GO analysis was conducted using DAVID to investigate potential signalling 
pathways as detailed in Chapter 2 Section 2.1.4.5. 
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Figure 4.8 IC25 Dose with 1 Week Recovery: fuzzy c-means cluster analysis. The change in log2 fold expression of genes within each cluster are shown over 
the course of the cisplatin rounds, highlighting some of the large fold changes seen over the course of treatment. The depth of red colour shows how strongly 
each gene is associated with a particular cluster. The far bottom right overlap plot shows the PCA between the clusters. The blue line on the PCA plot show 
the similarities between clusters 1 and 5, and between clusters 4 and 6, but using four clusters instead of six would give an unacceptably high number of genes 
per cluster. There are also significant differences in levels of log2 change in expression across the time course. 
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Cluster 6 showed high enrichment in GO terms that are involved in protein dimerization, 
glycoproteins and signal peptides (up to 31% of molecules in the annotation cluster), and 
response to environmental stimuli, such as hormones or organic compounds (3.47, 2.91, and 
2.85 respectively) in spite of p-values only approaching significance. Regulation of EMT, 
morphogenesis, differentiation, and development also had a strong enrichment score (2.52) 
and, in combination with other GO terms enriched in this cluster, is suggestive of highly 
active cells responding to their environment. 
For cluster 3, functional annotation clusters included a significantly high proportion of 
glycoproteins, including secreted signalling peptides (enrichment score 6.82; 14-38% of the 
molecules, B-H adjusted p-value 9.35E-08).  Transmembrane proteins were also enriched 
significantly (enrichment score 3.57, B-H adjusted p-value 5.12E-06), as were 
immunoglobulins (enrichment score 2.97; B-H adjusted p-value 9.0E-03). A full listing of the 
genes in Clusters 3 and 6, including their B-H adjusted p-values, is available in E-Appendix 
9.1.4. 
The genes showing the most significant differential expression from these two clusters of 
interest are discussed later in Section 4.6. 
For all the up- and down-regulated gene clusters (2 and 5 in IC50 dose 3 week recovery; 3 
and 6 in IC25 dose 1 week recovery), it is noteworthy that a slight sigmoidal curve is visible 
with the alteration in expression change occurring between rounds four and six of the IC50 
dose 3 week recovery time course and between rounds seven and nine of the IC25 Dose 1 
week recovery time course. It is possible that this small change reflects the acquisition of 
stronger resistance to cisplatin around this point in the time course as the exposure to the drug 
begins to take its effects on cells. 
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4.5 Gene Expression Analysis of Untreated A549 Cells 
It is feasible that some of the changes in global gene expression observed for the two time 
courses may be due to repeated passages of the A549 cells in culture over a prolonged period 
(Chapter 3 Section 3.5). To control for this and to establish the changing genomics of A549 
cells over numerous rounds of normal cell culture a time control was set up. 
Cells were grown using the same initial seeding density (2 x 10
6
 cells) as the IC50 dose 3 
week recovery time course and RNA and DNA were harvested at the same equivalent time 
points and passages (Chapter 2 Section 2.2.1). RNA extraction, processing, and microarray 
hybridisation were performed as detailed previously (Chapter 2 Sections 2.1.4.1 and 2.1.4.2). 
The same microarray quality control measures were implemented (Chapter 2 Section 2.1.4.3) 
and no outliers were identified across the 33 microarrays (Figures 4.9 and 4.10). 
 
Figure 4.9 Log Expression Signal of Normal Time Course showing that all the box and whisker plots 
for the 33 samples from round 0 to 10 have a similar median, interquartile range and total range.  
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Figure 4.10 Signal Density Distribution showing practically identical distributions across all the 33 
arrays. 
 
4.5.1 Comparisons of the Significantly Differentially Expressed Genes between the 
Untreated and Treated Time Courses  
Differential expression analysis was performed for the normal cell culture as outlined in 
Section 4.3 and the list of genes obtained was compared with those from the analyses of the 
IC50 dose 3 week recovery and IC25 dose 1 week recovery time courses. Using the same 
threshold of B-H adjusted p-value less than or equal to 1E-08, resulted in 865 differentially 
expressed genes for the normal cell culture time course, substantially fewer than that obtained 
for either of the cisplatin-treated time courses. Overall, 338 genes were found to have 
increased fold change expression on comparison between rounds 0 and 10, while 527 had 
decreased fold change over the same period. 
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Table 4.5 Normal untreated time course; top 25 differentially expressed genes. Fold change (increases in green, decreases in red) shows change in expression 







Gene Symbol > 3fold? > 5fold? 
In IC50 dose 3 week 
recovery? 
In IC25 dose 1 week 
recovery? 
8112980 0.02 485.87 9.18E-22 EDIL3 Yes Yes Yes Yes 
8172022 0.06 446.46 1.33E-21 TMEM47 Yes Yes Yes Yes 
8095303 0.03 426.94 1.55E-21 LPHN3 Yes Yes Yes Yes 
8128284 0.09 414.08 1.70E-21 EPHA7 Yes Yes Yes 
 8180234 35.31 393.78 2.56E-21 unknown Yes Yes Yes 
 8099633 0.08 370.12 4.64E-21 PPARGC1A Yes Yes Yes Yes 
8035095 27.03 315.48 2.94E-20 CYP4F11 Yes Yes Yes Yes 
8081036 0.07 304.00 4.08E-20 CADM2 Yes Yes Yes Yes 
8114920 3.16 262.88 2.23E-19 DPYSL3 Yes 
 
Yes Yes 
8036079 0.18 231.59 9.74E-19 DMKN Yes Yes 
 
Yes 
8142687 0.15 228.19 1.06E-18 GPR37 Yes Yes Yes Yes 
7927280 11.54 224.99 1.16E-18 PPYR1 Yes Yes Yes Yes 
8112731 10.88 222.56 1.23E-18 F2RL2 Yes Yes Yes Yes 
8148040 0.02 217.69 1.47E-18 MAL2 Yes Yes Yes Yes 
8115327 8.48 216.85 1.47E-18 SPARC Yes Yes Yes Yes 
8090180 0.37 213.12 1.71E-18 MUC13 
  
Yes Yes 
7957452 0.30 209.98 1.94E-18 ALX1 Yes 
 
Yes Yes 
8100541 5.21 208.02 2.06E-18 IGFBP7 Yes Yes Yes Yes 
8005048 7.02 204.04 2.48E-18 MYOCD Yes Yes Yes 
 8136662 0.27 201.17 2.70E-18 MGAM Yes 
 
Yes Yes 
7978801 0.10 201.00 2.70E-18 MDGA2 Yes Yes 
  8134098 0.16 196.28 3.47E-18 PFTK1 Yes Yes Yes 
 8160546 0.32 194.40 3.74E-18 LINGO2 Yes 
 
Yes Yes 
8155802 0.27 191.85 4.22E-18 GDA Yes 
 
Yes Yes 
8103415 0.24 188.89 4.92E-18 C4orf18 Yes 
 
Yes Yes 
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Table 4.5 shows the top 25 differentially expressed genes from the normal untreated time 
course. It is noteworthy that only one of these genes, MDGA2, is not found to be 
differentially expressed in either of the two treated time courses.  
The overlap of genes between the treated and untreated time courses, in general, was found to 
be quite high: 628 out of 1515 (41.5%) normal versus IC50 dose 3 week recovery and 560 
out of 1474 (38.0%) normal versus IC25 dose 1 week recovery.  It would be desirable to 
know if these significantly differentially expressed genes that overlap all three time courses 
(normal untreated, IC50 dose 3 week recovery, and IC25 1 week recovery) have the same 
expression profiles. To investigate this, fuzzy c-means clustering (Section 4.4) was performed 
on the 865 genes found to be significantly differentially expressed across the untreated time 
course. After testing several different numbers of clusters, five were chosen as each showed a 
unique expression patterns over the course of culture and contained a manageable number of 
genes (Table 4.6).  
Cluster 1 2 3 4 5 
No of Genes 114 160 208 183 200 
Table 4.6 Number of genes within each temporal expression cluster for the 865 differentially 
expressed genes from the untreated normal time course. 
The expression patterns of the five clusters (Figure 4.11) exhibited similar patterns to the 
clusters observed for the two cisplatin time courses (Figures 4.7 and 4.8). Clusters showing a 
gradual increase (Cluster 2) and a gradual decrease (Cluster 4) over the time course are 
present. Genes within these clusters with increasing or decreasing expression are of particular 
interest since if they have the same expression profile in the equivalent clusters in the treated 
time courses, these could be confounders when searching for potential biomarkers of cisplatin 
resistance. 
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Figure 4.11 Untreated Normal Time Course: fuzzy c-means cluster analysis. Each time point was matched as closely as possible to those from the treated 
time courses. The log2 fold expression change of the 865 differentially expressed genes across each cluster are shown over the “rounds”. The bottom right 
overlap plot shows the PCA between the clusters; each cluster is distinct, as indicated by five discrete expression profiles. 
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GO analyses of clusters 2 and 4 showed that for both clusters the most enriched functional 
annotation clusters were glycoproteins (4.95 enrichment score, 66 count, 1.2E-05 B-H 
adjusted p-value; 4.87 enrichment score, 70 count, 7.7E-05 B-H adjusted p-value  
respectively) closely followed by plasma membrane fraction terms, suggesting that signalling 
again may be the main focus of the normal time course. The absence of significant terms for 
the processes previously seen in the cisplatin-treated time course clusters (Section 4.4.1), 
including the response to stimuli or regulation of key cell processes such as differentiation, 
highlights that these pathways may be of importance in the response to cisplatin. 
Comparing the gene contents of each of these clusters with the comparable ones from the 
cisplatin time courses only a small proportion, generally less than ten per cent, were found to 
overlap in each of the respective clusters (Table 4.7 and Table 4.8). Nevertheless, since the 
effects of these genes may well confound genuine results or potential biomarkers of changes 
caused by cisplatin, these genes were excluded from further analyses. 
 
Up in Normal Cells 
(Cluster 2) 
 Down in Normal Cells 
(Cluster 4) 
Up in IC50 Dose 3 
Week Recovery 
(Cluster 2) 
11 / 227 
Down in IC50 Dose 3 
Week Recovery 
(Cluster 5) 
14 / 209 
Up in IC25 Dose 1 
Week Recovery 
(Cluster 6) 
27 / 285 
Down in IC25 Dose 1 
Week Recovery 
(Cluster 3) 
22 / 323 
Table 4.7 Comparison of the number of differentially expressed genes within each increasing or 
decreasing expression cluster with the up-regulated and down-regulated gene clusters in the untreated 









Increased Gene Expression in both 
the Treated and Untreated Time 
Courses 
Decreased Gene Expression in both 
the Treated and Untreated Time 
Courses 
IC50 dose 3 
weeks 
recovery 
LUM, CEACAM5, NTRK3, TNFSF10, 
RSPO3, ADAM28, THBD, PCOLCE2, 
ZNF160, PREX1, MAMLD1 
FXYD2, SNAI2, EHF, TSPAN12, 
RDH10, TF, IGFBP7, NKD1, FJX1, 
DCBLD1, SORT1, LIMA1, GNAL, 
FAM13A 
IC25 dose 1 
week 
recovery 
HAS2, LPHN2, MOBKL2B, RP11-
35N6.1, HGD, BCAS1, TM4SF20, 
LHFP, LOC554202, THY1, FRMD5, 
CNTNAP3, SERPINE2, CSF1, RASSF5, 
C1QTNF1, PBLD, TNFSF10, AKAP12, 
ZNF160, MYO15B, EFHD2, LAMB3, 
CREB5, THBD, GRB10, ST3GAL1 
RNF182, SERPINE1, TINAG, SPOCK1, 
LYPD1, IGFBP7, ANKS4B, LGALS2, 
ADORA2B, TIPARP, CEACAM6, 
FXYD2, FJX1, P4HA3, CYP4F3, 
LGALS3BP, MUC5B, GABARAPL1, 
CFI, TTC39A, GNAL, TMEM47 
Table 4.8 68 unique genes that share similar increasing and decreasing expression profiles over the 
course of cisplatin treatment and extended untreated cell culture rounds. Those genes in bold 
highlight those few genes that are seen to have the same expression profiles across both treated time 
courses as well as in the untreated. All genes within this table were excluded at this stage from future 
investigations. 
The combination of the relatively high overlap of differentially expressed genes (41% and 
38% Section 4.5.1) but the lack of overlap in temporal expression seen here is interesting. It 
is possible that the effects of cisplatin treatment are altering the normal processes of the cells 
to enable them to continue to survive in the presence of the drug. 
Comparing the untreated Clusters 2 and 4 with their equivalent clusters from the cisplatin 
time courses, it may be of interest that the up- and down-regulated clusters appear to have a 
more continuous increase or decrease in their expression profiles than their respective 
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4.5.2 Investigating the Overlap between the Time Courses 
Examination of the two gene lists, 1,515 genes for the IC50 dose 3 week recovery time 
course and 1,474 genes for the IC25 dose 1 week recovery time course revealed that 843 
genes were common to both time courses. It is likely that these genes are involved in 
mechanisms of resistance irrespective of the dosing regimen or the continuing propagation of 
the cell line over time. The 843 genes in common accounted for 55.6% and 57.2%  of the 
IC50 dose 3 week recovery and IC25 dose 1 week recovery genes respectively (Figure 4.12). 
 
Figure 4.12 Venn diagram showing the overlap of 843 gene between the those that are most 
significantly differentially expressed in the IC50 dose 3 week recovery time course and the IC25 dose 
1 week recovery time course. 
Three hundred and 75 of the 843 overlapping genes were found to be only present in the 
treated time courses and not in the untreated normal time course (threshold of adjusted B-H 
p-value of less than or equal to 1E-08). These 375 genes are of particular interest. The 28 
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genes with the largest fold changes when comparing round 0 with round 10 from the IC50 
dose 3 week recovery time course can be found in Table 4.9. A full list of all 375 genes can 
be found in E-Appendix 9.1.5. 
Two of these genes show especially large fold changes; ankyrin repeat domain 30A 
(ANKRD30A) had an 11.9-fold increase while tolloid-like1 (TLL1) exhibited a 12.5-fold 
decrease. Also in these genes is lysophosphatidic acid receptor 5 (LPAR5), a gene that 
encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors that 
are upstream regulators of Rho and Rac GTPase pathways (Fleming et al., 1997). 
Antagnoism of the receptor family has been shown to cause breast cancer tumour regression 
in vivo (Zhang et al., 2009). Other genes associated with GTPase pathways are also found in 
this list, such as TBC1 domain family member 2 (TBC1D2) that acts as a GTPase activating 
protein for RAB7A and a signal effector acting as a linker between RAC1 and RAB7A, 
eventually leading to reduced cell-cell adhesion (http://www.genecards.org). Galanin-GMAP 
prepropeptide (GAL) is a small neuropeptide that functions as cellular messenger in central 
and peripheral nervous system. It and its receptor GAIR1 have been identified as novel 
determinants of chemotherapy resistance and potential biomarkers in colorectal cancer 
(Stevenson et al., 2012). 
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Table 4.9 The 28 from the 375 overlapping differentially expressed genes  between the two treated time courses with at least a three-fold change in 
expression between the start (round 0) and end (round 10) using data from the IC50 dose 3 week recovery time course. Fold change is represented with green 
and red indicating an increase and decrease respectively. 
ID Fold Change Rd0v10 F Statistic B-H adj.p.value Gene Symbol > 3fold? > 5fold? 
8068202 0.13 398.05 3.85E-24 C21orf63 Yes Yes 
8098214 0.08 312.96 7.29E-23 TLL1 Yes Yes 
7927033 11.87 160.44 1.36E-19 ANKRD30A Yes Yes 
8023727 0.20 121.10 3.76E-18 DSEL Yes 
 8162759 0.19 104.47 2.25E-17 TBC1D2 Yes Yes 
7974835 0.26 100.73 3.35E-17 PRKCH Yes 
 7927058 3.78 67.24 4.74E-15 Transcript cluster on Chr10 Yes 
 8009243 0.23 66.51 5.29E-15 C17orf60 Yes 
 8109490 4.55 65.85 5.95E-15 SGCD Yes 
 7946067 5.50 62.42 1.13E-14 OR51B4 Yes Yes 
7946061 6.05 59.76 1.90E-14 HBE1 Yes Yes 
7960637 3.14 57.29 3.09E-14 LPAR5 Yes 
 8101762 0.31 57.24 3.12E-14 SNCA Yes 
 7947282 4.05 56.52 3.64E-14 DCDC5 Yes 
 8037750 0.24 54.97 5.07E-14 IGFL4 Yes 
 8088560 0.30 54.28 5.84E-14 ADAMTS9 Yes 
 8059680 3.50 51.89 9.95E-14 HTR2B Yes 
 8124351 5.57 49.95 1.56E-13 SLC17A3 Yes Yes 
7901175 0.32 43.54 8.13E-13 TSPAN1 Yes 
 7942064 4.59 42.49 1.08E-12 GAL Yes 
 8081488 3.56 41.40 1.49E-12 HHLA2 Yes 
 8062813 3.12 39.34 2.69E-12 R3HDML Yes 
 7903227 0.23 38.60 3.38E-12 PALMD Yes 
 7956867 3.85 35.15 9.98E-12 HMGA2 Yes 
 8151496 0.32 29.16 8.48E-11 ZNF704 Yes 
 8046078 0.33 23.34 1.04E-09 B3GALT1 Yes 
 8021695 0.32 19.64 6.88E-09 DOK6 Yes 
 8146633 0.29 19.53 7.34E-09 LOC643763 Yes 
 
Page | 141  
 
Further literature-based investigations into the full list of 375 genes (E-Appendix 9.1.5) have 
also yielded some more remarkable results. Known oncogenes and proto-oncogenes, 
including RAB26, adreno-receptor alpha 1B (ADRA1B), Jun B proto-oncogene (JUNB), and 
RAB38, are present as are genes known to have influences on important signalling pathways 
in cancer, including the EGFR and KRAS pathways. In addition the WNT beta-catenin 
pathway seems to be playing a role in these cisplatin-treated cells as genes encoding several 
regulators, ligands and receptors of this signalling cascade (necleoredoxin, NXN; secreted 
frizzled-related protein 4,  SFRP4; dickkopf 1 homolog, DKK1; frizzled family receptor 5, 
FZD5) are contained within the gene list (E-Appendix 9.1.5).  
Important regulators of the cell cycle are found within these 375 overlapping genes, such as 
Cyclin D3 (CCND3), which may indicate the cell is attempting to prevent the cells, damaged 
by cisplatin exposure, from replicating. The presence of these effectors is reinforced by a 
recent publication revealing that cisplatin-resistant NSCLC cells accumulate in the G0/G1 
phase of the cell cycle (Barr et al., 2013). The incidence of many candidate tumour 
suppressor genes including platelet-derived growth factor receptor-like (PDGFRL), H19, 
protein tyrosine phosphatase receptor type G (PTPRG), c-MYC binding protein bridging 
integrator 1 (BIN1), and patched 1 (PTCH1) also supports the idea that cell cycle control is 
being influenced by the presence of cisplatin. 
In agreement with the morphological changes that were observed in the cells undergoing 
cisplatin treatment (Chapter 3 Section 3.3.), several genes involved in cell adhesion, EMT, 
and junctions between cells, including NRCAM, L1 cell adhesion molecule (L1CAM), 
sidekick cell adhesion molecular 1 (SDK1), cadherin 12 type 2 (CDH12, Table 4.10), and 
components of collagen molecules, were found within the 375 genes significantly 
differentially expressed in the two treated time courses. 
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Within these 375 overlapping genes are several genes that overlap the same expression 
profile clusters (Sections 4.4.1.1 and 4.4.1.2). Twenty four genes appear in the two increasing 
clusters (Cluster 2 IC50 dose 3 week recovery time course and Cluster 6 IC25 dose 1 week 
recovery time course), while 21 genes are found in both decreasing clusters (Cluster 5 IC50 
dose 3 week recovery time course and Cluster 3 IC25 dose 1 week recovery time course). 
From Table 4.10 it can be seen that some of genes from this list of 45 have been implicated in 
cancer before, such as the EGFR family member, v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (ERBB3 [Young et al., 2013]), the cell cycle protein Cyclin G2 
(CCNG2 [Zimmermann et al., 2012]), the apoptosis regulator Fas cell surface death receptor 
(FAS [Wu et al., 2013]), and TOX high mobility group box family member 3 (TOX3 [Dittmer 
et al., 2011]), which has known genetic variants that are associated with breast cancer. 
Genes in both Increasing Expression Clusters Genes in both Decreasing Expression Clusters 
TOX3, ABCG2, TNC, NOTCH3, SCNN1A, 
HOXB2, LSR, ETV4, CCNG2, MCAM, FAM46A, 
GATSL1, MPZL3, ICA1, EBF1, COL5A1, 
DPYSL5, NR5A2, SFRP1, DUSP6, BACE2, 
MEIS2, PLCE1 
TSPAN8, C17orf60, C7orf68, TNS4, PAQR5, 
ERBB3, ACOX2, HHLA2, MAML3, GATM, 
PTPN14, HAPLN3, GJA1, CDH12, CXXC5, 
RIC3, FAS, ZYX, TLE4, UHRF1, FABP5 
Table 4.10 Genes overlapping the two increasing expression profile clusters (Cluster 2 IC50 dose 3 
week recovery time course and Cluster 6 IC25 dose 1 week recovery time course) and the two 
decreasing expression profile clusters (Cluster 5 IC50 dose 3 week recovery time course and Cluster 3 
IC25 dose 1 week recovery time course).  
GO analyses using DAVID of the 375 genes reinforce the findings from the individual genes. 
The most heavily enriched terms were “signal” and “signal peptide” (enrichment score 6.56; 
B-H adjusted p-value 4.31E-07; 107 genes), closely followed by response to stimuli, such as 
organic substance (GO:0010033), endogenous stimulus (GO:0009719), and steroid hormone 
stimulus (GO:0048545) (enrichment score 3.72; B-H adjusted p-value 0.019; 68 genes total). 
Cell adhesion also featured highly in the GO analysis (enrichment score 3.54; B-H adjusted 
Page | 143  
 
p-value 0.0019; 23 genes) and the epidermal growth factor receptor signalling pathway 
(GO:0007173) was found to be enriched (enrichment score 3.17). Other enriched annotation 
clusters also included heparin binding (enrichment score 2.85; B-H adjusted p-value 0.075) 
and regulation of cell size (enrichment score 2.51; B-H adjusted p-value 0.051). All these 




Investigating the differential gene expression profiles across the course of cisplatin treatment 
and continued cell culture has yielded some fascinating results. Temporal expression 
profiling of the time courses has given clusters of gene expression that can be used for 
identifying important candidates that may be involved in the mechanisms of cisplatin 
resistance. These clusters and the genes within in them may help elucidate ways the cells are 
evading death and continue to grow. 
Those genes that have increasing expression over the course of cisplatin treatment (IC50 dose 
3 week recovery cluster 2; IC25 dose 1 week recovery cluster 6; Section 4.4.1; E-Appendices 
9.1.3 and 9.1.4) may be considered as likely to contain genes that: 
 Promote proliferation in spite of the presence of cisplatin. 
 Enable cisplatin to be removed from the cells via transport. 
 Help the cell to avoid programmed cell death. 
 Enable damaged DNA to be repaired and allow continued cell survival and 
proliferation. 
 Promote an invasive cell phenotype. 
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 Enhance replicative potential. 
In contrast, those genes whose expression decreases over the course of cisplatin treatment 
(IC50 dose 3 week recovery cluster 5; IC25 dose 1 week recovery cluster 3; Section 4.4.1; E-
Appendices 9.1.3 and 9.1.4) may contain candidate genes that: 
 Act as tumour suppressors. 
 Promote cell death and apoptosis. 
 Cause cell cycle arrest. 
 Promote senescence of cells. 
Examples of genes for these processes have been seen in the clusters of interest, as have 
many that have already been associated with cancers, including NSCLC and others such as 
ovarian (Materna et al., 2007), breast (Shehata et al., 2008, Natarajan et al., 2012, Sukowati 
et al., 2012), prostate (Shehata et al., 2008), hepatocellular (Sun et al., 2010, Zhang et al., 
2013b), and colorectal (Zhang et al., 2013b) tumours.  
When examining the top differentially expressed genes (B-H adjusted p-value less than 1E-
14) showing increasing expression over the IC50 dose 3 week recovery time course (Cluster 
2, Section 4.4.1.1) excluding those named in Table 4.8, some candidates for further 
investigations appear, such as the transporter ATP-binding cassette sub-family G member 2 
(ABCG2, Table 4.10). ABCG2 is also known as the breast cancer resistance protein (BCRP) 
and is thought to be involved in the transport and efflux of drugs from cells (Sukowati et al., 
2012). MAL2 (Section 4.3.1) and UDP Glucuronosyltransferase 2 Family Polypeptide B15 
(UGT2B15) are other transporters belonging to this increasing expression cluster with links 
to breast and prostate cancer respectively (Shehata et al., 2008). Cysteine-rich Secretory 
Protein LCCL Domain Containing 1 (CRISPLD1, Section 4.3.1) is also a member of a family 
of proteins thought to have an association with the folate pathway (Chiquet et al., 2011). 
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In the decreased expression cluster for the same time course (Cluster 5, Section 4.4.1.1) are a 
number of adhesion molecules, including Cadherin-1 (CDH1), whose loss of function is 
thought to contribute to cancer progression by increasing proliferation, invasion, and 
metastasis, potentially through EMT (Ye et al., 2012, Zhang et al., 2013b) and Epithelial cell 
adhesion molecule (EPCAM), which is already in use as a target for immunotherapy 
treatment of human carcinomas (Martowicz et al., 2012). More transport proteins are found 
in this cluster also, such as CSAG2 (Section 4.3.1) whose expression has been shown to be 
predictive of clinical outcome in ovarian carcinoma patients (Materna et al., 2007), 
suggesting that alterations in the influx and efflux of cisplatin in and out of the cells may be 
regulated in several ways. 
The increasing and decreasing expression clusters (Clusters 6 and 3 respectively, Section 
4.4.1.2) from the IC25 dose 1 week recovery time course using the same B-H adjusted p-
value cut off of less than 1E-14, also yielded genes of potential interest. Of particular note is 
the presence of two genes, EGFR and EML4, which were previously discussed in Chapter 1 
(Sections 1.6.1 and 1.6.3). Their highly significant differential expression in this time course 
indicates that well-known cancer pathways could be altered for survival in the presence of 
cisplatin.  
Other genes associated with cancer include CCND3 (Section 4.5.2), whose protein has been 
shown to interact with and to be involved in the phosphorylation of the recognised tumour 
suppressor protein, retinoblastoma protein (Rb). It is also thought the Cyclin-dependent 
kinase 4 (CDK4) activity associated with this particular cyclin protein is necessary for the 
cell’s progression into the G2 phase of the cell cycle (Weng et al., 2012), and so its reduced 
expression in this model may link with recent research that cisplatin treatment leads to an 
accumulation of cells in the G0/G1 phase (Barr et al., 2013). 
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Top up-regulated differentially expressed genes in this time course have also been reported to 
be associated with various different types of cancer previously. EGF-like repeats and 
discoidin 1-like domains 3 (EDIL3) is one such example with high expression levels 
predicting poor prognosis of patients in hepatocellular carcinoma (Sun et al., 2010). In the 
cell model in this thesis it showed a two-fold change increase over the time course, while 
Secreted Frizzled-Related Protein 1 (SFRP1), a Wnt protein, may also delay the G1 phase 
and entry into the S phase through its downstream effectors on its increased expression (Ju et 
al., 2009), and so could potentially be working to keep the cells in this phase of the cell cycle, 
similar to CCND3. Increased expression of other genes, Homeobox B2 (HOXB2, Table 4.10), 
Meis Homeobox 2 (MEIS2, Table 4.10), and Melanoma Antigen Family A 2 (MAGEA2), 
have also been associated with pancreatic cancer (Segara et al., 2005), ovarian cancer (Crijns 
et al., 2007), and progression in prostate cancer (Suyama et al., 2010) respectively. 
The 375 significant genes that overlap both treated time courses but are not significantly 
differentially expressed in the untreated (Section 4.5.2), could provide clinically useful 
information on the mechanisms of cellular survival in the presence of repeated cisplatin 
doses. Further network analyses will be performed on these genes to augment the GO 
analyses performed in Section 4.5.2. The presence of GO terms that include growth factor 
receptor pathways and response to stimuli suggests the treated cells are being pushed towards 
growth as a result of the treatment of the cells as well as the cells’ own responses, so that 
understanding the system as a whole is vital. 
The genes found in both IC25 and IC50 regimens are varied and include some well-known 
cancer genes such as EGFR and JUNB (Section 4.5.2); transporter proteins, e.g. transporter 1 
ATP-binding cassette sub-family B (TAP1); adhesion molecules, e.g. basal cell adhesion 
molecule (BCAM), L1CAM (Section 4.5.2), melanoma cell adhesion molecule (MCAM, Table 
Page | 147  
 
4.10), and NRCAM  (Sections 4.3.1 and 4.5.2); RAS proteins, e.g. RAB26 (Section 4.5.2), 
RAS guanyl releasing protein 3 (RASGRP3), ras homolog family member U (RHOU), and 
RAB38 (Section 4.5.2); and even the previously mentioned cell cycle protein CCND3 
(Section 4.5.2), all of which are exciting findings. The combination of these genes may give 
an insight as to the key driving forces within the cell, many of which appear to indicate to the 
hallmarks of cancer discussed in Chapter 1 (Section 1.4). It is possible that the presence of 
transporter proteins in these lists may indicates they are playing a key role in helping the cells 
overcome the presence of cisplatin and survive its toxic effects. As discussed in Chapter 3 
(Section 3.6), the cells may also be using other methods to escape cisplatin-induced death, 
such as the accumulation of cells in the G0/G1 phase of the cell cycle and the presence of 
potential effectors of that found here could support this theory (Barr et al., 2013). 
The overlap between treated and untreated time courses is reflected in their top similar 
functional annotation clusters generated by DAVID, i.e. that signalling molecules or 
glycoproteins are consistently the most enriched in the increasing or decreasing expression 
gene lists, independent of the time course they come from, whether treated or not, whether 
there are more time points, whether the dose is large or small, or whether the recovery is long 
or short. This shows that the key processes maintaining the cells through repeated passages of 
culture consistently rely on signalling, both within and between the cells in a population.  
With the highly stringent threshold p-values, approximately 40% of genes overlap between 
the treated time courses and the untreated (Section 4.5.1) (41.5% IC50 dose 3 week recovery; 
38.0% IC25 dose 1 week recovery) but it is noteworthy that few of these genes seem to share 
the same increasing or decreasing expression profiles over time (Table 4.7 and Table 4.8). 
This suggests that the treated and untreated cells may be under similar controls and regulators 
– the high overlap in differentially expressed genes – but could be acting in dissimilar ways 
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to produce different expression profiles for the same genes. This in turn results in the low 
numbers of overlapping genes within similar increasing or decreasing expression clusters 
over time. 
Each of the 68 unique transcripts from Table 4.8 has been excluded from being defined as a 
gene of interest. A view of the whole system is however required for Network Analyses (see 
Chapter 5) and so they were retained in the list of differentially expressed genes used for 
these investigations.  
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5 Network Analysis 
5.1 Introduction to Network Analysis  
Global gene expression experiments capture an enormous amount of information with great 
accuracy. This information may be analysed in many different ways. In Chapter 4, the 
simplest form of analysis was used by identifying the genes that were the most significantly 
elevated or decreased at the end of the IC25 and IC50 dosing regimens. The use of clustering 
algorithms identified genes that shared distinctive patterns of up and down regulation over 
the entire course of the experiment. The membership of these clusters was determined by 
shared levels of expression at different time points. Genes may however be closely co-
regulated but expressed at widely different levels.  
Network analysis is an analytical tool that can be used to detect genes that are correlated in 
their expression, and will include genes that are negatively correlated as well as genes that 
have widely different absolute levels of expression. Summaries of the gene function (for 
example by GO analysis) of network members may reveal the function of the networks. 
Much can also be learned about co-ordinated gene function in a cellular system by examining 
network architecture, whereby highly connected genes (hubs) may identify suitable points for 
therapeutic intervention. The further level of information offered by network analyses could 
be of great value when investigating cisplatin resistance and has been explored here using 
weighted gene co-expression network analysis (WGCNA).  
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5.2 Weighted Gene Co-expression Network Analysis  
Methods that consider the relationships and correlation patterns between transcripts have 
been successfully applied to a number of complex human traits (Russell et al., 2003, Verdijk 
et al., 2007). These methods, which elucidate the underlying transcriptional network 
structure, have allowed the identification of discrete modules of co-expressed, highly 
correlated, and potentially interconnected genes that associate with disease, intermediate 
disease-related phenotypes, external sample traits, or specific cell types (Smyth, 2004). Here 
the advanced network construction algorithm, Weighted Gene Co-expression Network 
Analysis (WGCNA), was performed using the same differential gene expression data 
generated in Chapter 4 (Section 4.3).  
WGCNA involves several steps, the first of which is construction of a gene co-expression 
network that finds the interaction patterns among genes through their correlations. This 
correlation matrix is then used to identify modules using pathway-based analysis through 
hierarchical clustering (Section 5.2.1). The relationships between the trait of interest and the 
modules are compared (Section 5.2.2) and those of potential biological interest, with possible 
causal implications or particularly high connectivity can be investigated further. Here, the 
resultant modules have been related to inhibitory concentration value (IC25 or IC50 value) as 
a measure of cellular resistance at a particular time. 
 
5.2.1 Creating the Network 
For a weighted network, as is used in WGCNA, an adjacency matrix reports the connection 
strength between gene pairs. To generate the co-expression network, microarray gene 
expression data (pre-processed as outlined in Chapter 4 Section 4.2.3) can be used as the 
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basis of measuring the concordance of gene expression using Pearson correlations. The 
resultant matrix is then transformed continuously with a power adjacency function, which is 
approximately the equivalent of transforming data with highly skewed distributions before 
downstream analyses. The β statistic represents the power to which the correlation is raised.  
The choice of β value requires the choice of a soft threshold power to which the co-
expression similarity, i.e. the Pearson correlation, is raised to calculate adjacency. The lowest 
power for which the scale free topology fit index curve begins to flatten out after reaching a 
relatively high value was chosen (power 12 for IC50 dose 3 week recovery time course see 
Figure 5.1; power 10 for IC25 dose 1 week recovery time course). There is a trade-off 
between maximising scale free topology fit and maintaining a high mean number of 
connections; high signed r
2
 values may lead to networks with few connections. Mean 
connectivity is therefore also taken into account when choosing the value of β. 
 
Figure 5.1 A scale-free topology plot for the IC50 dose 3 week recovery time course. The power of 
12 was used to perform the WGCNA algorithm used for the generation of modules. It can be seen that 
12 also has a suitable mean connectivity (right hand plot) as the larger powers (14 and above) begin to 
have far fewer connections. 
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Once the adjacency matrix has been generated, network module definition can begin. 
Average linkage hierarchical clustering, coupled with a topological overlap dissimilarity 
measure has been used. The Topological Overlap Matrix (TOM) measures the overlap of the 
set of nearest neighbours of nodes or hubs, for example TOMij for hubs i and j. A value of 1 
for TOMij would infer i and j are connected to the same substrates whereas a value of 0 
would indicate that they do not share links to common substrates. The topological overlap 
dissimilarity (DistTOMij) is used as input of hierarchical clustering (Langfelder and Horvath, 
2008). 
This combination of hierarchical clustering and topological overlap dissimilarity allows for 
hubs in the network that have a high topological overlap to be close to each other and for the 
identification of distinct modules. Potential hubs within a network are then associated with 
different modules, with varying strengths. 
A dendrogram (Figure 5.2) was obtained by hierarchical clustering of the topological overlap 
dissimilarity with a height cut-off are used to arrive at clustering. The resultant modules 
correspond to the branches of the dendrogram and were assigned automatically on the 
datasets using Pearson’s correlations.  
Co-expression similarity of an entire module was calculated by their eigengene (the vector of 
the first principal component). These were used to identify transcript clusters which best 
match the module expression profile, summarised by its first principal component, and 
therefore may represent key genes within the pathway. All modules with genes that were 
highly co-expressed or contained fewer than 30 genes were merged. Eigengenes are also used 
as the vector to seek relationships between modules and a range of clinically relevant 
physiological and biochemical parameters. 
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Figure 5.2 The hierarchical cluster dendrogram showing the assignment of genes to modules (colour 
band) based on the TOM for the IC50 dose 3 week recovery time course. 
 
5.2.2 Relating Modules with Traits of Interest 
In order to identify modules that are significantly associated with a particular trait, for 
example IC value as a measure of resistance, the eigengenes generated can be correlated 
quantitatively with the external trait of interest (Figure 5.3). Associations of individual genes 
with the trait of interest can then be quantified by defining Gene Significance (GS) as the 
absolute value of correlation between a particular gene and the trait. The larger the GS value 
is, the more biologically significant it is for that gene and this in turn gives rise to a module 
significance measure. 
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A quantitative measure of module membership (MM) as the correlation of the expression 
profile of the gene and the module eigengene can also be derived. This enables the 
quantification of the similarity of all genes to each module. This statistic, ki, is closely related 
to the concept of intra-modular connectivity (kME) and is a useful indicator of hub gene 
status that may be used to detect key driver genes in modules of interest for a particular trait. 
MM is a measure of kME and so the higher it is, the more likely the gene is to be a key driver 
in that module.  
The most significantly differentially expressed genes within a certain module and their values 
within the TOM are selected out and used to generate Circos plots (Section 5.2.3) to visualise 
the connections. Circos plots are used to map this connectivity in a quantified way; red 
connections show high correlation (98-100%), decreasing the correlations through the 
spectrum (dark orange >96%, yellow >94%, green >92%, royal blue >90%) through to pale 
blue connections, showing a lower correlation (80-90%). For interpretation ease, where the 
number of genes within a module were 50 or less, the Circos plots were created using the 
entire module but for modules with larger numbers of genes, the most significant 
differentially expressed genes (p-value less than 1E-14, same threshold as applied in Chapter 
4 [Section 4.4]) have been used. Combining this representation of connectivity with the top 
kME genes allowed the top hubs within each module of interest to be identified. 
The emphasis on modules and pathways instead of individual genes in WGCNA greatly 
alleviates the problem of multiple comparisons. The use of gene expression data for module 
definition ensures no prior pathway information is used and the use of the power of 
correlations allows for a unified approach for relating variables of interest. 
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5.2.3 IC50 Dose 3 Week Recovery Time Course Modules of Interest 
The 1,515 genes, found to be differentially expressed in the IC50 dose 3 week time course, 
(Chapter 4 Section 4.3) were subject to WGCNA. A total of eight co-expression modules 
were identified using the automatic network construction algorithm and each module was 
assigned a unique identifier (the name of a colour). A total of six transcript clusters remained 
unassigned, showing no significant correlation with any of the observed modules (Figure 5.3, 
full gene lists E-Appendix 9.2.1).  
 
Figure 5.3 A module-trait relationship matrix for the IC50 dose 3 week recovery time course 
modules. The intensity of the red and green colour corresponds to positive and negative correlation 
respectively of that module with the IC50 value. Of particular interest here are the blue and pink 
modules that show significant positive correlation whereas the green and yellow modules show 
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When examining Figure 5.3, it can be seen that the blue and pink modules had the highest 
positive correlation with the IC50 value (r
2
 0.79 p-value 9E-09; r
2
 0.77 p-value 4E-08
 
respectively) while the green and yellow modules had the highest negative correlation (r
2
 -
0.69 p-value 3E-05; r
2
 -0.58 p-value 2E-04 respectively).  Further analyses conducted were 
therefore focused around these four key modules. 
GO analysis of the genes contained within each module showed strong enrichment for 
signalling peptides and glycoproteins for both the blue and green modules. The blue module 
also showed significant levels of “EGF-like domains” (B-H adjusted p-value 2.08E-04) and 
localisation to the plasma membrane region (GO:0031226 B-H adjusted p-value 0.0015).  
The green module genes appeared to have preferential locations to the plasma membrane 
region and the extracellular space although these did not reach significance (GO:0005886 B-
H adjusted p-value 0.039; GO:0005576 B-H adjusted p-value 0.017 respectively). The yellow 
module showed enrichment for lipid biosynthesis and membrane fraction location 
(GO:0008610 B-H adjusted p-value 0.014; GO:0005624 B-H adjusted p-value 0.055 
respectively). The pink module, however, produced no significant functional annotation 
clusters. 
Circos plots of connectivity for the most significant genes within each module were 
generated to visualise potential hubs and their interactions within the module. Figure 5.4 is 
the Circos plot for the blue module (see Appendix 9.3.1 for those of other modules from the 
IC50 Dose 1 Week Recovery Time Course). Certain genes appeared more highly connected 
than others, both in number of connections, indicated by the number of lines emanating from 
each gene’s segment and strength of correlation. For a connection to be seen on the Circos 
plot the correlation has to be over 80% and the strength of this correlation is indicated by the 
colour of the connection; red for the strongest (greater than 98%), pale blue for the weakest 
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(between 80%-90%). Some genes appear to be highly connected with several strong 
connections, such as BAAT, CRISPLD1, the non-coding RNA ENSG00000252867 
(Chromosome 5), MAL2, PFTK1, SGCD, SLC6A14, and ST6GAL2. Interestingly two of the 
most highly connected genes: CRISPLD1 and epithelial marker/transmembrane protein 
MAL2 (Figure 5.4) were found in the increasing temporal expression cluster (Cluster 2) over 
the course of cisplatin treatment (Chapter 4 Sections 4.3.1 and 4.6). 
 
Figure 5.4 Circos plot of the Blue module from the IC50 dose 3 week recovery time course. Several 
strong correlations are visible between the 57 genes on the plot, as shown by the colour intensity. 
Several transcripts have multiple connections (several lines) to other transcripts, some of which are 
especially high in correlation as shown by their red or orange colour. 
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In order to verify mathematically what can be seen visually on the Circos plots, kMEmodule 
values (a measure of eigengene-based connectivity) were used to find potential hubs, 
mathematically (Table 5.1). As expected, the visual connection hubs seen in the Circos plots 
(Figure 5.4 and Appendix 9.3.1) are present in the genes with the greatest kME values, such 
as ENSG00000252867, SLC6A14, and MAL2 in the blue module; SLC40A1 and SCN9A in the 
pink module; LPPR1 and CDH19 in the green module; and CACNG6 and TP53INP1 in the 
yellow module. 
Module 
High Connectivity Genes  
(kME for module >0.92) 
Blue 
ENSG00000252867, SLC6A14, FOXQ1, CRISPLD1, BAAT, GREM1, MAL2, 
ST6GAL2, CHL1, PFTK1, DSEL, MAN1A1, ENPP4, AFAP1, DIRAS3, 
SLC27A6, JAM3, MSX2, SLC16A9, MMP16, MYO5B 
Pink CDCP1, SLC40A1, SCN9A, CXCL1, PSMB9, 
Green LPPR1, CDH19, ACSS3, ITM2A, VSIG1, ANKS4B, UGT2B15 
Yellow 
CADPS2, CACNG6, SCEL, SPARC, CDH6, TP53INP1, TRIM29, BMP7, 
ZNF717, PCDHB5, NFKBIZ, ST3GAL5, CARD8, ETHE1, FDFT1, DHTKD1, 
TP53 
Table 5.1 Most highly connected genes within modules that have the most significant associations 
with IC50 value. The genes in bold correlate with particularly high kME values of greater than 0.95 
(0.97 for the green module). 
Across the four modules of interest generated in the WGCNA, there are genes that were also 
found in the increasing and decreasing temporal expression clusters (Chapter 4 Section 4.4, 
E-Appendices 9.1.3 and 9.1.4; Table 5.2; E-Appendix 9.2.2). The change in expression over 
the time course of any of these hub genes could be of great interest, not just for their 
individual effects but also for the way they affect other substrates in their pathways. Genes of 
particular interest from these investigations will be discussed later (Section 5.3). 
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IC50 Dose 
3 Week Recovery 
Blue (278) Pink (50) Green (150) Yellow (152) 
Up (227) 42 6 24 14 
Down (209) 36 10 14 22 
Table 5.2 Number of genes showing increasing (up) and decreasing (down) expression from the 
temporal expression clustering, conducted in Chapter 4 Section 4.4, across the modules of greatest 
correlation with IC50 value from the IC50 dose 3 week recovery time course. 
 
5.2.4 IC25 Dose 1 Week Recovery Time Course Modules of Interest 
The 1,474 genes found to be differentially expressed in the IC25 dose 1 week time course 
(Chapter 4 Section 4.3) were subject to WGCNA. A total of five co-expression modules were 
identified using the same algorithm for automatic network and module generation (Section 
5.2.3), using a power of 10 for the generation of the adjacency matrix via the use of a scale 
free topology plot. Each module was again identified by a unique colour and a total of three 
transcript clusters remain unassigned, showing no significant correlation with any of the 
observed modules. 
Only three of the modules were found to be significantly correlated with the IC25 value 
(Figure 5.5, for module full gene lists see E-Appendix 9.2.3). The blue module was positively 
correlated (r
2
 0.45 p-value 0.006) whilst the brown and yellow modules were negatively 
correlated (r
2
 -0.84 p-value 2E-10; r
2
 -0.57 p-value 3E-04 respectively). 
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Figure 5.5 A module-trait relationship matrix for the IC25 dose 1 week recovery time course 
modules. The intensity of the red and green colour corresponds to positive and negative correlation 
respectively of that module with the IC25 value. Of particular interest here is the blue module that 
shows significant positive correlation whereas the brown and yellow modules show significant 
negative correlation with IC25 value. The number of genes within each module is shown alongside. 
GO analysis of the genes contained within each module showed strong enrichment for 
signalling peptides and glycoproteins for both the brown and yellow modules (B-H adjusted 
p-value 0.0027 and B-H adjusted p-value 6.57E-04 respectively). The blue module, although 
not significant, showed partial enrichment for cell adhesion processes (GO:0007155). 
Circos plots were generated for these modules of interest to visualise potential hub genes of 
interest (Appendix 9.3.2) and there were genes with several, highly correlated connections 
that are potential hubs. Interestingly within the blue module, these potential hubs include 
well-known genes associated with treatment implications in lung adenocarcinomas, for 
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As seen for the IC50 dose 3 week time course (Section 5.2.3), there appeared to be several 
significantly differentially expressed genes that lie within either increasing or decreasing 
temporal clusters (Chapter 4 Section 4.4; E-Appendices 9.1.3 and 9.1.4), in each of the three 
modules of interest in the IC25 dose 1 week recovery time course (Table 5.3, E-Appendix 
9.2.4). The difference in proportion between the two time courses may be due to the shorter 
time between cisplatin exposure and extraction of RNA or due to the fewer number of 
modules generated from the automatic WGCNA algorithm. Genes of particular interest from 
these investigations will be discussed later (Section 5.3). 
IC25 Dose 
1 Week Recovery 
Blue (349) Brown (319) Yellow (171) 
Up (285) 72 46 30 
Down (323) 73 73 31 
Table 5.3 Number of genes showing increasing (up) and decreasing (down) expression from the 
temporal expression clustering, conducted in Chapter 4 Section 4.4, across the modules of greatest 
correlation with IC25 value generated by the automatic WGCNA module generation algorithm from 
the IC25 dose 1 week recovery time course. 
Due to the large number of genes within modules, e.g. 774 within the turquoise module 
(Figure 5.5), a more stringent level of hierarchical clustering was applied to these modules. 
Conducting the same procedure on the data from the IC50 dose 3 week time course led to no 
changes in module generation. Seventeen modules were produced and correlated with the 
IC25 value. It can be seen from Figure 5.6 that the modules with greatest gene significance 
for IC25 value are the midnight blue, green, green yellow and purple modules (for full gene 
lists of all modules, see E-Appendix 9.2.5). The green yellow module has the highest positive 
correlation (r
2
 0.72 p-value 7E-07) while the midnight blue, green, and purple have the 
highest negative correlations (r
2
 -0.86 p-value 2E-11; r
2
 -0.81 p-value 2E-09; r
2
 -0.72 p-value 
9E-07 respectively). These modules will be the focus in the search for potential hub genes. 
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Figure 5.6 A module-trait relationship matrix for the IC25 dose 1 week recovery time course modules 
generated by cutting higher on the clustering dendrogram, reducing the number of modules. The 
intensity of the red and green colour corresponds to positive and negative correlation respectively of 
that module with the IC25 value. Of particular interest are the midnight blue, green, and purple 
modules that show significant negative correlation whereas green yellow module shows significant 
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As outlined in Section 5.2.2, kMEmodule values were used to mathematically find potential 
hubs within these four modules (Table 5.4). As is to be expected, the high connectivity genes 
in these modules overlap heavily with those from the automatic network construction 
modules. 
Module 
High Connectivity Genes  
(kME for module >0.95) 
Midnight Blue CCDC80, TP63, CA2, NEDD9, RH3HDML, SULT2B1, LSR, FOXA3, 
TGFBR1, UBASH3B, ZNF850P, CNTNAP1 
Green  BAAT, GLI3, TGM2, DMKN, ITGA11, SDR42E1, 
Green Yellow ETS2, ZNF616, DOK6, PDLIM7, EML4, LPCAT2, UTY, KDM5D, 
DENND5B 
Purple DPYSL3, C21orf63, CA8, A1CF, ITM2A, DCDC5, RH3HDML, CADM2, 
PPP1R1C, CRABP1, HHLA2, HNF4A, DEDDD2D  
Table 5.4 Most highly connected genes within the reduced modules that have the most significant 
associations with IC25 value. 
The decrease in the number of genes within the modules of interest subsequently leads to a 
decrease in the proportion that appear in the increasing and decreasing temporal expression 
clusters over the course of cisplatin treatment (Chapter 4 Section 4.4, Table 5.5, E-Appendix 
9.2.6) compared with earlier in this section (Table 5.3). Using these smaller modules allows 
more specific potential genes of interest to be elucidated. Genes of particular interest from 
these investigations will be discussed later (Section 5.3). 
IC25 Dose 







Up (285) 6 23 9 8 
Down (323) 8 31 12 12 
Table 5.5 Number of genes showing increasing (up) and decreasing (down) expression from the 
temporal expression clustering, conducted in Chapter 4 Section 4.4, across the modules of greatest 
correlation with IC25 value for reduced WGCNA modules from the IC25 dose 1 week recovery time 
course. 
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5.2.5 Normal Untreated A549 Cells Time Course  
In order to perform comparisons, the 865 genes found to be differentially expressed in the 
normal untreated time course (Chapter 4 Section 4.5.1) was subject to WGCNA Three co-
expression modules were identified (each assigned a unique colour) with ten transcript 
clusters remain unassigned (Table 5.6, E-Appendix 9.2.7). 
Module Blue Brown Grey Turquoise 
No of Genes 278 154 10 423 
Table 5.6 The number of genes within each module colour after the WGCNA algorithm has been 
performed on the 865 differentially expressed genes from the normal time course. The grey module 
contains genes that cannot be assigned to a module. Full gene lists are available in E-Appendix 9.2.7. 
GO analysis was performed to see what processes were enriched in the normal time course 
modules. All three modules involve a membrane-associated GO term (Table 5.7) and a 
glycoprotein (turquoise and blue modules) or signal (brown module) term, suggesting that 
these are the main processes within normal A549 cells not under the selection pressure of the 
presence of cisplatin. The presence of these GO terms in the untreated time course WGCNA 
modules suggests that it may be worth focusing on the functional annotation clusters that do 
not match these exactly in the treated time courses WGCNA (Sections 5.2.3 and 5.2.4). The 
lack of references to growth receptors, regulation of differentiation, responses to various 
stimuli, and similar terms that have been seen in previous GO analyses (Chapter 4 Sections 
4.4.1.1, 4.4.1.2 and 4.5.3; Chapter 5 Sections 5.2.3 and 5.2.4) suggests these may be the key 
terms that result from cisplatin exposure. 
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Module GO Term Enrichment Gene Count B-H p-value 
Turquoise 
Plasma membrane 9.4 100 2.9E-10 
Glycoprotein 8.13 160 2.1E-12 
Plasma membrane 5.76 145 1.2E-10 
Cell migration,  motion, and 
locomotion 
5.2 18 7.0E-04 
Blue 
Glycoprotein 5.53 96 6.3E-05 
Membrane fraction 3.82 30 2.8E-03 
Complement and 
coagulation cascade 
2.27 10 3.1E-04 
Brown  
Plasma membrane 4.51 37 2.7E-03 
Signal 3.83 49 1.6E-04 
Cell adhesion 1.99 11 4.4E-02 
Table 5.7 Highly enriched GO term functional annotation clusters for the modules created by the 
automatic network generation WGCNA algorithm for the 865 differentially expressed genes from the 
normal untreated time course. 
 
5.2.6 Differentially Expressed Genes in both Treated Time Courses but not present in the 
Untreated Time Course 
Previous analyses (Chapter 4 Section 4.5.3) that had taken into consideration changes in 
expression observed without cisplatin treatment found that 375 genes were differentially 
expressed in both treatment time courses when taking the normal time course into account. It 
is conceivable that key genes involved in evasion of cisplatin-induced cell death are 
contained within this set of genes and that their interactions together and with other genes 
may be highly biologically relevant.  
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The RMA data from the IC50 dose 3 week recovery time course was used as the expression 
data required for the WGCNA, rather than the IC25 dose 1 week recovery time course, 
because of the smoother increase in IC50 value over the course of cisplatin exposure (Chapter 
3 Section 3.4) and for the matching of time points with the normal untreated time course. The 
adjacency matrix was created using a power of 26, according to scale free topology (Section 
5.2.1) and the automatic network generation algorithm was used to give the modules outlined 
in Figure 5.7. Fifteen transcript clusters remained unassigned, showing no significant 
correlation with any of the observed modules. 
As previously described, the eigengenes of these modules were correlated with increasing 
IC50 value. From Figure 5.7, it can be seen that the green, yellow, and blue modules have the 
highest positive correlation with the IC50 value (r
2
 0.82 p-value 11E-09; r
2
 0.75 p-value 1E-
07; r
2
 0.59 p-value 1E-04
 
respectively). It is noteworthy that all modules with a significant 
association with IC50 value have a positive correlation. 
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Figure 5.7 A module-trait relationship matrix for the 375 genes only differentially expressed in the 
treated time courses using the IC50 dose 3 week recovery time course data. The intensity of the red 
and green colour corresponds to positive and negative correlation respectively of that module with the 
IC50 value. Of particular interest here are the green, yellow and blue modules that show significant 
positive correlation with IC50 value. The number of genes within each module is given alongside. 
MM within the yellow module was found to exhibit a positive correlation with the gene 
significance for increasing IC50 value (cor= 0.66, p-value = 6E-07), confirming this may be 
meaningful biologically and suggest the presence of hub genes. The same can be said for the 
MM of the blue module (cor= 0.45, p-value = 1.7E-04) and the blue module (cor= 0.62, p-
value = 1.5E-05). 
In order to investigate the potential presence of hub genes within the three modules of 
interest, Circos plots (Appendix 9.3.3) and measures of intra-modular connectivity, kME 
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strength of correlation between the module members than has been seen previously. GO 
analyses however yielded no significant functional annotation clusters. 
Module High Connectivity Genes  
(kME for module >0.9) 
Green TLL1, DSEL, SGCD, FGFR1, PCDH7, CCDC146, JAM3, NID2 
Yellow CDCP1, DCDC5, SCN9A, BTBD11, L1CAM, RHOU, FAS, TAP1, PLCD3 
Blue 
HHLA2, SLN, C21orf63, ANKRD30A, TBC1D2, PRKCH, OR51B4, CTSH, 
NRCAM, LPAR5, R3HDML, SPATA18, PTPRG 
Table 5.8 Most highly connected genes from the 375 overlapping genes within modules that have the 
most significant associations with IC50 value. 
 
5.3 WGCNA Discussion 
The focus of this chapter has been to explore further the differential gene expression findings 
for the two cisplatin time courses by using WGCNA to identify modules of genes that may be 
under co-regulation or working together. There are a number of genes, identified through 
these network analyses which are of particular interest due to prior studies implicating them 
in cancer pathways and phenotypes, and drug transport. 
For both time courses, genes were found to overlap both modules with an association for the 
IC value and the increasing and decreasing temporal expression clusters (Chapter 4 Section 
4.4). Any potential hubs that show increasing or decreasing expression over cisplatin rounds 
could be important genes. As discussed earlier in this chapter (Sections 5.2.3 and 5.2.4), 
combining information gleaned from temporal expression clusters and the modules generated 
from WGCNA on genes of interest, it is possible to begin to build a picture of those genes 
that may be exhorting a driving force for survival of cells when exposed to cisplatin in 
culture. 
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Eight modules were generated using the data from IC50 dose 3 week recovery time course 
and those of interest that show correlation with the IC50 value (blue, pink, green, and yellow) 
all contain genes that have previously been implicated in various cancers. These genes are 
also within temporal expression clusters of interest (Chapter 4 Section 4.4.1.1) 
The blue module from the IC50 dose 3 week recovery time course has a large proportion of 
the genes that increase and decrease in correlation with cisplatin treatment and there were a 
couple of genes that could be of particular interest that were highly significantly differentially 
expressed (B-H adjusted p-value less than 1E-14). ABCG2 that encodes the Breast Cancer 
Resistance Protein (BCRP), known to be associated with drug transport and efflux (Sukowati 
et al., 2012), showed a significant increase in expression over the time course, while GPC6 
decreased over the course of treatment.  Interestingly a homolog of GPC6, GPC1 has been 
implicated in pancreatic cancer (Whipple et al., 2008). 
In the pink module, the Tenascin C gene was seen to increase over the course of cisplatin 
treatment and previously its product has been shown to enhance cancer cell growth and 
motility, affecting cell adhesion through integrin pathway activation (Paron et al., 2011).  
The green module contained many of the genes with the smallest B-H adjusted p-values with 
increases and decreases in expression over the cisplatin treatment time. Some have already 
been shown to have effects on tumour progression and invasiveness on increased expression 
including UGT2B15 that has been shown to have differential protein expression in prostate 
tumour cells during cancer progression (Pâquet et al., 2012). The taxol-resistance-associated 
gene CSAG2 also had significant differential expression within this module and is known to 
be predictive for clinical outcome in ovarian carcinoma patients (Materna et al., 2007). 
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In the yellow module, a further three genes of potential interest were found to have either 
highly significant differential increases or decreases in expression. VSNL1, also known as 
VILIP1, is a putative suppressor that counteracts EGF-induced epithelial-mesenchymal 
transition (EMT) in squamous carcinoma cells (Schönrath et al., 2012) and is known to be 
down-regulated during NSCLC mechanisms (Fu et al., 2008), as has been seen in the time 
course experiment of this present study. The other two genes are: TP53INP1 a known target 
for a miRNA, miR-17-5p, that regulates cell proliferation and apoptosis in cervical cancer 
(Wei et al., 2012) cells and BMP7 expression has been proposed to possibly affect lung 
cancer cell invasion ability, potentially with clinical significance (Liu et al., 2012). 
The same is true for the IC25 dose 1 week recovery time course. Five modules were 
generated using the automatic network construction and those of interest showing correlation 
with the IC25 value (blue, brown, and yellow) all contain genes that have previously been 
implicated in various cancers. Several of these are also within temporal expression clusters of 
interest (Chapter 4 Section 4.4.1.2).  
The blue module contained many genes known to be associated with cancer pathways, such 
as EML4 (Chapter 1 Section 1.6.3), TNS4 a target of KRAS signalling (Al-Ghamdi et al., 
2011), and SGK1 that is known to be required for mTORC1 activity in breast cancer (Hall et 
al., 2012), as well as decreasing drug sensitivity of colon cancer cells (Amato et al., 2012). 
Another potentially important gene in this module is PDXK.  PDXK encodes the protein that 
phosphorylates vitamin B6, a step key in its metabolism, which may influence intracellular 
accumulation of cisplatin (Galluzzi et al., 2013a) and may have effects on oncogenesis, 
tumour progression and therapeutic responses (Galluzzi et al., 2013b). SLIT3 (Dickinson et 
al., 2011), MEIS2 (Crijns et al., 2007) and FOSL2 (Hein et al., 2009) also have altered 
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expression in this module over the time course and have been associated with ovarian cancers 
and malignant potential.  
Interestingly several cancer-related-pathway genes were found to have significant differential 
expression in the brown module. SPARC protein expression has already been shown to 
correlate with clinical characteristics of NSCLC (Huang et al., 2012) and IGFBP7 down-
regulation has been observed in cisplatin-resistant NSCLC (Okamura et al., 2012) so the 
decreasing expression of these two genes over the time course, is not wholly unexpected. 
Other genes with previous reports of association with NSCLC were also present in this 
module with significant changes in expression. These include CDH12, associated with 
NSCLC promotion and progression (Bankovic et al., 2010), potentially by enabling invasion 
and HMOX1, associated with NSCLC tumour invasiveness and poor clinical outcome (Tsai et 
al., 2012), potentially through autophagy- and apoptosis-related molecules (Banerjee et al., 
2012). Similar to findings for the other modules, genes associated with other cancers as novel 
biomarkers were also observed in the brown module such as DMKN a prognostic indicator of 
early stage colorectal cancer (Tagi et al., 2010). Genes and their products with links to 
ovarian cancer also appear: PAQR5 (Charles et al., 2010), TUSC3 (Pils et al., 2013), FILIP1 
(Xie et al., 2011), and SCN9A (Yildirim et al., 2012). 
In the yellow module, again there were several genes with significant differential expression 
of potential interest. ALX1 is known to promote EMT through SNAIL expression and has 
been found in global expression changes for A549 cells exposed to anti-cancer drugs (Yuan 
et al., 2013). Constitutive activity of other members of this module, found to have increasing 
expression over the cisplatin time course, have also been associated with poor prognosis in 
other cancers: EDIL3 (Sun et al., 2010), LPAR1 (Marshall et al., 2012), TNC (Paron et al., 
2011), SFRP1 (Elzi et al., 2012). Hypo-expression of other members CADM2 (Chang et al., 
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2010) and PLA2G4A (Zhang et al., 2013a) are thought to correlate with unfavourable 
outcomes in prostate and gastric cancers respectively. 
Modules generated with the greater hierarchical clustering stringency also contain genes of 
biological interest. The midnight blue module, , contains a few genes that have already been 
highlighted as potential markers for cancer prognosis (MAP7 [Blum et al., 2008], TSPAN7 
[Wuttig et al., 2012], and CXXC5 also known as RINF [Knappskog et al., 2011]). SIK1 is 
also present in this module. It is induced by TGF beta to negatively regulate type I receptor 
kinase signalling (Kowanetz et al., 2008) and couples the known cancer gene LKB1 (Chapter 
1 Section 1.6.7) to induce p53-dependent cell-detachment apoptosis (Cheng et al., 2009), and 
acts as a tumour suppressor and prevents metastasis (Shaw, 2009). 
Genes in the green module have already been associated with various cancers and even 
responses to treatment. Two up-regulated genes have been identified as potential markers in 
chemo-resistant epithelial ovarian cancer (RNF125 [Ju et al., 2009]) and for NSCLC (KRT15 
[Sanchez-Palencia et al., 2011]). ERGIC1 has also been identified as a potential drug target 
in prostate cancer (Vainio et al., 2012). Potential oncogenes and tumour suppressors are also 
found in this module. RASGRP3 has been found to contribute to the tumorigenic phenotype 
in human melanoma (Yang et al., 2011) as well as forming and maintaining of the prostate 
cancer phenotype (Yang et al., 2010) and a knockdown of the FGFBP1 has been shown to 
have anti-tumour effects on knockdown in colon carcinoma (Schulze et al., 2011). RASSF8 
(Lock et al., 2010), ZFP36 (Upadhyay et al., 2013), and CRIP2 (Cheung et al., 2011) appear 
to have anti-tumour effects through suppression of tumorigenesis, angiogenesis, and invasion. 
ATIC also resides in this module and is another potential fusion partner for ALK (Zhang et 
al., 2010) (Chapter 1 Section 1.6.3), similar to EML4 (Blue/Green Yellow module). 
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Two genes with decreased expression over the course of cisplatin treatment in the green 
yellow module have previously used there down-regulation as a marker for disease and 
prognosis, or with poor survival (DPP4 [Javidroozi et al., 2012] and POPDC3 [Luo et al., 
2012]). The adhesion molecule, JAM3, also in this module, has also had its expression 
correlated with progression in gastric adenocarcinoma (Hajjari et al., 2013), while TGFBI has 
been associated with tumour suppression in mesothelioma (Li et al., 2012) and MED29 has 
shown both oncogenic and tumour suppressive characteristics (Kuuselo et al., 2011). 
The purple module contains three genes previously seen in the automatic modules generated 
by the WGCNA algorithm (TNC, LPAR1, and CADM2) but also contains the cancer/testis 
antigen 45 A5 (CT45A5) that is thought to be a potential novel target for therapy 
(http://ncbi.nlm.nih.gov/gene) and TGFBR3, whose transient overexpression is thought to 
induce apoptosis in nasopharyngeal carcinoma cells (Zheng et al., 2013).  
Genes such as EML4 and EGFR are already known to play roles in NSCLC. Others observed 
here that may have been seen in other cancers or are less well known in NSCLC, such as 
CSAG2, ABCG2, PDXK, IGFBP7, HMOX1, ALX1, SPARC, and VSNL1, may be key players 
in driving the cisplatin-resistant phenotype of the A549 cells.  
Across all the modules of significance that have been focused on, there appear to be highly 
significant, differentially expressed genes that may be involved in oncogenic or tumour 
suppressor roles; that affect the adhesion status of the cell; initiate or propagate 
tumorigenesis, invasion, or metastasis; influence the apoptotic potential of the cells; are 
suggested to have involvement in EMT; are within key cancer-related pathways; or affect 
drug metabolism or efflux in to or out of the treated cells. 
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WGCNA also allows one to identify within modules potential key hub genes through 
measures of intra-modular connectivity, producing even more potential candidate driver 
genes. Some occur with high significance within modules, such as EML4, DMKN, and 
CADM2 appearing in the IC25 dose 1 week recovery, independent of how the modules were 
created. In the IC50 dose 3 week recovery time course, even more hubs defined by high intra-
modular connectivity appear in the top significantly differentially expressed genes, such as 
MAL2, JAM3, UGT2B15, TP53INP1, and BMP7. Other well described cancer genes such as 
TP53 and TP63 (Su et al., 2012) are also seen as potential hubs in the two treated time 
courses. SPARC and ITM2A are two genes that are statistically suggestive of being hub genes 
with strong significant differential expression in both treated time courses, although the 
possible action of ITM2A is less well explored than SPARC. 
Some of the other high intra-modular connectivity genes seen here have previously shown 
association with cancer phenotypes. SLC6A14, a member of the IC50 dose 3 week recovery 
time course blue module the latter correlating with IC50 value, could be a potential 
transporter of interest as it has already been related to cervical cancer (Gupta et al., 2006), 
colorectal cancer and metastasis (Gupta et al., 2005), and suggested as a potential drug target 
(Karunakaran et al., 2011). FOXQ1, in the same blue module over expression is thought to 
influence NSCLC prognosis and associate with EMT (Feng et al., 2012a) as well as 
promoting glioma cell proliferation and migration (Sun et al., 2013).   
Hub genes found only in the IC25 dose 1 week recovery include NEDD9, GLI3, and ETS2. 
NEDD9 is associated with poor predictive prognosis of NSCLC (Kondo et al., 2012) and may 
be capable of mediating lung cancer progression through LKB1 loss (Feng et al., 2012b). 
This may link in with the SGK1 gene discussed earlier (IC25 dose 1 week recovery blue 
module). GLI3 is a hedgehog activator signal that enhances the tumour phenotype of 
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colorectal cancer through the up-regulation of adherence-related genes (Iwasaki et al., 2012), 
which may help to explain the abundance of adherence genes seen in the differentially 
expressed genes. ETS2 has been proposed as a potential candidate gene for squamous lung 
cancer (Bai and Hu, 2012) as well as possibly promoting etoposide resistance in cooperation 
with mutant p53 (Do et al., 2012). 
Investigations of the WGCNA generated modules for the 375 differentially expressed genes 
in common between the two time courses, but not present the untreated time course, yielded 
further potential hubs, some of which can be found in the top genes from the individual time 
courses e.g. JAM3 and SCN9A. Others have been associated with cancer too, such as FGFR1, 
TAP1 and SGCD. FGFR1 has had oncogenic amplifications in lung cancer documented 
(Oxnard et al., 2013, Pros et al., 2013) whilst overexpression of transporter, TAP1, has been 
associated with increased cancer cell-specific apoptosis and anti-tumour immune response in 
prostate cancer (Qiu et al., 2012). An intronic SNP  within the SGCD gene has  been 
associated with increased expression of SGCD and subsequent paclitaxel sensitivity in the 
NCI60 cancer cell line (Eng et al., 2011). 
In amongst all these potential genes could be key mutated driver genes that encourage the 
tumour progressive or cisplatin-resistant phenotype seen in the cultured cells over the time 
course (Chapter 3 Section 3.4). The recurrence of well-known cancer genes appearing as 
potential hubs from the WGCNA analyses suggest that the cancer or drug resistant phenotype 
investigated here, though obviously heterogeneous, may be as a result of previously 
characterised signalling pathways, for which the GO analyses provides some evidence. It is 
possible that the mechanisms of resistance to platinum compounds and other 
chemotherapeutics are general within cancer cells. To reduce the numbers of genes and 
validate potential biomarkers, comparison of these results with differential gene expression 
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data from patients, both of normal and tumour tissue, especially those of treated versus 
untreated with platinum chemotherapy (Chapter 4 Section 4.5.2), will be vital. 
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6 Gene Expression Analysis of Patient Samples 
6.1 The Need for Validation in Patient Samples 
The in vitro cellular model of cisplatin dosing that has been optimised and established 
(Chapter 3 Sections 3.2-3.4) has generated, through transcriptome studies, a number of gene 
lists of potential interest in relation to cisplatin resistance (Chapters 4 and 5).  These genes 
now require investigation in an in vivo setting in order to validate their potential as indicators 
of changing genomic response to platinum compounds. If any show substantial and 
significant differences between platinum-treated and untreated patients, it is possible they 
may be useful markers of response to platinum or be helpful in the elucidation of the 
pathways of evasion from cisplatin-induced death. 
Two cohorts of patients have been used for this validation but there are some important 
factors that have to be considered when working with whole tissue samples. Perhaps the most 
critical is the recognition that samples are heterogeneous in nature. It is feasible that the 
biopsy taken is not representative of the tumour, or normal lung tissue, as a whole. The fact 
that all the patients are individuals with their own genetic backgrounds may also lead to 
strong inherent variability between the samples that are subsequently grouped together for 
analyses. Tumours may appear to have mixed morphologies too that may alter their genomics 
and lead to different profiles. This may also be the case with tumours at different stages or 
with different nodal involvements and therefore careful phenotyping is essential. 
The use of different surgical approaches may lead to the potential for some variability in the 
samples, such as biopsy from lung resection versus biopsy from rigid bronchoscopy, which 
may also lead to differences in the genomics of the tissue. In addition surgeons may be 
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limited spatially as to what tissue is available for biopsy.  Areas of necrosis and fibrosis must 
also be avoided in an attempt to acquire an adequate viable sample of the tumour.  
The selection of matched “normal” tissue from an individual is difficult to choose; it is 
possible, if not probable that the area surrounding the tumour is not equivalent to true normal 
lung due to its proximity to the tumour itself and so may phenotypically be closer to a 
neoplastic phenotype. “Normal” samples may even be of a totally different structure such as 
fat tissue, and not be representative of the non-neoplastic lung. If a large sample is taken that 
is then dissected into smaller samples for research, this adds another level of potential 
sampling error. Small sample sizes are equally a problem as their representativeness is 
questionable and downstream processing, such as physical handling, and RNA and DNA 
extraction is technically more challenging.  
The freezing of the sample after biopsy may affect tissue integrity. As little delay as possible 
between excisions and freezing should be attempted to ensure that the state of the tumour is 
as similar to in situ as possible. The freezing process should be rapid to prevent any large 
crystal formation within the sample that could affect the cellular structure.  
In spite of these various limitations and potential pitfalls, human samples give us the 
opportunity to look at what is actually happening in human lung cancers. Tissue samples 
from two patient cohorts, RESTORE-AIR and EQUALITY, both ascertained and recruited 
through St George’s Hospital London, were available to explore further the WCGNA and 
expression clustering findings from the in vitro cellular model of cisplatin resistance.  
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6.2 RESTORE-AIR – Randomised Evaluation of STents to Open 
REstricted AIRways in patients with centrally placed non-small cell 
lung cancer 
The RESTORE-AIR study builds upon a previous pilot study that had shown good 
improvement in breathlessness in lung cancer patients with the insertion of a bronchial stent. 
Patients with a NSCLC diagnosis and a central tumour suitable for rigid bronchoscopy and 
bronchial stenting were evaluated for study inclusion.  
Patients were consented for voluntary tissue biopsy, by rigid bronchoscopy, at time of stent 
insertion. If consent was given, three sets of biopsies were taken under general anaesthetic 
whenever possible. The first set of tumour and normal bronchial tissue biopsies were 
immediately placed in RNALater [Qiagen] (RNAse inactivation buffer). The second pair 
were frozen in liquid nitrogen and subsequently stored at -80
o
C, whilst the final pair were 
used to make formalin-fixed, paraffin embedded (FFPE) blocks for immuno-histochemical 
staining by the pathology laboratory. 
A total of eight paired samples stored in RNALater were available for the investigations done 
as part of this thesis. Demographics for the seven patients are given in Table 6.1. Seven out of 
eight patients had been treated with platinum and the majority (six out of seven) of these had 
relapsed. It is worth noting that sample 203 had been exposed to many more lines of drug 
therapy than any other (eight compared to zero to two). This may have had a marked effect 
on the comparative gene expression profiles and genome in general after many potentially 
cytotoxic drug exposures.   
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101 74 Current White British Y 2 Y 12 
203 81 Ex White British Y 8 Y 19 
204 67 Ex White British Y 1 Y 7 
206 59 Ex White British Y 1 Y 21 
207 63 Current White British Y 2 Y 17 
208 61 Current White British N 0 N 0 
214 61 Ex White British Y 1 Y 4 
215 70 Never White British N 1 Y 5 
Table 6.1 Demographics for the seven RESTORE-AIR study participants. Details include exposure to 
and relapse after chemotherapy treatment with platinum compounds. Seven patients have been treated 
with platinum and six of these have relapsed. Sample 203 has been exposed to many more lines of 
drug therapy than any other (eight compared to zero to two). All samples were collected by rigid 
bronchoscopy. 
 
6.3 EQUALITY – Expression QUAntitative trait Loci mapping In 
Tumours collected at biopsY 
EQUALITY is an on-going prospective study to identify expression quantitative trait loci in 
patients with thoracic cancers undergoing biopsy. Patients, referred to St George’s Hospital 
for consideration of clinically indicated biopsy by rigid bronchoscopy or thoracic surgery, 
with a likely or proven diagnosis of NSCLC, SCLC, mesothelioma, or pulmonary carcinoid 
have been recruited (nine in total at the time of this current study). Only those of subtypes of 
NSCLC i.e. adenocarcinomas and squamous cell carcinomas were included for this study. 
During rigid bronchoscopy or thoracic surgery, three sets of research biopsies were taken 
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when feasible, with processing and storage identical to that used for the RESTORE-AIR. In 
addition, at the time of registration, samples of the participants’ blood, plasma and urine were 
taken for future genetic, metabolomic and proteomic work. 
Only four of the nine EQUALITY samples collected, all obtained by rigid bronchoscopy, 
were suitable (NSCLC adenocarcinoma or squamous histological subtypes) to be combined 
with those from the RESTORE-AIR study for the validation work. All available 
demographics are given in Table 6.2. Details such as relapse after therapy and platinum-free 
interval were unavailable. 
ID Age Subtype Smoker? Ethnicity Previous 
Platinum 
treatment? 
No. of Previous  
Lines of Drug 
Therapy 
EQ3 70 Squamous Ex White British Y 1 
EQ4 82 Squamous Ex White British N 0 
EQ6 52 Squamous Ex White British Y Unknown 
EQ7 60 Adenocarcinoma Ex White British Y 1 
Table 6.2 Demographics for EQUALITY patients that can be combined with those from the 
RESTORE-AIR study for these investigations. 
 
6.4 RNA Extraction from Tissue Samples  
RNA was extracted from patient tissue samples using the QIAgen RNeasy Fibrous Tissue 
Mini kit with a few minor modifications to the manufacturer’s instructions in order to 
optimise yield (Chapter 2 Section 2.2.3.1). To improve disruption and homogenisation of the 
tissue rather than conducting a single homogenisation of 20-40s with the TissueRuptor, 
several 30s homogenisations were done up to a maximum of five with samples being placed 
on ice in-between bursts. In addition the length of the Proteinase K digestion was increased 
from 10 minutes to two hours. All resulting RNAs had RINs ≥ 8.5. 
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Despite these optimisations it was observed that normal non-tumour tissue in general tended 
to result in lower yields of RNA, insufficient for microarray work, compared to tumour 
tissues, although a few of the latter gave miniscule yields. This difference (normal versus 
tumour tissue yield) could be due to intrinsic differences in the activity of tissues, such as 
some tumours may be more highly genomically active, giving larger yields of RNA than their 
normal tissue counterparts, or there may be inherent variability between some tissues and 
others leading to the wide variation seen in RNA concentrations.  
A final contributing factor might be the fact that RESTORE-AIR is an historic collection and 
the recommended protocol for storing tissue in the RNA stabilisation reagent RNALater has 
since been modified from when the original collection took place and the present time. 
Originally tissue was stored in the RNALater at -20
o
C over the course of 24 hours before 
being transferred to -80
o
C for long term storage.  Recently the manufacturers (Qiagen – 
suppliers of RNALater and the RNAeasy fibrous kit) recommend removing the stabilisation 




C for archival storage. This suboptimal 
procedure combined with a relatively long freeze (at least four years) could have potentially 
led to some of the reduced yields observed upon extraction. The same procedure was applied 
for the EQUALITY sampling.  
In total, nine tumour and six normal samples were successfully extracted (Table 6.3) and 
subject to processing for Affymetrix Human Gene 1.1 ST arrays (Chapter 2 Section 2.2.3.2). 
Four normal (RA203N, RA204N, EQ3N, and EQ4N) and three tumour samples (RA101T, 
RA204T, and EQ7T) gave too low RNA yield after extraction for further global gene 
expression analyses.  
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RESTORE-AIR 203 Squamous T 97.2 
RESTORE-AIR 206 N/A N 47.6 
RESTORE-AIR 206 Squamous T 2787.2 
RESTORE-AIR 207 N/A N 186.7 
RESTORE-AIR 207 Squamous T 58.9 
RESTORE-AIR 208 N/A N 338.8 
RESTORE-AIR 208 Squamous T 72.6 
RESTORE-AIR 214 N/A N 227.9 
RESTORE-AIR 214 Squamous T 1273.6 
RESTORE-AIR 215 N/A N 75.1 
RESTORE-AIR 215 Adenocarcinoma T 60.8 
EQUALITY 3 Squamous T 48.2 
EQUALITY 4 Squamous T 326.8 
EQUALITY 6 N/A N 310.5 
EQUALITY 6 Squamous T 1150.9 
Table 6.3 RNA extraction from tissue for RESTORE-AIR and EQUALITY samples showing the 
resulting concentrations. Four normal and three tumour samples gave too low RNA yield after 
extraction for further global gene expression analyses. The remaining fifteen were subject to RNA 
processing and microarray hybridisation for gene expression analyses. 
 
6.5 A Dataset for Comparisons of Platinum Treatment versus Non-
Treated Samples 
Data from a set of non-platinum-treated tumour samples was available (Molecular Genetics 
Group: unpublished data) was used as a control for the platinum-treated patient tumour 
tissues These 35 control samples were taken at the time of surgical resection. The dataset 
consists of global gene expression profiles of paired (normal and tumour) tissue samples, 
either adenocarcinoma (20 samples) or squamous cell carcinoma (15 samples). The untreated 
samples selected for comparative analysis from this extensive dataset were matched as 
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closely as possible for age, gender, smoking status (Current, Ex or Never) and subtype at the 
time of biopsy, to those from the EQUALITY and RESTORE-AIR studies. Careful batch 
removal and outlier detection was required to ensure any false positives and negatives were 
eliminated as far as possible. All patients were of white British or Irish ethnicity. For ease of 
analyses, all adenocarcinoma samples (including RA215T) were removed to retain focus on 
the squamous subtype. 
6.5.1 Outlier Detection and Removal, and Microarray Quality Control 
The selected six cases (platinum-treated) and eleven out of a possible fourteen controls (non-
platinum-treated) (Table 6.4) were subject to the same quality control measures as previous 
CEL files (details given in Chapter 4 Section 4.2) prior to differential expression analysis. 
Briefly the seventeen CEL files for the proposed matches between cases and controls were 
subject to RMA normalisation using APT, followed by stringent outlier removal using inter-
array correlation (IAC) – the Pearson’s correlation coefficient of the expression levels for a 
given pair of microarrays using all probe sets for which data are available.  
The removal of outliers is extremely important, especially in investigations where a historical 
dataset is being used for comparison. IAC outlier exclusion is based solely on microarray 
samples with divergent gene expression levels, with no operator bias or input and so produces 
a dataset with overall consistent and comparable of gene expression amongst all the samples 
used. The RMA box plot of the seventeen CEL files used for these analyses (Figure 6.1) 
infers that some of these samples may be strong outliers, a fact which was confirmed after 
rounds of IAC (Figure 6.2 and 6.3). Any sample with a mean IAC more than two standard 
deviation of away from the total mean IAC was therefore excluded as an outlier and 
successive rounds of this logical sample removal strategy were implemented until none of the 
CEL files fitted this criterion (Figure 6.4). 
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Study ID Age Gender Histology Pt 
Treatment 
Smoker Ethnicity 
EQUALITY 3 70 F Squamous Y Ex White British 
EQUALITY 4 82 M Squamous N Ex White British 
EQUALITY 6 52 F Squamous Y Ex White British 
RESTORE-AIR 203 81 M Squamous Y Ex White British 
RESTORE-AIR 206 59 M Squamous Y Ex White British 
RESTORE-AIR 207 63 M Squamous Y Current White British 
RESTORE-AIR 208 61 M Squamous N Current White British 
RESTORE-AIR 214 61 M Squamous Y Ex White British 
Lung Resection Study 1052 66 F Squamous N Ex White British 
Lung Resection Study 1065 63 M Squamous N Ex White British 
Lung Resection Study 1114 71 F Squamous N Ex White British 
Lung Resection Study 1119 74 M Squamous N Ex White British 
Lung Resection Study 1121 78 M Squamous N Ex White Irish 
Lung Resection Study 1175 82 M Squamous N Ex White British 
Lung Resection Study 1178 82 M Squamous N Ex White British 
Lung Resection Study 1179 68 M Squamous N Current White British 
Lung Resection Study 1186 81 F Squamous N Never White British 
Lung Resection Study 1199 76 M Squamous N Ex White British 
Lung Resection Study 1206 63 F Squamous N Current White British 
Lung Resection Study 1209 68 F Squamous N Current White British 
Lung Resection Study 1211 71 F Squamous N Ex White British 
Lung Resection Study 1223 68 M Squamous N Current White British 
Table 6.4 Demographics for Patient Samples for differential expression analyses. Samples 1052, 
1065, 1114, 1121, 1175, 1178, 1179, 1211, 1223 and RA208 were used as controls to match the six 
platinum-treated patients (RA203, RA206, RA207, EQ3, EQ4, and EQ6) for age, gender, and 
smoking status as closely as possible. All patients were of white British or Irish ethnicity and any 
adenocarcinoma cases were excluded to prevent possible batch effects.  
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Figure 6.1 Box plot of normalised intensities (log expression signal) of the seventeen patient samples. 
X1065T.CEL and X1178T.CEL appear smaller than the other boxes and with a greater number of 
potential outlier points (red dots at the end of the whisker of the plot). 
 
 
Figure 6.2 Hierarchical cluster dendrogram of all seventeen .CEL files using 1-IAC as the distance 
metric. It can be seen that X1065T.CEL and X1178T.CEL appear again as outliers on this plot, as 
observed in Figure 6.1. 
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Figure 6.3 Plot showing the distribution of the mean IAC for each array, where numbersd equals (the 
array mean IAC – mean of all mean IAC) divided by the standard deviation of the mean IAC. An 
outlier was defined as being at least two standard deviations outside the mean of all mean IAC. Here it 
can be seen that one sample (X1178T.CEL) fulfils this criteria and was subsequently removed. A 
further round of this outlier removal led to X1065T.CEL and RA203T.CEL also being excluded. 
 
Figure 6.4 Plot showing the distribution of mean IAC for each array after outlier removal with no 
CEL files falling outside the standard deviation cut off. All these remaining fourteen samples were 
taken into PCA. 
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The method of IAC outlier exclusion led to the removal of 1178T.CEL, 1065T.CEL and 
RA203T.CEL and the remaining fourteen samples were subject to PCA to check for potential 
batch effects in this reduced dataset. As can be seen in Figure 6.5, there is a definite split 
between the samples from the lung resection study (blue points, legend = LR) and the 
EQUALITY and RESTORE-AIR studies (red and green points, legend = EQ and RA 
respectively). This is most likely a reflection of the different methods of tissue sampling, 
surgical lung resection versus biopsy by rigid bronchoscopy. The RNA extraction methods 
and array platforms implemented for all samples were the same. Fortunately this split can be 
removed thanks to the presence of untreated controls in the rigid bronchoscopy studies, thus 
differences due to treatment will be retained. 
 
Figure 6.5 PCA plot showing the distribution of the three studies. It can be seen that the red and green 
(EQUALITY (EQ) and RESTORE-AIR (RA) samples) cluster together on the right hand side of the 
plot while the blue (Lung Resection (LR) Study) cluster on the left of the plot. Thanks to the presence 
of untreated samples in both clusters this batch effect, potentially caused by the two different methods 
of biopsy, can be corrected for. 
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After correction for this strong batch effect in the RMA data another PCA was performed. 
Batch correction led to a more even scattering of the samples across the PCA plot (Figure 
6.6) although one single outlier (1211T.CEL) still remained and was therefore excluded. This 
strong batch effect was removed in the study design for linear modelling before analysis of 
differential expression between treated and non-treated tumours took place.  
 
Figure 6.6 PCA plot showing how the batch effect of study has been removed to give a more even 
dataset. Only one outlier 1211T.CEL remained and was subsequently removed and excluded from 
further analyses. The same legend applies as for Figure 6.5, i.e. red are for EQUALITY (EQ) 
samples, green are for RESTORE-AIR (RA) samples, and blue are for the Lung Resection Study 
(LR). 
Due to the mixture of three different studies, RESTORE-AIR, EQUALITY and the Lung 
Resection Study, all of which originally had different purposes, the numbers and matches of 
treated and untreated patients has not been easy. The presence of an untreated sample within 
both rigid bronchoscopy data sets (RESTORE-AIR and EQUALITY) is fortunate as it 
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allowed the strong batch effect of “Study” (Figure 6.5) to be controlled and the data to be 
compared.  
The only platinum-treated sample to be removed by outlier detection was RA203T; the only 
patient to have received more than two lines of previous drug therapy. It is possible that the 
many rounds of successive therapies caused gross genetic changes to the patient’s tumour, 
and possibly normal lung tissue. The tumour may also have evolved naturally over time, as 
the patient may have lived longer than the others in order to receive these therapies. These 
may have been so profound that their expression profile was extensively different from the 
other samples and could have led to its outlier status. 
 
6.6 Differential Expression Analysis  
The RMA data from the thirteen samples that had passed quality control and outlier exclusion 
(Section 6.5.1) were used to explore the differences in expression of the genes from the lists 
and modules of interest generated from the cisplatin resistance cell model (Chapters 4 and 5). 
These gene lists of interest were the increasing and decreasing expression clusters from the 
IC50 dose 3 week recovery time course and the IC25 dose 1 week recovery time course 
(Chapter 4 Sections 4.4.1.1 and 4.4.2.1) and modules of interest comprised of those with 
strong positive and negative correlations with IC value of cisplatin (Chapter 5 Sections 5.2.3, 
5.2.4 and 5.2.6) (Table 6.5). 
Each individual gene list, ranging between 31 and 323 genes, was subject to a separate 
differential expression analysis, conducted using the RMA data from the patient samples 
comparing those platinum-treated cases with untreated control patients. Study, gender, and 
smoking status were all included as batch effects in the linear model performed using the R 
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package Limma. The additional variable of the age of patient could not be included, as the 
linear model could not be generated with few individuals being of exactly the same age 
(range=52-82, mean=70, 14 unique ages, Table 6.4). Each treated sample was contrasted with 
every untreated sample to give a T-statistic for each gene and the resultant p-value was B-H 
adjusted for multiple comparisons, as with all previously reported statistics. Use of these gene 
lists reduces the number of comparisons performed in one analysis and hence should yield 
statistically significant and stringent p-values. With this in mind, the threshold applied for 
significance was B-H adjusted p-value <0.01. Most clusters or modules harboured genes that 
were significantly differentially expressed between the treated and untreated samples with 
twenty one genes with B-H adjusted p-values <0.01 with a number exhibiting substantial fold 











Page | 192  
 
 
Time Course Module or Cluster Number of Genes 
IC50 Dose 3 Week Recovery Increasing expression 227 
IC50 Dose 3 Week Recovery Decreasing expression 209 
IC25 Dose 1 Week Recovery  Increasing expression 285 
IC25 Dose 1 Week Recovery  Decreasing expression 323 
IC50 Dose 3 Week Recovery Blue Module – Positive 
Correlation with IC50 value 
278 
IC50 Dose 3 Week Recovery Pink Module – Positive 
Correlation with IC50 value 
50 
IC50 Dose 3 Week Recovery Green Module – Negative 
Correlation with IC50 value 
150 
IC50 Dose 3 Week Recovery Yellow Module – Negative 
Correlation with IC50 value 
152 
IC25 Dose 1 Week Recovery  Midnight Blue Module – Negative 
Correlation with IC25 Value 
31 
IC25 Dose 1 Week Recovery  Green  Module – Negative 
Correlation with IC25 Value 
138 
IC25 Dose 1 Week Recovery  Green Yellow Module – Positive 
Correlation with IC25 Value 
49 
IC25 Dose 1 Week Recovery  Purple Module – Negative 
Correlation with IC25 Value 
65 
IC25 Dose 1 Week Recovery  Light Cyan Module – Negative 
Correlation with IC25 Value 
25 
IC25 Dose 1 Week Recovery  Blue Module – Negative 
Correlation with IC25 Value 
171 
IC25 Dose 1 Week Recovery  Salmon Module – Positive 
Correlation with IC25 Value 
40 
375 Overlapping Genes Green Module – Positive 
Correlation with IC50 Value 
41 
375 Overlapping Genes Yellow Module – Positive 
Correlation with IC50 Value 
46 
375 Overlapping Genes Blue Module – Positive 
Correlation with IC50 Value 
64 
Table 6.5 The time course expression clusters and WGCNA modules, including the number of genes 
per list, used to perform differential expression analyses between the treated and untreated patient 
tissues. Positive and negative correlations with respective IC50 or IC25 value have been indicated. 
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Table 6.6 Top 21 Genes, seen in patients, from differential expression analyses using the genes of interest taken from the in vitro cellular model. From 




























Galanin-GMAP prepropeptide – a small neuropeptide that functions as cellular 
messenger in central and peripheral nervous system. It contracts the smooth muscle of 
gastrointestinal and genitourinary tract, regulates growth hormone release, modulates 
insulin release, and the control of adrenal secretion. 
Disruption of galanin expression or galanin receptor signalling has been seen in many 
multifactorial conditions suggesting role in development and/or pathology of certain 
diseases, including cancer. It and its receptor GAIR1 have been identified as novel 
determinants of chemotherapy resistance and potential biomarkers in colorectal 















Internexin – neuronal intermediate filament protein alpha. It covers the axoskeleton 
and functionally maintains neuronal calibre. It may play a role in intracellular 
transport to axons and dendrites and be involved in neuronal morphogenesis. 
Immunohistochemical detection of IDH1 mutation, p53 and internexin as prognositc 
















Sodium Channel voltage-gated type IX alpha subunit. 
Significant role in nociception signalling mutations associated with primary 
erythromalgia, channelopathy-associated insensitivity to pain. 
 












α/β hydrolase domain containing 4. 
A genome-wide short-hairpin RNA screen identified ABHD4 as a potential novel 
regulator of resistance to apoptosis induced by anchorage-dependent cells detaching 










Alternative gene name SPTSSB – Serine palmitoyltransferase small subunit B. It 
catalyses the first committed and rate-limiting step in sphingolipid synthesis and may 










Cytochrome P450 family 2 subfamily S polypeptide 1 – a monooxygenase, which 
catalyses many reactions involved in drug metabolism and synthesis of cholesterol, 
steroids and other lipids. Its homologous protein in rodents has been shown to 






















RAB15 – a member of the KRAS signalling pathway. 
Expression has been shown to correlate with retinoic acid-induced differentiation of 











Ubiquitously transcribed tetratricopeptide repeat gene Y-linked – is a potential 
histone de-methylase. It contains tetratricopeptide repeats that are thought to be 
involved in protein-protein interactions. 




0.00198 0.0804  3wk Blue 
Module 
 
Actin filament associated protein 1 – an SRC binding partner and potential modulator 
of actin filament integrity in response to cell signals. It may function as adaptor 
protein by linking SRC family members and/or other signalling proteins to actin 
filaments.  
It has been potentially shown to play role in development and progression of prostate 
adenocarcinoma by regulating cell-matrix adhesions and migration in cancer cells. 
CYorf15A 
0.00316 0.277  IC25 Green 
Yellow Module 
TXLNG2P – Taxilin Gamma 2 Pseudogene. 
KDM5D 
0.00315 0.209  IC25 Green 
Yellow Module 
Lysine-specific demethylase 5D Y-linked. 
MAP2K3 
0.00420 2.80 IC25 Down Cluster 
 
 Mitogen activated protein kinase kinase 3 – a dual specificity protein kinase that can 
be activated by insulin and by cytokines/environmental stress. It catalyses 
concomitant phosphorylation of threonine and tyrosine residue in MAP kinase p38. 
Proteome profiling of immortalisation to senescence transition of human breast 
epithelial cells identified MAP2K3 as a senescence-promoting protein, which is 
down-regulated in human breast cancer (Jia et al., 2010). 
RAS oncogene expression was found to result in the accumulation of this kinase’s 
active form, subsequently leading to constitutive activation of MAPK14 and 
conferred oncogenic transformation of primary cells. 
MGC70870 
0.00941 0.348  IC25 Green 
Module 
C-terminal binding protein 2 pseudogene. 
 
QRFPR 






Pyroglutamylated RFamide peptide receptor – receptor for the orexigenic 
neuropeptide QRFP. 
Its activity is mediated by G proteins that modulate adenylate cyclase activity and 
intracellular calcium levels. 




0.000286 2.71  IC25 Salmon 
Module 
Regulator of G-protein signalling - acts as GTPase activating proteins for G alpha 
subunits of heterotrimeric G proteins and drive G proteins into inactive GDP-bound 
forms. It has roles in leukemogenesis and the negative feedback control pathway for 
adenylyl cyclase signalling. It also binds EIF2B5 and blocks its activity inhibiting 
translation of mRNA into protein.  
In human airway epithelial cells, RGS 2 has been shown to inhibit acid-induced 
mucin5AC hypersecretion, and its relatives RGS10 and 17 regulate chemoresistance 
in ovarian cancer cells (Liu et al., 2013, Sethakorn and Dulin, 2013). 
RPS4Y1 
0.000140 0.166  IC25 Green 
Module 
Ribosomal protein S4 Y-linked 1. 
Patient gender is associated with distinct patterns of chromosomal abnormalities and 
sex chromosome linked gene-expression profiles in meningiomas. 
SERINC5 
0.00420 1.95 IC25 Down Cluster 
 
 Serine Incorporator 5. 
Enhances the incorporation of serine into phosphatidylserine and sphingolipids. 
SLC46A3 
0.00642 0.500  3wk Blue 
Module 
Solute carrier family 46 member 3.  
ST3GAL1 
0.00407 2.19  IC25 Green 
Module 
ST3 beta-galactoside alpha-2,3-sialyltransferase – a type II membrane protein that 
catalyses the transfer of sialic acid from CMP-sialic acid to galactose-containing 
substrates. 
Transcript levels of ST3GAL1 and other glycosyltransferase genes were significantly 
elevated in colon cancer cells undergoing EGF/bFGF-induced epithelial-
mesenchymal transition, possibly through the action of known cancer gene, cMYC 
(Sakuma et al., 2012). 
USP9Y 
0.00657 0.283  IC25 Green 
Yellow Module 
Ubiquitin specific peptidase 9, Y-linked – a member of peptidase C19 family that 
may play an important regulatory role at protein turnover level. It is an essential 
component of TGFbeta/BMP signalling cascade and deubiquitinates 
monoubiquitinated SMAD4, opposing the activity of E3 ubiquitn-protein ligase 
TRIM33. 
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The genes INA, SCN9A, ABHD4, C3orf57, CYP2S1, RAB15, HMCN1, MAP2K3, QRFPR, 
RGS2, and ST3GAL1 all show an increase of at least two fold between the treated and non-
treated group and so the combination of this with their low B-H adjusted p-values marks 
them out as potential genes for further investigations. Even larger fold changes are observed 
as QRFPR, SCN9A, and INA showed over a five-, seven-, and ten-fold increase in expression 
in platinum-treated patients respectively. As well as genes with substantial increases in gene 
expression when contrasting treated with untreated patients, there are several genes that show 
the inverse pattern, i.e. a substantial decrease in those treated with platinum. GAL, UTY, 
AFAP1, CYorf15A, KDM5D, MGC70870, RPS4Y1, SLC46A3, and USP9Y all show at least a 
two-fold decrease in the platinum-treated samples when compared with the untreated patients 
and RPS4Y1 showed over a six-fold decrease. With a large proportion of these 21 genes 
showing such large fold changes, their potential importance and changes in their related 
signalling pathways and networks of genes that they may interact with cannot be overlooked. 
The large fold increase in INA expression in patients is corroborated by its appearance in 
IC50 dose 3 week recovery time course blue WGCNA module, which shows positive 
correlation with increasing IC50 value (Figure 6.7). RAB15 and ABHD4 are also found in this 
module, as well as the increased expression over the course of the IC50 dose 3 week recovery 
time course, which is replicated in these patient samples (Figures 6.8 and 6.9). 




Figure 6.7 Box and whisker plot showing the expression of INA across the samples, separated into 
non-platinum-treated (left – n, N=8) and platinum-treated (right – y, N=5). A substantial increase in 
expression can be seen in the treated samples compared with the untreated. 
 
Figure 6.8 Box and whisker plot showing the expression of RAB15 across the samples, separated into 
non-platinum-treated (left – n, N=8) and platinum-treated (right – y, N=5). A substantial increase in 
expression can be seen in the treated samples compared with the untreated, so much so that the 
interquartile ranges of the two groups do not overlap. 




Figure 6.9 Box and whisker plot showing the expression of ABHD4 across the samples, separated 
into non-platinum-treated (left – n, N=8) and platinum-treated (right – y, N=5). A substantial increase 
in expression can be seen in the treated samples compared with the untreated. 
The direction of association with platinum treatment between patient gene expression and the 
in vitro model’s gene lists are not always correlated. AFAP1 lies in the same blue WGCNA 
module from the IC50 dose 3 week recovery time course as INA, RAB15 and ABHD4, 
however in the patient analyses, a large decrease of over twelve-fold (the reciprocal of 0.0804 
Table 6.6) between the treated and untreated patients was observed and can be seen in Figure 
6.10. 




Figure 6.10 Box and whisker plot showing the expression of AFAP1 across the samples, separated 
into non-platinum-treated (left – n, N=8) and platinum-treated (right – y, N=5) patient samples. A 
substantial decrease in expression can be seen in the treated samples compared with the untreated. 
To investigate this further, the potential hubs (high connectivity genes) from the WGCNA 
networks (Chapter 5 Section 5.2), were compared with these 21 genes, as well as a further 82 
unique transcripts that showed significant at a lower B-H adjusted p-value threshold of 0.05 
differences in expression between non-platinum treated versus platinum-treated patient 
samples.  
Of the top 21 genes, four appear as hubs in the various modules; SCN9A, AFAP1, UTY and 
KDM5D, two of which (SCN9A and AFAP1) have very large fold changes when comparing 
treated and untreated tumour samples. Using the less stringent p-value, the number of hubs 
increases with an additional eight genes (CGB5, CGB, GLI2, ZNF28, DCDC5, VSIG1, 
CRISPLD1, and ATP1A3). 
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When examining theses 82 less significant transcripts (B-H adjusted p-value of less than 
0.05), there are a few particularly interesting candidates. Several genes also fall into 
functional groups with associations with cancer or signalling pathways that may have effects 
on the metabolism or transport of drugs or xenobiotics, or that affect the proliferative, 
transcriptional, and metabolic activities of the tissues.  
The known oncogene, FOS, is found in the increasing expression cluster of the IC25 dose 1 
week recovery time course, and MXD1, a histone deacetylase recruiter, may also affect 
cancer signalling pathways through c-MYC antagonism. DDIT4 (or REDD1) shows a two-
fold decrease in platinum-treated samples and is a negative regulator of the mTORC1 
complex that in turn is a positive regulator of transcription and protein synthesis. This 
reduction of DDIT4 in the presence of platinum could lead to a pro-proliferative signal in 
these samples and may also allow for cell survival after DNA damage (Vadysirisack et al., 
2011). 
As mentioned previously Barr et al. (2013) have suggested there are alterations in the cell 
cycle with the accumulation of cisplatin-resistant cells in the G0/G1 phase. The lower 
significance threshold gene list of this present study shows differential expression of 
transcripts with potential to influence these processes. CDKN1A, found to have nearly a two-
fold increase in the treated cohort, is an inhibitor of cyclin-dependent kinases and so is a key 
regulator of cell cycle progression at G1. It has also been found to be up-regulated in 
radiotherapy resistant A549 cells (Yang et al., 2013), suggesting this halt at G1 could be key 
in DNA damage growth arrest in resistant cells. GADD45B is also a gene whose transcript 
levels increase following stressful growth arrest conditions and treatment with DNA-
damaging agents, mirrored by its near two-fold increase of the treated patient cohort. This has 
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also been reported tin human colorectal carcinoma (Wang et al., 2012). RB1, like p53, is vital 
in control of the cell cycle and it is potentially regulated by another gene in the list of 103 
transcripts – SMYD2, a lysine methylase. It has a near two-fold decrease in the treated group, 
which may also be promoting cell cycle arrest by the lack of phosphorylation of RB1 in the 
presence of platinum (Cho et al., 2012).  
TMEM45 shows a three-fold increase in treated patients compared to untreated and is thought 
to be essential for hypoxia-induced chemo-resistance in breast and liver cancer cells (Flamant 
et al., 2012). SIDT1, over two-fold increase in platinum-treated samples, facilitates small 
RNA transfer between human cells and thus can allow intercellular transfer of a miRNA that 
drives chemo-resistance (Elhassan et al., 2012). 
When the top 21 genes (B-H adjusted p-value of less than 0.01) are focused on, similar gene 
groups can be found. MAP2K3 and RAB15 are known to be associated with or involved in 
cancer-related pathways. The active form of MAP2K3 is thought to accumulate on expression 
of the oncogene KRAS, and confers oncogenic transformation of primary cells. The MAPK 
family have also been implicated in cellular response to cisplatin and subsequent resistance 
(Brozovic and Osmak, 2007) and NSCLC cisplatin resistant cell lines have been shown to 
have higher base line levels of MAP2K3 protein and potentially inhibit cell death, via p38 
MAPK on exposure to cisplatin (Galan-Moya et al., 2011). RAB15 is a member of the same 
oncogene family and its alternative splicing has been suggested to serve as a biomarker to 
discriminate tumour-initiating cells from non-tumour-initiating cells in neuroblastoma (Pham 
et al., 2012).   
Signalling pathways and molecules have already been shown to be important in the cellular 
model and this theme continues with the top 21 genes. GAL is a small signalling molecule in 
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the central and peripheral nervous system (http://www.genecards.org) and QRFPR is thought 
to have G-proteins coupled receptor activity and have a role in control of neuroendocrine 
functions and adipogenesis (Mulumba et al., 2010, Chartrel et al., 2011). RGS2 as its name 
suggests, is also involved in G-protein signalling and acts as a GTPase activating protein, 
driving G proteins into their inactive GDP-bound forms. It has been shown to be down-
regulated in the majority of solid tumours including lung cancers (Sethakorn and Dulin, 
2013). The PI3K pathway that is associated with proliferation also appears to be altered.  
The potential for the increase in cellular activity may also lead to further cellular synthesis, 
possibly through C3orf57 and CYP2S1, both of which are involved in various lipid synthesis 
and an increase in the latter is thought to have effects on drug metabolism (Thum et al., 
2006).  
As well as leading to changes in the DNA damage response and cell cycle, platinum 
resistance may be the result of alterations in the transport properties of the cells, something 
that is suggested by the large increase in SCN9A expression in the treated samples. 
Overexpression of SCN9A mRNA has already been reported in cervical cancer (Hernandez-
Plata et al., 2012). The presence of another relatively unknown solute carrier in top 21 genes 
(SLC46A3) suggests there may be other mechanisms at work that also result in alteration of 
the potential across membranes. This may be reinforced by the presence of other genes in the 
lower significance list that have association with chemo-resistance.  
The presence of UTY and KDM5D may indicate differences in epigenetic regulation of the 
genomics between the treated and untreated samples. Both are histone demethylases, and 
KDM5D has lysine-specific activity and have almost five-fold decreases in expression in the 
platinum-treated cohort in comparison with the untreated. This is suggestive of a reduction of 
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histone de-methylation, and in turn of an alteration in chromatin structure and potentially 
subsequent global gene expression changes. Both are apparent hubs of connectivity (Chapter 
5 Section 5.2), which is unsurprising as a change in histone methylation could lead to and 
correlate with differential expression of several other genes. 
AFAP1, identified as a hub in the WGCNA analysis, is a binding partner for the tyrosine 
kinase proto-oncogene SRC. It may modulate the actin filament integrity in response to 
cellular signals and has been suggested to play a role in development and progression of 
prostate adenocarcinoma by regulating cell-matrix adhesion and migration in the cancer cells 
(Zhang et al., 2007). The large over twelve-fold decrease seen of this mRNA transcript 
suggests a substantial change between the treated and untreated cohorts, and potentially the 
loss of cell-cell interactions or adhesions which may have implications for progressive 
disease and possibly be indicative of forthcoming move to an invasive phenotype. 
It would also be worth investigating these top 21 genes in more depth at both a sequence and 
epigenetic level to establish what is causing the differences at transcriptome level, such as 
whether there is DNA variation in the promoter affecting the binding of key transcription 
factors or promoter methylation. Studies into the downstream effects of the differential 








This preliminary study looking into a small number of patient samples in an attempt to find 
validation for results from the previously described cisplatin-resistance cellular model has 
been relatively successful, in spite of its limitations. A small cohort has been produced for the 
comparison between platinum-treated and non-platinum-treated tumours of squamous origin.  
The small numbers of samples remaining after stringent outlier detection and removal 
(Section 6.5.1) means the statistical strength of the differential expression investigations 
performed here is limited. Some genes that do not reach the adjusted statistical significance 
threshold applied here could nonetheless be involved in the mechanism of response and 
resistance towards cisplatin and platinum compounds in general, but without more patient 
samples no firm conclusions can be drawn. Ideally, a specific tissue collection should be set 
up for patients with NSCLC for both those treated with cisplatin and other platinum treatment 
regimes, possibly several cycles of treatment, and those of the same age, gender and smoking 
status that had never been exposed to any platinum or DNA-damaging therapy. This would 
provide a more suitable cohort of samples for comparison with the cellular models of 
cisplatin resistance. These types of studies are beginning to be established, but primary care 
of patients is obviously of primary importance and therefore it is not always feasible to get 
patients before their first chemotherapy exposure, especially due to the risks associated with 
lung biopsy. 
Despite this present study’s limitations, genes of interest from the cell model have been found 
to have significant and large fold changes of differential expression between the treated and 
untreated samples. These are found in both the temporal expression clusters and the WGCNA 
modules of interest that show both positive and negative correlations with the relevant IC 
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value. Several of these genes appear to have links with various known cancer pathways 
already. INA, which showed a ten-fold increase in platinum-treated samples, has been 
suggested as a prognostic marker for glial tumours when combined with p53 and IDH1 
mutations (Takano et al., 2012). RAB15 is a member of the RAS oncogene family that has 
been implicated in neuroblastoma initiation (Nishimura et al., 2011) and shows two-fold 
increase in treated patients. The MAPK family have already been associated with cisplatin 
resistance (Brozovic and Osmak, 2007). It could be suggested that others such as SCN9A and 
SLC46A3, may be involved in the transport in the cells and therefore alter their phenotype or 
even affect resistance to cisplatin. CYP2S1 has also been implicated in xenobiotic metabolism 
that may affect the cellular response to cisplatin when differentially expressed. It would 
therefore be worthwhile to explore these 21 genes further in larger cohorts of patients and 
validate that the changes seen in gene expression occur at the protein level as well. 
The substantial fold changes seen for some of the top 21 genes (up to a ten-fold increase or a 
twelve-fold reduction) combined with their importance shown in network analyses (Chapter 5 
Section 5.2) suggest these highly connected genes could be having considerable effects on 
their environment and influencing other members in their signalling pathways. One could 
infer these alterations in a handful of genes might be having a large impact on the 
transcriptome as whole and consequently the tumour on exposure to platinum treatment. It is 
interesting to note that some of the genes identified as WGCNA hubs (Chapter 5 Section 5.2 
and Section 6.6) are present in both the top 21 genes as well as those of lower significance 
thresholds (B-H adjusted p-value of less than 0.05, e.g. ATP1A3, CRISPLD1, GLI2, and 
VSIG1) and may therefore be worthy of further investigation. AFAP1, a hub in the top 21 
genes with a greater than twelve-fold decrease in treated patients, is thought to act as an 
adaptor for SRC family members, which themselves are implicated in the activation of human 
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cancer (Irby and Yeatman, 2000). This preliminary study of patient samples, despite its 
limitations has nevertheless generated some genes worthy of further investigation. 
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7 Discussion and Future Work  
Cancer is a highly diverse disease characterised by multiple mutations that produce the 
resulting final phenotype seen in an individual patient. Within lung cancer itself there are 
many different subtypes which may exhibit great heterogeneity in different patients, and in 
different sites in the same patient and in their subsequent response to treatment. It is therefore 
highly possible that two individuals, or even two sites of a tumour in the same individual, 
may not react to the same treatments in the same manner.  
In this research project, an attempt has been made to begin to dissect out the complex 
genomic (RNA expression) response to cisplatin treatment in order to begin to understand the 
genes and signalling pathways and involved in cisplatin resistance.   
 
7.1 Discussion 
7.1.1 A549 Cellular Models of Cisplatin Resistance 
Following extensive optimisation, two robust cellular models of repetitive cisplatin dosing 
were successfully established using the A549 cell line (Chapter 3).  These two models were 
run over the course of several weeks. At each dosing time point, a measure of resistance 
(IC25 or IC50 value) was calculated and DNA and RNA were harvested from the cells in for 
in-depth genomic investigation. By synchronisation of cell harvesting and dosing, an 
overview of the cells’ genomic environment at the time of treatment was feasible.  
These datasets have yielded detailed information about the population genomic dynamics of 
the model. Because the response to cisplatin may be, to some extent, random and 
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heterogeneous the model may reflect the heterogeneity within an individual tumour that is 
often seen in patient histological specimens. 
 
7.1.2 Temporal Gene Expression Profiling 
The unique approach of studying profiles of differentially expressed genes over the two 
treated cisplatin time courses as well as the untreated normal time course, has allowed 
investigations of changes in global gene expression that may result from cisplatin dosing. The 
study of multiple time points allowed the evolution of changes within the treatment regime to 
be investigated. This provides more information than solely focusing on the comparison 
between resistant and chemo-naïve cells, as is frequently the case in the published literature. 
The application of a highly stringent B-H adjusted p-value has produced genes of robust 
significance that show distinct changes over the course of cisplatin treatment (Chapter 4 
Section 4.3).  A number of changes seen may have potentially large effects. Those changes 
that are simplest to interpret biologically (i.e. increasing and decreasing gene expression with 
increasing cisplatin doses) have been focused on with the anticipation of finding genes that 
may be of particular interest.  
It is hoped that the removal of genes in common between treated and untreated cells will 
reduce or even eliminate any changes in transcription that appear simply as a result of 
extended cell culture (Chapter 4 Section 4.5.2). It is conceivable however that some of these 
genes may also be of importance in promoting cisplatin resistance despite their presence in 
untreated cells. It is possible that extended cell culture is a model for cellular immortalisation, 
which may show hallmarks of cancer, such as cell cycle progression and replication in spite 
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of DNA damage. The difference in and absence of certain DAVID GO terms between the 
untreated and treated time courses (Chapter 4 Section 4.6) however, suggest that the systems 
in action on exposure to cisplatin are distinct from those for continued cell culture. 
One limitation of the data from the normal untreated time course is the lack of information on 
the change in IC25 or IC50 value over time. It is possible that the IC value will increase over 
the repeated rounds of extended cellular passage, irrespective of treatment with cisplatin. If 
the cells accumulate mutations over this period, it is possible that these changes will alter the 
response to cisplatin, without being exposed to it, and thus affect their IC value. 
The application of highly stringent p-values may have had their own limitations in the gene 
expression analyses. Although the ~33,000 transcripts interrogated by the Affymetrix Gene 
Arrays needed to be reduced to a manageable number for statistical investigations, it is 
possible that some low penetrance genetic effects could be masked when using such a harsh 
statistical threshold. A compromise was made to give a balance between stringency and 
workability and, several potential genes of biological interest have been found. These include 
genes encoding the transporter proteins ABCG2, CSAG2, MAL2 and UGT2B15, the 
adhesion molecules CDH1 and EPCAM, and known cancer genes EGFR and EML4, all of 
which have been previously implicated in other cancers. Others have already been shown to 
be involved in chemo-resistance (the genes ABCG2, CSAG2 and SFRP1). 
The direct comparisons between the two time courses, with similar numbers of significant 
differentially expressed genes using the stringent threshold, allowed overlapping genes 
(N=375) between the two treatment time courses to be identified. These overlapping genes, 
also not present in the untreated time course, may be the key to the potential mechanisms of 
survival in the presence of repeated cisplatin dose, irrespective of treatment regime (Chapter 
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4 Section 4.5.2). The 375 genes were a varied mixture of known cancer genes, transporter 
proteins, adhesion molecules, and cell cycle proteins. This assortment of genes and the 
potential subsequently activated pathways gives an indication as to how complex the system 
of chemo-resistance and continued proliferation and survival is.  Nonetheless the 375 genes 
may prove to be key signalling hubs and therefore are of significant interest. 
 
7.1.3 Network Analysis 
The use of correlation matrices of gene expression data from the Affymetrix Gene Arrays and 
the resulting WGCNA have enabled a more general overview of significant differential 
expression within the cellular models to be generated. Using this approach has meant that the 
possible interactions between genes were investigated as a whole. 
Investigating the correlations in expression profiles via the intermediary of eigengenes allows 
their (and their corresponding modules) to be compared with the trait of interest which was 
IC value in this thesis. Consequently it becomes possible to identify hub genes within 
modules highly positively and negatively correlated with the trait. The hub genes can then be 
teased out of the large dataset both visually through Circos plots and statistically by 
investigating their module membership, to give possible candidate genes of interest to be 
investigated biologically and be compared with the results from the temporal expression 
clustering. 
Four modules were found to be significantly correlated with IC50 value for the IC50 dose 3 
week recovery time course while the smaller modules for the IC25 dose 1 week recovery 
Page | 212  
 
 
time course led to correlating modules containing fewer genes and a further reduction of 
genes of interest (Chapter 5 Sections 5.2.3 and 5.2.4). 
Genes already investigated with increasing or decreasing expression over the time course that 
were found in modules with positive or negative correlation to IC value included the 
transporters ABCG2, CSAG2 and UGT2B15 in the IC50 dose 3 week recovery regime.  In the 
IC25 dose 1 week recovery time course, one module contained many genes known to be 
associated with cancer pathways, including EML4. Only EML4 appeared to be a highly 
connected hub gene. Other hub genes may not be in the increasing or decreasing temporal 
expression clusters, but might be exerting their effects on signalling cascades in other ways. 
For example, other hubs across the treated time courses include the genes TP63, ETS2 and 
FOSL2 (Chapter 5, Table 5.5 and Figure 5.14), all of which could be having significant 
effects on cancer-related pathways to enhance the proliferative and/or cisplatin-resistance 
phenotype. 
The 375 genes overlapping the two treated but not the untreated time courses also underwent 
network analyses and yielded hub genes of their own including SCN9A (another hub gene 
from the individual time courses) and the gene encoding FGFR1, a receptor known to be 
involved in cancer-related signalling cascades. 
Between the WGCNA analyses and the temporal expression clustering, several genes worthy 
of further investigation in a more advanced setting were found. A combination of these gene 
lists of WGCNA modules and temporal expression clusters were therefore the focus when 
looking at the global gene expression data generated from the patient tissues (Chapter 6 
Section 6.6). 
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7.1.4 Potential Future Work: Cellular Model 
7.1.4.1 Other Cellular Models 
The cellular model could be expanded by using other NSCLC cell lines including those with 
different baseline genetic backgrounds, such as an EGFR baseline mutation or one with as 
few known cancer mutations as possible with the aim of reflecting early stage disease. By 
expanding the same robust model into different cell line genotypes, a more comprehensive 
overview of lung cancer responses to cisplatin could be produced. Further comparisons with 
patients could be performed, such as matching the original subtype of the cell line with 
tumours of that particular subtype for further tissue-based investigations. 
Further studies of the cellular models described in this thesis could also be conducted. RNA 
extractions after cisplatin dosing and removal could be performed at varying intervals, such 
as one, four, eight, twelve, sixteen, twenty-four, and forty-eight hours to examine the 
changing genomic landscape immediately after treatment of chemo-naïve cells and those 
towards or at the end of the repeated dosing regime, In order to do this, a smaller or shorter 
cisplatin dose would be required and further optimisation needed to ensure retention of 
sufficient healthy cells to remain for harvesting and nucleic acid extraction. With the new 
technology of single cell sequencing of the transcriptome, the limitation of cell numbers is 
becoming a reality of the future, although this was not feasible during the time of this thesis. 
 
7.1.4.2 Gene Expression over the Time Course 
In this thesis, only fold change differences in gene expression between the start and end 
points of the time course have been studied in detail. Additional research into the fold 
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changes of the genes of particular interest across the whole time course could add extra 
information to the dataset by comparing with chemo-naïve cells and at other points along the 
dosing regime. These further comparisons across the time course could become highly 
complex to interpret biologically but may be important; for example, to look into the apparent 
sigmoidal shape observed around the middle of increasing and decreasing temporal 
expression clusters in both time courses (Chapter 4, Figures 4.7 and 4.8).  
 
7.1.4.3 Genome of the Cisplatin Resistance Model 
One obvious extension to this work is the need for DNA investigations to combine with the 
extensive RNA work performed here. As previously stated, DNA was extracted at the same 
time as RNA from the cells for each dosing time point. DNA aliquots from the start, middle, 
and end of each of the two time courses have been sent to collaborators with the plan to 
conduct whole genome sequencing.  This would allow structural and sequence changes 
occurring over the course of treatment to be identified. Examination of whether changes 
found relate to changes seen in the transcriptome would also be feasible. Results of DNA 
sequencing for the middle time point could also potentially shed light onto the sigmoidal 
change observed in the temporal expression clusters and whether there is a genome-related 
reason behind it.  
Ideally these DNA studies would be completed across all the time points of both regimes, as 
this would enable as full a picture of the genomic landscape as possible to be gained. If 
RNAseq could also be performed, the entire coding region could be subject to investigation, 
including non-coding and novel transcripts as well as those that are well documented. 
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Sequencing of the DNA might also give an indication as to changes in the telomere length 
over time. It would be interesting to see if the telomeres continued to retract as the model 
progressed. If this were not the case, one could suggest that the cisplatin treatment was 
increasing the replicative potential of the cells beyond the normal immortalisation of cell 
lines. 
Other important mechanisms that could be involved in cisplatin resistance involve 
epigenetics, such as CpG islands or histone modification, which are key in controlling gene 
expression.  A logical next step after conducting Whole Genome Sequencing of the DNA 
therefore would be to look into global methylation. 
 
7.1.5 Investigating Genes of Interest from the Cellular Model of Resistance between 
Platinum Treated and Untreated Patients 
Two cohorts of cases were included in a preliminary study investigating the differential 
expression of the genes of interest between patients treated with platinum and those without 
exposure to any platinum compounds. One cohort was from RESTORE-AIR, a historical 
NSCLC stent-intervention study, whilst the other was from EQUALITY, an on-going broad 
spectrum recruitment into many types of lung cancer that is collecting tissue, urine, and blood 
samples to explore eQTLs. Both RESTORE-AIR and EQUALITY had collected (and 
continue to collect) tissue samples taken at rigid bronchoscopy with immediate storage of 
them in RNA stabilisation buffer. This meant that the tissue samples were ideal substrates for 
transcriptome analyses and would allow the opportunity for comparison of the data generated 
with the data from the cisplatin-resistance models. For a control normal tissue cohort data 
generated previously within the group from a project investigating the differentiation between 
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adenocarcinoma and squamous cell subtypes based on transcriptome signatures/expression 
profiles was utilised. 
Controls were selected based on age, gender, smoking status (current, ex, or never), and 
subtype to match as closely as possible the RESTORE-AIR and EQUALITY samples. 
Stringent quality control was performed through methodological outlier detection using the 
IAC methodology (Chapter 6 Section 6.5.1). The substantial batch effect caused by the 
marked variances of the studies was removed before differential expression analysis between 
the platinum-treated and the untreated patients was performed. Unlike the cellular model, a 
less stringent B-H adjusted p-value was used to reduce the number of statistically significant 
differentially expressed genes from the gene lists of interest. By using the gene lists generated 
by temporal expression clustering and WGCNA (Chapters 4 and 5), the number of 
comparisons performed in the differential expression analysis was reduced and so a smaller 
p-value was applied. Twenty one genes of interest that overlap this patient study and the 
cellular model were identified. These genes showed highly significant and large fold changes 
and in several cases have previously been linked with various cancers. Importantly the 
WGCNA explorations identified a number of them to be key hubs and these genes are 
therefore potentially good biological candidates for driver mutations in the response against 
cisplatin. 
 
7.1.5.1 Future Work: Tumour Tissue Samples 
In an ideal world, a specific tissue collection in advanced stage NSCLC patients with 1) a 
fresh biopsy prior to starting platinum-therapy, 2) a fresh biopsy at time of first response-
assessment CT scan, 3) a biopsy at time of completing planned number of platinum 
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chemotherapy cycles, and 4) with a final fresh biopsy at point of disease relapse would 
provide substantial insight into and more robust research to compare with the A549 cellular 
model discussed in previous chapters. This level of interventional biopsy work would 
however at present not be clinically feasible. Nevertheless, a more limited protocol of biopsy 
prior to therapy and then again on relapse is clinically achievable. Even with this potentially 
ideal dataset, there may still be issues with the heterogeneity of cancer as a whole with 
different patients responding to treatment in variable ways. Patients would also need to be 
well-phenotyped with substantial follow-up in order to exploit the full potential of such a 
resource. Additional biopsies of multiple metastatic sites would add further information on 
potentially relevant resistance mechanisms. 
Snap-frozen tissue from these patients and the control cohort, excised at the same time as that 
used for RNA extraction, is available for DNA extraction. Investigations into differences in 
structural variation of the DNA of these two cohorts would be worthwhile. If the potential 
future work discussed in Section 7.1.4.3 was performed using the DNAs from the model, the 
same investigations could be carried out to provide another comparative cohort to examine 
whether the DNA variants and changes seen over the course of the cellular model are 
reflected in the patient samples. These would add to the understanding of why cisplatin 
resistance is occurring. 
Further analyses that could be of use would include examining the differential expression 
between treated and untreated patients, irrespective of the genes of interest from the cisplatin 
cellular model, especially in light of the fact that patients may have been exposed to 
combination therapies. Exploration into the changes in gene expression between these two 
cohorts alone could provide more known cancer markers and potentially other unknown 
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biological candidates, which could be further pointers to the mechanisms of survival, and 
even growth, in the presence of cytotoxic platinum compounds.  
The availability of some matched tumour-normal samples from both the RESTORE-AIR and 
EQUALITY studies, which may be either platinum-treated or non-platinum-treated, would 
allow comparative analyses to be run to see if there are inherent differences in the host 
genetics that could drive particular mutations or gene expression profiles observed, as well as 
their response to chemotherapy and so provide useful insights into disease progression. 
 
7.2 General Conclusion 
In spite of the limitations of the cellular model, it has yielded candidate genes for cisplatin 
resistance that show significant changes in patient tissues that have been exposed to platinum 
treatment. 
The strong overlap in the top hits for genes across the two dosing time courses has identified 
genes that may be core to resistance to cisplatin. In performing gene expression analyses on 
A549 cells over extended cell culture, the changes that occur over this period have been 
controlled for. Variation in the gene lists of differentially expressed genes between the two 
dosing time courses, as well as some of their patterns of expression in clusters shows there is 
an individual and stochastic element to the response to cisplatin. Characterisation of the up- 
and down-regulated genes has been possible by GO analysis and so general mechanisms 
through which the cells gain resistance have been identified. Network analysis has allowed 
the differentially expressed genes to be organised and enabled hubs to be found. These genes 
and hubs may be of therapeutic value. 
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When examining the patient tissue samples, several genes from the cellular model have been 
observed that are highly differentially expressed in cisplatin treated squamous cell carcinoma 
and, as such these genes are potential therapeutic targets. The twenty one genes (discussed in 
detail in Chapter 6 Section 6.6) are worthy of further investigations, both in an in vitro 
setting, including conducting protein-based assays to assess if the changes at mRNA level are 
being retained post translation. Further genome-based investigations would also be 
worthwhile (Section 7.1). 
The published research conducted by Barr et al. (2013), is to some extent complimentary to 
investigations performed here. Barr et al. (2013) also generated cisplatin-resistant cell lines 
over a long time period using an isogenic model, but they then characterised the cells using 
cellular biochemistry techniques as opposed to genetic and genomic approaches. Their 
comparisons were performed between parent chemo-naïve cells and resistant cells that had 
been developed over time consistently in media containing cisplatin. They found the cells to 
have decreased proliferation capacity and as well as observing an accumulation of resistant 
cells in the G0/G1 phase of the cell cycle.  Support of this latter observation comes from the 
RNA work conducted in this current thesis. In the cellular models the increase in expression 
of related genes involved in the β-catenin/WNT pathway and the changing abundance of 
adhesion molecules, reflects the apparent up-regulation of markers for EMT, c-Met, and β-
catenin seen by Barr et al. (2013). The observation by Barr et al. (2013) that the resistant 
cells had a reduction in cisplatin uptake is potentially supported by this thesis as alterations in 
the gene expression of transporters were seen in the cellular model, particularly those which 
have already been implicated in other cancers. 
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A large database of gene expression data has been generated as a result of this work and it is 
possible that the highly stringent p-values implemented (for the cell model data for 
expression clustering and WGCNA analyses) may have removed low level key players in the 
survival phenotype. It is hoped that the methodical reasoning applied here has generated 
results that may help understand the complexity of response to platinum treatment and that 
the top hits from the large quantity of data produced may lead not only to a better 
understanding of the mechanisms of cisplatin resistance but provide biomarkers that can be 
used to help in the prognosis of those going undergoing therapy.  
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9.1 E-Appendices for use in conjunction with Chapter 4 
9.1.1  Differentially Expressed Genes from the IC50 Dose 3 Week Recovery Time course    
B-H adjusted p-value <1E-14 
9.1.2  Differentially Expressed Genes from the IC25 Dose 1 Week Recovery Time course B-
H adjusted p-value <1E-14 
9.1.3  Genes from the Temporal Expression Clusters of Interest, IC50 Dose 3 Week Recovery 
Time course  
9.1.4  Genes from the Temporal Expression Clusters of Interest, IC25 Dose 1 Week Recovery 
Time course 
9.1.5  375 Genes of Overlap found in to be Differentially Expressed in Both Treatment Time 
Courses but not in the Normal Untreated Time Course 
 
9.2 E-Appendices for use in conjunction with Chapter 5 
9.2.1  Gene Membership for WGCNA Modules from the IC50 Dose 3 Week Recovery Time 
Course 
9.2.2  Genes Overlapping WGCNA Modules from the IC50 Dose 3 Week Recovery Time 
Course and Temporal Expression Clusters of Interest 
9.2.3  Gene Membership for WGCNA Modules from the IC25 Dose 1 Week Recovery Time 
Course 
9.2.4  Genes Overlapping WGCNA Modules from the IC25 Dose 1 Week Recovery Time 
Course and Temporal Expression Clusters of Interest 
9.2.5  Gene Membership for the Reduced WGCNA Modules from the IC25 Dose 1 Week 
Recovery Time Course 
9.2.6  Genes Overlapping Reduced WGCNA Modules from the IC25 Dose 1 Week Recovery 
Time Course and Temporal Expression Clusters of Interest 
9.2.7 Gene Membership for WGCNA Modules from the Normal Untreated Time Course 
9.2.8  Gene Membership for WGCNA Modules from 375 Genes Differentially Expressed in 
both Treatment Time Courses but not in the Normal Untreated Time Course 
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9.3 Circos Plots of Gene Interconnectivity within Modules 
9.3.1 IC50 Dose 3 Week Recovery Time Course 
 
Figure 1 Circos plot of the all 50 genes in the Pink module from the IC50 dose 3 week recovery time 
course. Some strong connections are visible between the genes although the majority of the 
connections appear to be pale blue and consequently are less well correlated connections. Genes that 
appear to be highly connected include BIN1, BTBD11, CXCL1, GARNL4, GSTM2, PLCD3, PTPRE, 
RHOU, SCN9A, SLC40A1, TAP1 (three transcripts for this gene in the module) and TRHDE. 




Figure 2 Circos plot of the all 46 genes in the Green module from the IC50 dose 3 week recovery. 
Genes that appear to be highly connected include ANKRD30A, CSAG2 (two transcripts), 
ENSG00000244402, ITGBL1, ITM2A, LUM, MAGEA2 (two transcripts), MAGEB2, RP11-35N6.1, 
and VSIG1. 




Figure 3 Circos plot of the top 50 genes in the Yellow module from the IC50 dose 3 week recovery. 
Genes that appear to be highly connected include BMP7, CADNG6, ETHE1, FGFR1, SCEL, SPARC, 
ST3GAL5, TINAGL1, TRIM29, VSNL1, and ZNF717. 
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9.3.2 IC25 Dose 1 Week Recovery Time Course 
 
Figure 4 Circos plot of the Brown module from the IC25 Dose 1 Week Recovery Time Course. 
Strong connections are visible between the 48 genes on the plot. Highly connected genes include 
BAAT, DMKN, DUSP1, GLI3, ITGA11, RNF212, SDR42E1, SPARC, and TGM2. All these transcripts 
have multiple connections to other transcripts, some of which are high in the connectivity levels. 




Figure 5 Circos plot of the Blue module from the IC25 Dose 1 Week Recovery Time Course. Strong 
connections are visible between the 55 genes on the plot. Highly connected genes include C1orf130, 
C5, EGFR, EML4, ETS2, FOSL2, FSTL3, PDLIM7, PTPRF, and TNS4. All these transcripts have 
multiple connections to other transcripts, some of which are high in connectivity level.  
 




Figure 6 Circos plot of the yellow module from the IC25 Dose 1 Week Recovery Time Course. 
Strong connections are visible between the 46 genes on the plot. Highly connected genes include 
C21orf163, CA8, DPYSL3, HLA-DMA (three transcripts), ITM2A, LGALS2, LUM, OR51B4, 
PPP1R1C, and RNF182. All these transcripts have multiple connections to other transcripts, some of 
which are high in connectivity level. 
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9.3.3 375 Overlapping Genes between the two treated time courses 
 
Figure 7 Circos plot of the Green module from the 375 genes only differentially expressed in the 
treated time courses using the IC50 dose 3 week recovery time course data. Strong connections are 
visible across all 41 genes. Despite this, certain hubs with several, strongly correlated connections 
appear prominent, such as CCDC146, DSEL, FGFR1, and TLL1. 




Figure 8 Circos plot of the Blue module from the 375 genes only differentially expressed in the 
treated time courses using the IC50 dose 3 week recovery time course data. Strong connections are 
visible across all 65 genes.  
 
 




Figure 9 Circos plot of the yellow module from the 375 genes only differentially expressed in the 
treated time courses using the IC50 dose 3 week recovery time course data. Strong connections are 
visible across all 46 genes. Despite this, certain hubs with several, strongly correlated connections 
appear prominent, such as BTBD11, CDCP1, DCDC5, FAS, L1CAM, RHOU, SCN9A, and TNS4.
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